var title_f38_43_39600="Beckers nevus";
var content_f38_43_39600=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68895&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68895&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Becker's nevus (Becker's melanosis)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the hypertrichosis and \"islands\" of hyperpigmentation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jean L Bolognia, MD, and Julie V Schaffer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_43_39600=[""].join("\n");
var outline_f38_43_39600=null;
var title_f38_43_39601="ARDS CT";
var content_f38_43_39601=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F71931&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F71931&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    ARDS CT",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 413px; height: 292px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    ARDS due to sepsis after pneumococcal pneumonia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_43_39601=[""].join("\n");
var outline_f38_43_39601=null;
var title_f38_43_39602="Lichen planus gingivitis";
var content_f38_43_39602=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F73340&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F73340&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lichen planus gingivitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 268px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Ridley, CM, Neill, SM (Eds), The Vulva, 2nd ed, Blackwell Science, Oxford 1999. Copyright &copy; 1999 Blackwell Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_43_39602=[""].join("\n");
var outline_f38_43_39602=null;
var title_f38_43_39603="Self-blood glucose monitoring in diabetes mellitus";
var content_f38_43_39603=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?38/43/39603/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/43/39603/contributors\" id=\"au5149\">",
"       David K McCulloch, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?38/43/39603/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/43/39603/contributors\" id=\"se6384\">",
"       David M Nathan, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?38/43/39603/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/43/39603/contributors\" id=\"de1470\">",
"       Jean E Mulder, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?38/43/39603?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      BLOOD SUGAR TESTING OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     If you have diabetes, you have an important role in your own medical care, and testing your blood glucose (also called blood sugar) is an opportunity for you to take control of your health.",
"    </p>",
"    <p>",
"     Although diabetes is a chronic condition, it can usually be controlled with lifestyle changes and medication. The main goal of treatment is to keep blood sugar levels in the normal or near-normal range. Checking your blood sugar is one of the best ways to know how well your diabetes treatment plan is working. Continuous glucose monitors have also become popular, especially for people who use an insulin pump. (See",
"     <a class=\"local\" href=\"#H15\">",
"      'Continuous glucose monitoring'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     A healthcare provider will periodically order a laboratory blood test to determine your blood sugar levels and hemoglobin A1c (A1C). This test gives an overall sense of how blood sugar levels are controlled since it indicates your average blood sugar level of the past two to three months (",
"     <a class=\"graphic graphic_table graphicRef76310 \" href=\"mobipreview.htm?6/10/6316\">",
"      table 1",
"     </a>",
"     ). However, fine-tuning of blood sugar levels and treatment also requires that you monitor your own blood sugar levels on a day-to-day basis.",
"    </p>",
"    <p>",
"     Self-blood glucose monitoring allows you to know your blood glucose level at any time and helps prevent the consequences of very high or very low blood sugar. Monitoring also enables tighter blood sugar control, which decreases the long-term risks of diabetic complications.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      HOW TO PERFORM BLOOD SUGAR TESTING",
"     </span>",
"    </p>",
"    <p>",
"     The following steps include general guidelines for testing blood sugar levels; you should get specific details for your blood glucose monitors from the package insert or your healthcare provider. Never share blood glucose monitoring equipment or fingerstick lancing devices. Sharing of this equipment could result in transmission of infection, such as hepatitis B.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Wash hands with soap and warm water. Dry hands.",
"      </li>",
"      <li>",
"       Prepare the lancing device by inserting a fresh lancet. Lancets that are used more than once are not as sharp as a new lancet, and can cause more pain and injury to the skin.",
"      </li>",
"      <li>",
"       Prepare the blood glucose meter and test strip (instructions for this depend upon the type of glucose meter used).",
"      </li>",
"      <li>",
"       Use the lancing device to obtain a small drop of blood from your fingertip or alternate site (like the skin of the forearm) (",
"       <a class=\"graphic graphic_picture graphicRef57918 \" href=\"mobipreview.htm?34/36/35394\">",
"        picture 1",
"       </a>",
"       ). Alternate sites are often less painful than the fingertip. However, results from alternate sites are not as accurate as fingertip samples when the blood glucose is rising or falling rapidly (",
"       <a class=\"graphic graphic_picture graphicRef63375 \" href=\"mobipreview.htm?34/37/35408\">",
"        picture 2",
"       </a>",
"       ).",
"       <br/>",
"       <br/>",
"       If you have difficulty getting a good drop of blood from the fingertip, try rinsing your fingers with warm water, shaking the hand below the waist, or squeezing (\"milking\") the fingertip.",
"      </li>",
"      <li>",
"       Apply the blood drop to the test strip in the blood glucose meter. The results will be displayed on the meter after several seconds.",
"      </li>",
"      <li>",
"       Dispose of the used lancet in a puncture-resistant sharps container (not in household trash).",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      FREQUENCY OF BLOOD SUGAR TESTING",
"     </span>",
"    </p>",
"    <p>",
"     Studies have proven that people with type 1 and 2 diabetes who maintain normal or near normal blood sugar levels have a lower risk of diabetes-related complications than those who have high blood sugar levels. How frequently you test will depend upon the type of diabetes you have (1 or 2) and which treatment(s) you use (insulin versus oral medications or lifestyle changes).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Type 1 diabetes",
"     </span>",
"     &nbsp;&mdash;&nbsp;For people with type 1 diabetes, frequent testing is the only way to safely and effectively manage blood sugar levels. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/26/36259?source=see_link\">",
"      \"Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Most people need to test at least four times per day. If you use an insulin pump, give three or more insulin injections per day, or are a woman with type 1 diabetes who is pregnant, you may need to test as many as seven times per day or more. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/45/10966?source=see_link\">",
"      \"Patient information: Care during pregnancy for women with type 1 or 2 diabetes mellitus (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     People who test frequently, especially those using intensive insulin therapy, may consider purchasing several blood glucose monitors to keep at home, work, school, or in a purse or backpack. This allows easier access to testing equipment, which can increase testing frequency and therefore improve blood sugar control.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Type 2 diabetes",
"     </span>",
"     &nbsp;&mdash;&nbsp;Blood sugar monitoring is also important for people with type 2 diabetes. The recommendations for how often you should test are based upon individual factors such as type of treatment (diet versus oral medication versus insulin), level of hemoglobin A1c (A1C), and treatment goals. A healthcare provider can help you determine how frequently to test. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/22/9572?source=see_link\">",
"      \"Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      INTERPRETING BLOOD SUGAR RESULTS",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Blood sugar testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;The results of blood sugar testing tell you if your diabetes treatments are on target. However, blood sugar results can be affected by activity levels, foods eaten, and medications (including insulin and oral diabetes medications). To interpret results, it is important to consider all of these factors.",
"    </p>",
"    <p>",
"     You should review your blood sugar results regularly with a healthcare provider. The record should include the time and date, blood glucose result, and dose of medication used; additional notes about what you ate, exercise, and difficulties with illness or stress can also be helpful but are not generally required every day.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Need for urine testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with type 1 diabetes should perform urine testing for ketones if the blood sugar level is above 240",
"     <span class=\"nowrap\">",
"      mg/dL",
"     </span>",
"     (13.3",
"     <span class=\"nowrap\">",
"      mmol/L),",
"     </span>",
"     during periods of illness or stress, or if you have symptoms of ketoacidosis, such as nausea, vomiting, and abdominal pain.",
"    </p>",
"    <p>",
"     Ketones are acids that are formed when the body does not have enough insulin to get glucose into the cells, causing the body to break down fat for energy. Ketones can also develop during illness, if an inadequate amount of glucose is available (due to skipped meals or vomiting). Ketoacidosis occurs when high levels of ketones are present and can lead to serious complications such as diabetic coma.",
"    </p>",
"    <p>",
"     Urine ketone testing is done with a dipstick, available in pharmacies without a prescription. If you have moderate to large ketones, you should call your healthcare provider immediately to determine the best treatment. You may need to take an additional dose of insulin, or your provider may instruct you to go to the nearest emergency room.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      ADJUSTING TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Home blood sugar monitoring can provide useful and motivating information. For people who are treated with insulin, the results will help guide you to choose the appropriate doses from meal to meal. In the beginning of your treatment, you will need to consult with your healthcare provider as you learn to make adjustments in treatment. However, with time and experience, most people are able to learn how to make adjustments on their own.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      ACCURACY OF HOME BLOOD SUGAR MONITORING",
"     </span>",
"    </p>",
"    <p>",
"     The accuracy of a blood glucose monitor can be affected by several factors, including the type of blood glucose strip and monitor.",
"    </p>",
"    <p>",
"     Check the accuracy of a blood glucose monitor occasionally by bringing it to visits with a healthcare provider when blood work is done; use your home monitor to check your blood sugar at the same time that blood is drawn.",
"    </p>",
"    <p>",
"     When comparing glucose monitor results with those from a laboratory, there should be no more than a 15 percent difference; larger differences may indicate a problem with your monitor, blood glucose strips, or your monitoring technique.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Blood glucose meters",
"     </span>",
"     &nbsp;&mdash;&nbsp;Blood glucose meters are reasonably accurate. However, there can be some variability from one unit to the next, so it is always wise to exercise caution and common sense when using the readings from these machines. As an example, if a reading does not fit with your symptoms (or lack of symptoms), take a second reading or use an alternate method for testing your blood sugar (such as a different meter). Blood glucose meters are least accurate during episodes of low blood sugar.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Alternate site testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;Blood sugar results can be less accurate if you test at places other than the fingertips (eg, arm, hand, leg). This should not be a problem if you always use one site. However, when the blood sugar is rising rapidly (eg, immediately after eating) or falling rapidly (in response to insulin or exercise), testing at alternate sites may give significantly different results than a fingerstick reading. In these situations, fingertip testing is preferred.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Help for people with vision impairment",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with vision impairment sometimes have difficulty using glucose meters. Meters with large screens and \"talking\" meters are available. People with impaired vision can get assistance from the American Association of Diabetes Educators (AADE) at (800) 338-3633.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      SELECTING A BLOOD GLUCOSE MONITOR",
"     </span>",
"    </p>",
"    <p>",
"     There is no single blood glucose monitor that is better than others. A number of factors should be considered when choosing a monitor:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Expense &mdash; Special offers, rebates, and trade-ins are almost always available on blood glucose monitors, making them affordable for most people. Also check the cost of the supplies that go along with a monitor, including test strips. Over time, supplies will be more costly than the monitor. Many insurance carriers cover the cost of the monitor",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       supplies. Medicare now covers all of the costs of blood glucose monitoring.",
"      </li>",
"      <li>",
"       Ease of use &mdash; Some monitors are easier to use than others. Some require a tiny sample of blood, meaning that a smaller and less painful finger stick is possible. Meters vary in how quickly they give the result (some in as little as five seconds). When possible, check with a pharmacist, diabetes nurse, or other healthcare provider for a recommendation.",
"      </li>",
"      <li>",
"       Accuracy &mdash; Newer meters typically provide the most reliable results.",
"      </li>",
"      <li>",
"       Sophistication &mdash; Some meters allow you to enter events (like eating or exercising) and come with software programs that allow you to download data to a computer. This is most helpful for people who test frequently and use intensive insulin treatment.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      CONTINUOUS GLUCOSE MONITORING",
"     </span>",
"    </p>",
"    <p>",
"     Continuous glucose monitoring systems (CGMS) use a glucose sensor (contained in a small needle) to determine the level of glucose in the fluid under the skin. The sensor is attached to the skin with a sticky patch, and it wirelessly transmits results to a small recording device (the size of a pager or cell phone), which you wear on your clothing, carry in a purse or bag, or place near you (eg, a bedside table). The monitor updates and displays your blood sugar level every few minutes.",
"    </p>",
"    <p>",
"     You must remove and replace the sensor in a different place on your body approximately once per week. In addition, you must continue to perform finger stick blood sugar testing several times daily to ensure that the continuous monitor is correctly calibrated.",
"    </p>",
"    <p>",
"     Currently, continuous blood glucose monitors are recommended only for people with type 1 diabetes who use intensive insulin therapy, often with an insulin pump. A combined insulin pump and continuous glucose monitor is also available. Many experts think that continuous glucose monitoring may be most useful in people who have difficulty recognizing when they have low blood sugar.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Advantages",
"     </span>",
"     &nbsp;&mdash;&nbsp;The continuous glucose monitor displays your blood sugar level every few minutes, allowing you to see if the level is increasing, decreasing, or is stable. The receiver can also be set to alarm if your blood sugar level is above or below a pre-set level, which can be especially helpful for people who cannot feel when they have low blood glucose (so called hypoglycemia unawareness).",
"    </p>",
"    <p>",
"     You can download blood sugar results from the continuous monitor to your computer, allowing you to see blood sugar trends over time. You can use this information to determine if you need to adjust your insulin dose.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Drawbacks",
"     </span>",
"     &nbsp;&mdash;&nbsp;The continuous glucose sensors currently available are not as accurate as most blood glucose monitors, especially when blood glucose levels are rapidly rising. In one study, over 70 percent of the blood and continuous glucose values differed by 10 percent or more, and 7 percent of the readings differed by over 50 percent [",
"     <a class=\"abstract\" href=\"mobipreview.htm?38/43/39603/abstract/1\">",
"      1",
"     </a>",
"     ]. The CGMS tends to be less accurate when the blood sugar is low (&lt;70",
"     <span class=\"nowrap\">",
"      mg/dL",
"     </span>",
"     or 3.9",
"     <span class=\"nowrap\">",
"      mmol/L)",
"     </span>",
"     and therefore may not be able to reliably indicate when you are low.",
"    </p>",
"    <p>",
"     Thus, most experts do not recommend continuous glucose monitoring alone for information about your blood glucose levels. It is important to do several fingersticks daily to calibrate the CGMS device and to verify that the sensor readings are accurate.",
"    </p>",
"    <p>",
"     In addition, the costs associated with continuous glucose monitors are much greater than those of traditional glucose monitors. Not all continuous glucose meters and supplies are covered by commercial health insurance companies.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3498679407\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27350619\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/44/33475?source=see_link\">",
"      Patient information: Type 2 diabetes (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/58/28579?source=see_link\">",
"      Patient information: Using insulin (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/49/16147?source=see_link\">",
"      Patient information: Treatment for type 2 diabetes (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/12/14531?source=see_link\">",
"      Patient information: Low blood sugar in people with diabetes (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/62/31714?source=see_link\">",
"      Patient information: Care during pregnancy for women with type 1 or type 2 diabetes (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/48/18179?source=see_link\">",
"      Patient information: My child has diabetes: How will we manage? (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/25/36243?source=see_link\">",
"      Patient information: Keeping your child&rsquo;s blood sugar under control (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/11/38066?source=see_link\">",
"      Patient information: Managing diabetes in school (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/33/5651?source=see_link\">",
"      Patient information: Giving your child insulin (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/26/39331?source=see_link\">",
"      Patient information: Checking your child&rsquo;s blood sugar level (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/2/36898?source=see_link\">",
"      Patient information: Diabetic ketoacidosis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/6/25699?source=see_link\">",
"      Patient information: Hyperosmolar nonketotic coma (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/52/20292?source=see_link\">",
"      Patient information: Diabetes and infections (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27350634\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/26/36259?source=see_link\">",
"      Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/45/10966?source=see_link\">",
"      Patient information: Care during pregnancy for women with type 1 or 2 diabetes mellitus (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/22/9572?source=see_link\">",
"      Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29641?source=see_link\">",
"      Blood glucose self-monitoring in management of adults with diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/45/11993?source=see_link\">",
"      Estimation of blood glucose control in diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/9/40090?source=see_link\">",
"      Management of type 1 diabetes mellitus in children and adolescents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/42/682?source=see_link\">",
"      Treatment of type 2 diabetes mellitus in the elderly patient",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niddk.nih.gov/\">",
"      www.niddk.nih.gov/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Diabetes Association (ADA)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(800)-DIABETES (800-342-2383)",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.diabetes.org/\">",
"      www.diabetes.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Hormone Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.hormone.org/public/diabetes.cfm\">",
"      www.hormone.org/public/diabetes.cfm",
"     </a>",
"     , available in English and Spanish)",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?38/43/39603/abstract/2-5\">",
"      2-5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 24, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?38/43/39603?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39603/abstract/1\">",
"      Metzger M, Leibowitz G, Wainstein J, et al. Reproducibility of glucose measurements using the glucose sensor. Diabetes Care 2002; 25:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39603/abstract/2\">",
"      Faas A, Schellevis FG, Van Eijk JT. The efficacy of self-monitoring of blood glucose in NIDDM subjects. A criteria-based literature review. Diabetes Care 1997; 20:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39603/abstract/3\">",
"      Nettles A. User error in blood glucose monitoring. The National Steering Committee for Quality Assurance Report. Diabetes Care 1993; 16:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39603/abstract/4\">",
"      Self-monitoring of blood glucose. American Diabetes Association. Diabetes Care 1994; 17:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39603/abstract/5\">",
"      Most RS, Gross AM, Davidson PC, Richardson P. The accuracy of glucose monitoring by diabetic individuals in their home setting. Diabetes Educ 1986; 12:24.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f38_43_39603=[""].join("\n");
var outline_f38_43_39603=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           BLOOD SUGAR TESTING OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           HOW TO PERFORM BLOOD SUGAR TESTING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           FREQUENCY OF BLOOD SUGAR TESTING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           INTERPRETING BLOOD SUGAR RESULTS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           ADJUSTING TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           ACCURACY OF HOME BLOOD SUGAR MONITORING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           SELECTING A BLOOD GLUCOSE MONITOR",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           CONTINUOUS GLUCOSE MONITORING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/36/35394\" title=\"picture 1\">",
"           Fingertip testing PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/37/35408\" title=\"picture 2\">",
"           Alternate site testing PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/10/6316\" title=\"table 1\">",
"           A1C and blood sugar PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f38_43_39604="Anatomy of dorsalis pedis artery";
var content_f38_43_39604=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F54240&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F54240&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anatomy of dorsalis pedis artery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 644px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The dorsalis pedis artery is located lateral to the extensor hallucis longus tendon.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from American Heart Association. Textbook of Advanced Cardiac Life Support, 1994.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_43_39604=[""].join("\n");
var outline_f38_43_39604=null;
var title_f38_43_39605="Anatomy common femoral artery";
var content_f38_43_39605=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F51298&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F51298&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 519px\">",
"   <div class=\"ttl\">",
"    Anatomy common femoral artery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 499px; height: 610px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_43_39605=[""].join("\n");
var outline_f38_43_39605=null;
var title_f38_43_39606="Fibrolamellar carcinoma Light";
var content_f38_43_39606=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F61794&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F61794&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fibrolamellar hepatocellular carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 438px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power view of a liver biopsy shows a lamellar pattern of fibrosis surrounding cords and nests of atypical hepatocytes with abundant eosinophilic granular cytoplasm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_43_39606=[""].join("\n");
var outline_f38_43_39606=null;
var title_f38_43_39607="Homesickness";
var content_f38_43_39607=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Homesickness",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/43/39607/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/43/39607/contributors\">",
"     Christopher A Thurber, PhD, ABPP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/43/39607/contributors\">",
"     Edward Walton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/43/39607/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/43/39607/contributors\">",
"     Marilyn Augustyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/43/39607/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/43/39607/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/43/39607/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Homesickness is the distress and functional impairment caused by an actual or anticipated separation from home and attachment objects such as parents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/1\">",
"     1",
"    </a>",
"    ]. It is characterized by acute longing and preoccupying thoughts of home.",
"   </p>",
"   <p>",
"    Almost all children, adolescents, and adults experience some degree of homesickness when they are apart from familiar people and environments. In some individuals, the subjective distress and level of impairment related to this separation may be extreme.",
"   </p>",
"   <p>",
"    Primary care providers can help families understand the etiology of homesickness, identify which children are at risk, and develop strategies for prevention",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    treatment. An overview of homesickness, including techniques for prevention with planned separations, such as summer camp, and treatment strategies for unanticipated or traumatic separations, such as hospitalization, will be presented below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Homesickness is defined as the distress and functional impairment caused by an actual or anticipated separation from home and attachment objects such as parents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/1\">",
"     1",
"    </a>",
"    ]. Severe homesickness is classified as an adjustment disorder with mixed anxiety and depressed mood according to the American Psychiatric Association taxonomy (diagnostic code 309.28) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Homesickness is characterized by recurrent cognitions focused on home (eg, parents, house, loved ones, home cooking, family pet); it is always precipitated by an actual or anticipated separation from home. These features distinguish homesickness from other adjustment disorders, anxiety disorders, and mood disorders, as well as from the separation anxiety felt by children when caregivers leave home (eg, because of divorce, military service, etc.) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most individuals experience some degree of homesickness when they leave familiar surroundings and enter a new environment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Homesickness may be a significant source of distress and impairment for children and adolescents in the following settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Summer camp",
"     </li>",
"     <li>",
"      Boarding school",
"     </li>",
"     <li>",
"      College and university",
"     </li>",
"     <li>",
"      Hospital admission",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Homesickness also affects immigrants, foreign students, foreign employees, displaced persons, refugees, and military personnel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/11-18\">",
"     11-18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimates of the prevalence of homesickness vary depending upon the definition of homesickness, the population studied, the circumstances of separation, the type of measurement, and when the homesickness was assessed (eg, during a separation or retrospectively). As an example, estimates for homesickness among adolescent boarding-school students range from 16 to 91 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/10\">",
"     10",
"    </a>",
"    ]. In the studies where homesickness was measured during the separation, the reported prevalence ranged from 83 to 95 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/6,19\">",
"     6,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Homesickness is equally prevalent among children attending summer camp and those who are hospitalized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/9,20\">",
"     9,20",
"    </a>",
"    ]. Younger children are at greater risk for homesickness than older children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/6\">",
"     6",
"    </a>",
"    ]. The prevalence and intensity are similar between boys and girls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/4,19\">",
"     4,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 20 percent of boys and girls who are away from home experience moderate to severe homesickness (defined by rating the average intensity of their homesickness at or above the midpoint of the rating scale used in the particular study) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/4,6,19,20\">",
"     4,6,19,20",
"    </a>",
"    ]. However, only 6 to 9 percent of children report homesickness that is associated with severe symptoms of depression",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anxiety [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/4,6,9,19\">",
"     4,6,9,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Homesickness in hospitalized children is more severe and less predictable than in children in less stressful environments. Across a variety of presenting problems, approximately 50 percent of hospitalized children ages 8 to 18 reported moderate to severe levels of homesickness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/21\">",
"     21",
"    </a>",
"    ]. The best predictors of homesickness were negative hospitalization attitudes and previous separations from home (eg, placement in foster care). In contrast to children in other settings, homesickness in hospitalized children was not predicted by insecure attachment or low perceived control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Risk factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Data regarding the incidence and severity of homesickness in children with cognitive or developmental delay are lacking. However, it can be inferred that these children respond to separation from home and attachment objects in a manner consistent with their developmental age, separation attitudes, attachment style, and previous experiences away from home.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for homesickness include lack of experience with separation or the new environment, negative attitudes toward the separation or the environment, insecure attachment to the primary caregiver, and little or no involvement in the decision-making process. These risk factors fall into four interrelated categories: experience, attitude, personality, and family.",
"   </p>",
"   <p>",
"    Most of the information regarding these factors is derived from studies in adults, particularly the information about personality factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/22\">",
"     22",
"    </a>",
"    ]. However, increasing information regarding the etiology of homesickness in children and adolescents is becoming available.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Experience factors &mdash; In studies of children at summer camps and boarding schools, the experience factors most predictive of homesickness include [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/20,23-25\">",
"       20,23-25",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Little previous experience away from home",
"     </li>",
"     <li>",
"      Little or no previous experience at the camp or school (lack of familiarity, social support, and connections)",
"     </li>",
"     <li>",
"      Young age",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Age is often a proxy for experience, which is the more powerful predictor of homesickness. An eight-year-old child with lots of experience away from home, as an example, is at lower risk to become homesick at summer camp than a 12-year-old with little experience away from home. Experience is probably most valuable when it refines coping strategies. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Coping strategies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In contrast, previous experience away from home does not protect against homesickness in hospitalized children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/21\">",
"     21",
"    </a>",
"    ]. This observation suggests that the types of prior separation experiences shape expectations of future separations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/26\">",
"     26",
"    </a>",
"    ]. If early separations are negative experiences (as may be the case with foster placements and traumatic hospitalizations), then expectations of future separations may be negative, predisposing to homesickness, as discussed below.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Attitude factors &mdash; Beliefs that homesickness will be strong, coupled with negative first impressions and low expectations for the new environment, are powerful predictors of homesickness [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/20\">",
"       20",
"      </a>",
"      ]. Expectations of intense homesickness and negative experiences can become self-fulfilling prophecies. This was illustrated in a study of college freshmen in whom perceived absence of social support was a strong predictor of homesickness [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/24\">",
"       24",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A child's attitudes regarding separation are largely shaped by his or her history of time spent away from home. In a study of boys ages 8 to 16 who spent two weeks at camp, a combination of little previous experience away from home, low perceived control (discussed below), negative attitudes about the separation, and high expectations of homesickness accounted for nearly 70 percent of the variance in the intensity of homesickness [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Personality factors &mdash; Insecure attachment to primary caregivers is the most frequent personality risk factor for homesickness [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/20\">",
"       20",
"      </a>",
"      ]. In particular, children and adolescents with an anxious-ambivalent attachment style are likely to experience significant distress upon separation from home. Secure attachment, on the other hand, is associated with independence, a proclivity to explore, and social skills, all of which help young people adjust to a novel environment.",
"      <br/>",
"      <br/>",
"      Two other personality factors that increase the risk of homesickness in children and adolescents are low perceived control and anxious or depressed feelings in the months before a separation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/20\">",
"       20",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In adults, homesickness is predicted by low self-directedness, high harm avoidance, rigidity, and a \"fantasy\" or \"wishful thinking\" coping style [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/22,27\">",
"       22,27",
"      </a>",
"      ]. However, it is not clear whether these personality factors can be generalized to predict homesickness in children and adolescents. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Coping strategies'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Family&nbsp;factors &mdash; The family factor most predictive of homesickness is low \"decision control\" [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/20\">",
"       20",
"      </a>",
"      ]. A child who is forced by the parents to spend time away has very little decision control and is more likely to feel homesick upon separation.",
"      <br/>",
"      <br/>",
"      Other family factors that are weaker predictors of homesickness include caregivers who express anxiety or ambivalence about the separation (eg, \"Have a great time at camp. I don't know what I'll do without you\") and the presence of an unresolved negative life event [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/20\">",
"       20",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Conventional wisdom holds that a recent move, divorce, or similarly disruptive event might predispose a child to homesickness. However, this assumption is not supported by research [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/6\">",
"       6",
"      </a>",
"      ]. It is plausible that if children have had a chance to process the thoughts and emotions associated with a recent negative life event, they are not at increased risk for homesickness.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most children with homesickness present with withdrawn or depressed behaviors (eg, tearfulness) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/4,6,28\">",
"     4,6,28",
"    </a>",
"    ]. However, some children present atypically with externalizing behaviors (eg, anger, irritability, fighting, swearing, or destroying property) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/4,6,7,19\">",
"     4,6,7,19",
"    </a>",
"    ]. Other children and adolescents may present with somatic complaints.",
"   </p>",
"   <p>",
"    Of the children who somaticize their distress, only a small percentage present to a medical provider during the separation. In one study of 1412 consecutive visits to a summer camp health center by boys and girls aged 6 to 15 years, only 2 percent were classified as \"psychiatric\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Severe homesickness is associated with social problems, behavior problems, significant symptoms of depression and anxiety, coping deficits, and feelings of helplessness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/4,19,30-32\">",
"     4,19,30-32",
"    </a>",
"    ]. In academic settings, homesickness among adolescents and young adults can be associated with non-traumatic ailments, such as some aches and headaches (some of which are undoubtedly somatization) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/33-35\">",
"     33-35",
"    </a>",
"    ], academic difficulties [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/36-38\">",
"     36-38",
"    </a>",
"    ], absentmindedness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/33,34,36,37\">",
"     33,34,36,37",
"    </a>",
"    ], low self-esteem [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/37,39\">",
"     37,39",
"    </a>",
"    ],",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    obsessive thoughts and behaviors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. These factors are generally thought to be sequelae of homesickness, though some, such as social problems, can also be precipitants of homesickness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Clinical course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Longitudinal changes in the intensity of homesickness in children and adolescents have been studied in children and adolescents attending summer camp or requiring hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/4,6,9,19\">",
"     4,6,9,19",
"    </a>",
"    ]. In these populations, two trajectories of homesickness have been described:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The least homesick 80 percent of children begin their stay away from home with a low level of homesickness and maintain that level throughout their time away.",
"     </li>",
"     <li>",
"      The most homesick 20 percent of children begin their stay with an elevated level of homesickness, and the intensity increases over the course of several weeks, decreasing somewhat just before reuniting with their caregivers. With preventive interventions, this trajectory can be altered significantly [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Prevention'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The longitudinal course of homesickness for children and adolescents in other environments, such as refugee camps and foster homes, is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most useful diagnostic tool is simply asking the question, \"How homesick have you been feeling?\" Asking this question as part of a broader assessment of positive and negative moods, even on a daily basis, does not worsen symptoms of homesickness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/4\">",
"     4",
"    </a>",
"    ]. Quite the opposite: it puts adult caregivers in a better, more educated position to help.",
"   </p>",
"   <p>",
"    Homesickness may be comorbid with other behavioral, emotional, cognitive, and physical problems that warrant clinical attention. In addition, injuries or illnesses that occur during a separation may exacerbate or induce homesickness. Thus, it is important to exclude any contemporaneous but distinct physical ailments (eg, menstrual pain, influenza, otitis media), before attributing complaints to homesickness-related somatization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary care clinicians and parents can work together to prevent homesickness. Anticipatory guidance regarding homesickness can be provided during the following types of office visits:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Physical examination before camp or boarding school",
"     </li>",
"     <li>",
"      Establishment of care following a recent move (whether from a nearby town or from a different country)",
"     </li>",
"     <li>",
"      Prehospitalization evaluation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Anticipatory guidance should emphasize homesickness as a normal feeling and include strategies for prevention. Talking about homesickness does not cause homesickness, but helps children or adolescents to understand it and encourages them to utilize effective coping strategies while they are away [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Normalization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Separation from home is a normal developmental milestone, and an upcoming separation should be framed as a positive developmental experience, especially in the case of a planned separation. It is important for children and adolescents to know they are likely to miss certain aspects of home when they are away. Such feelings are normal and indicate there are things about home they love and to which they are attached.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Planned separations",
"    </span>",
"    &nbsp;&mdash;&nbsp;For planned separations (eg, boarding school, overnight camp), the primary care provider can:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Help families assess their child's readiness to spend time away from home. Knowing when the time is right for a planned separation is the cornerstone of homesickness prevention [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/40\">",
"       40",
"      </a>",
"      ]. If conversations with a parent or child suggest great anxiety about a planned separation, the parents may want to consider postponing the separation until they and child are more comfortable with it.",
"     </li>",
"     <li>",
"      Ask about previous separations; little previous experience away from home or with the particular new environment is predictive of homesickness. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Encourage practice time away from home, and encourage families to use the prevention strategies described briefly below and in greater detail in the table (",
"      <a class=\"graphic graphic_table graphicRef53354 \" href=\"mobipreview.htm?16/30/16877\">",
"       table 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/1\">",
"       1",
"      </a>",
"      ]. (The table can be printed and given to the parents as a reference.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Involve the child in the decision to spend time away from home",
"     </li>",
"     <li>",
"      Educate the child regarding the normalcy of homesickness",
"     </li>",
"     <li>",
"      Provide explicit instructions for coping",
"     </li>",
"     <li>",
"      Arrange for practice time away from home",
"     </li>",
"     <li>",
"      Practice letter writing with the child",
"     </li>",
"     <li>",
"      Work with the child to learn about the new environment",
"     </li>",
"     <li>",
"      Help the child get to know at least one person in the new environment",
"     </li>",
"     <li>",
"      Encourage the child to make new friends and seek the support of trusted adults",
"     </li>",
"     <li>",
"      Refrain from expressing anxious or ambivalent feelings about time away from home",
"     </li>",
"     <li>",
"      Maintain predictability and perspective about the time away",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assess the child's coping skills. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Coping strategies'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Strongly dissuade parents from making pick-up deals. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Pick-up deals'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Help families select a school or camp that is well matched to their child's interests, abilities, and developmental needs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Be sure the family has a plan for keeping in touch and they understand the school's or camp's policies regarding phone calls, e-mails, and visits.",
"     </li>",
"     <li>",
"      Help educate surrogate caregivers (eg, camp counselors, resident advisors) about the symptoms of homesickness and the most effective treatments and coping strategies. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Treatment'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Hospitalization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary care provider's role in the prevention and treatment of homesickness in hospitalized children depends upon whether the hospitalization is planned.",
"   </p>",
"   <p>",
"    For unplanned hospitalizations, the best approach may be to educate parents about the normalcy of adjustment difficulties encountered during hospitalizations, including homesickness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/21\">",
"     21",
"    </a>",
"    ]. The clinician can then coach the parents (",
"    <a class=\"graphic graphic_table graphicRef77922 \" href=\"mobipreview.htm?8/41/8861\">",
"     table 2",
"    </a>",
"    ) and hospital staff (",
"    <a class=\"graphic graphic_table graphicRef66701 \" href=\"mobipreview.htm?42/52/43852\">",
"     table 3",
"    </a>",
"    ) regarding ways to bolster the child's coping skills [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/1\">",
"     1",
"    </a>",
"    ]. (The homesickness prevention table can be printed and given to families as a reference.) Frequent, predictable contact between children and their primary caregivers is of paramount importance.",
"   </p>",
"   <p>",
"    For planned hospitalizations, anticipatory guidance should focus on creating positive attitudes about the hospitalization. Negative separation attitudes are a strong predictor of homesickness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/20\">",
"     20",
"    </a>",
"    ]. Thus,",
"   </p>",
"   <p>",
"    it is essential that parents and clinicians convey positive expectations about the helpful outcomes of the hospitalization. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Anecdotal evidence also suggests that orienting children to the hospital unit, to various medical procedures, and to the staff who will be caring for them reduces anxiety and minimizes homesickness. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Special populations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Displaced families",
"    </span>",
"    &nbsp;&mdash;&nbsp;For displaced families, it is helpful for the primary care provider to take the time to understand the circumstances of the recent move, how it affected the family members, and what the child misses most about where he or she used to live.",
"   </p>",
"   <p>",
"    Homesickness in displaced families is ameliorated by settling into and becoming a part of the new community [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/12\">",
"     12",
"    </a>",
"    ]. Parents and children alike benefit from social support, a sense of purpose (eg, work, school, sports), and feelings of security [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/32,42\">",
"     32,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pediatric health care providers can be instrumental in helping families to access the social, educational, and vocational opportunities in the new community. Connecting a newly displaced family with an established family of the same ethnicity or country of origin can be particularly helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Children with special health care needs",
"    </span>",
"    &nbsp;&mdash;&nbsp;For children with special mental, physical, or emotional needs, the primary care provider can help ensure the school or camp has the appropriate resources in place to support and care for the child. Elective interruptions in pharmacologic therapy for behavioral or psychiatric disorders (eg, \"drug holidays\") should be avoided during transitions to the new environment, but may be considered after a month or more of positive adjustment in the new setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     General guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treating homesickness involves the following strategies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/9,25\">",
"     9,25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normalizing homesickness (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Normalization'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Coaching children and adolescents on effective ways to cope (see",
"      <a class=\"local\" href=\"#H20\">",
"       'Coping strategies'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Working on building new social connections",
"     </li>",
"     <li>",
"      Helping children and adolescents maintain perspective on the duration of the separation",
"     </li>",
"     <li>",
"      Involving children and adolescents with the new environment in ways that foster their commitment to it",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Summer camp stays",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Coping strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies in children (aged 8 to 16 years) who spent two weeks at overnight summer camp have revealed several strategies that are effective for coping with homesickness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Distraction and social connection (eg, doing something fun, like playing with friends, to forget about homesick feelings)",
"     </li>",
"     <li>",
"      Contact with home (eg, writing a letter or looking at a family picture to feel closer to home)",
"     </li>",
"     <li>",
"      Social support (eg, going to see someone whom they can talk with to help them feel better)",
"     </li>",
"     <li>",
"      Optimism (eg, thinking about good things, like activities and friends, to feel better)",
"     </li>",
"     <li>",
"      Perspective (thinking that the time away is short, to make the time go by faster)",
"     </li>",
"     <li>",
"      Cognitive avoidance (trying not to think about home and loved ones to forget about homesickness)",
"     </li>",
"     <li>",
"      Vicarious social support (thinking about what loved ones would say to help)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Boys and girls report using these strategies with nearly equal frequency, except for social support, which girls report using more often than boys [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional studies have identified strategies that are not helpful (eg, relinquished control, fantasy, delinquent behavior, escape) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/27,30,31\">",
"     27,30,31",
"    </a>",
"    ]. Few children respond to the stress of separation from home with these approaches, but some, particularly boys, may try. The ineffective strategies are mentioned here so that caregivers can steer children away from them and toward something more helpful.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Relinquished control (eg, doing nothing because of a belief that nothing would help make things better)",
"     </li>",
"     <li>",
"      Fantasy or wishful thinking (eg, wishing that camp or school would end tomorrow)",
"     </li>",
"     <li>",
"      Doing something angry or mean to get sent home (aggressive or delinquent behavior)",
"     </li>",
"     <li>",
"      Escape (eg, trying to get home)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Contact with home",
"    </span>",
"    &nbsp;&mdash;&nbsp;Professional opinions are mixed and research is scant regarding phone calls and e-mail contact during planned separations. The kind and frequency of child-caregiver contact should ultimately be dictated by the goals of the separation.",
"   </p>",
"   <p>",
"    At summer camps, for example, anecdotal evidence suggests that phone calls, and to a lesser extent instant messaging, exacerbate homesickness during stays of less than four weeks. Such real-time correspondence also erodes the burgeoning independence that camps and trips are designed to nurture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/43\">",
"     43",
"    </a>",
"    ]. Thus, parents should be strongly discouraged from insisting they talk with their homesick child during a short stay away. It is likely that such contact will increase the distress for both parties.",
"   </p>",
"   <p>",
"    Old-fashioned letters may be the best way to maintain contact with home. Letters lack the emotionally evocative quality of a phone call, and they require narrative reflection, which promotes understanding of one's experience [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/44\">",
"     44",
"    </a>",
"    ]. Such reflection may even serve a therapeutic function, as does keeping a journal.",
"   </p>",
"   <p>",
"    During longer separations (eg, camp stays longer than four weeks, boarding school, college), scheduled phone calls and one-way e-mails (from parent to child) do not seem to interfere with the child's enjoyment of the experience, although such contact still may be evocative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/12\">",
"     12",
"    </a>",
"    ]. In college students, scheduled phone calls and e-mails from parents are associated with decreased risk of homesickness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/25\">",
"     25",
"    </a>",
"    ]. Although no studies have been conducted in boarding school students, it is reasonable to assume the same conclusion applies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Pick-up deals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Under no circumstances of planned, recreational separations from home should parents make a \"pick-up deal\" with their child [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/1,41,45\">",
"     1,41,45",
"    </a>",
"    ]. Promising, \"If you don't like it, I'll come pick you up,\" reduces the child's likelihood of success for several reasons.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The subtext of such deals is, \"I have so little confidence in your ability to cope with this normal response to separation that I believe the only solution is for me to rescue you.\" Such expressions of anxiety and doubt contradict the recommended expressions of optimism and confidence outlined in the prevention strategies (",
"      <a class=\"graphic graphic_table graphicRef53354 \" href=\"mobipreview.htm?16/30/16877\">",
"       table 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Such deals plant the seeds of homesickness by giving young people the expectation that they will not like the new place. Negative separation attitudes are powerful predictors of homesickness [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Such deals prevent the development of effective coping by pointing young people toward an escape route.",
"     </li>",
"     <li>",
"      Such deals paralyze surrogate caregivers who, after enthusiastic support and coaching, may be faced with a child who says, \"My parents said that if I didn't like it here, they would come to get me.\" Parents are then faced with two equally unsatisfactory choices:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Fulfill their promise, pick the child up, and deprive him or her of a wonderful opportunity to grow and develop",
"     </li>",
"     <li>",
"      Renege on their promise and suffer an erosion of trust in their relationship with the child",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Hospital stays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Research examining the association between contact with home and adjustment in hospitalized children is scarce. A review of these studies suggests that the quality, rather than the quantity, of child-caregiver contact is associated with adjustment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because the goal of hospitalization is good health, rather than increased self-reliance, a different approach to child-caregiver contact is warranted than for children at camp. Whereas minimal contact is encouraged during a stay at camp, maximal contact (both in-person and electronic) is appropriate for children hospitalized with medical problems. During psychiatric hospitalizations, staff can advise parents on the appropriate quality and quantity of child-caregiver contact. Indeed, this contact may be an integral part of treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     RESOURCES FOR FAMILIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resources for families are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef77248 \" href=\"mobipreview.htm?25/18/25899\">",
"     table 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39607/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Homesickness is defined as the distress and functional impairment caused by an actual or anticipated separation from home. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for homesickness include lack of experience with separation or the new environment, negative attitudes toward the separation or the environment, insecure attachment to the primary caregiver, and little or no involvement in the decision-making process. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most children with homesickness present with withdrawn or depressed behaviors. However, some present with somatic complaints or externalizing behaviors (eg, anger, irritability, fighting, swearing, or destroying property). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Moderate/severe",
"      </span>",
"      homesickness typically does not improve spontaneously, but can be largely prevented. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of homesickness is made by asking the question, \"How homesick have you been feeling?\" (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Primary care clinicians and parents can work together to prevent homesickness during planned separations (",
"      <a class=\"graphic graphic_table graphicRef53354 \" href=\"mobipreview.htm?16/30/16877\">",
"       table 1",
"      </a>",
"      ) or hospitalizations (",
"      <a class=\"graphic graphic_table graphicRef77922 \" href=\"mobipreview.htm?8/41/8861\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Planned separations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Hospitalization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of homesickness involves normalizing homesickness, teaching effective coping strategies, building social connections, helping children maintain perspective, and fostering commitment to the new environment. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'General guidelines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Effective coping strategies include distraction, social connection, remote contact with home (eg, writing a letter, looking at a photograph), social support, optimism, perspective, cognitive avoidance, and vicarious social support. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Coping strategies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Coping strategies that are ineffective include relinquished control, fantasy, delinquent behavior, and escape. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Coping strategies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The kind and frequency of child-caregiver contact during separation depends upon the goals of the separation. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Contact with home'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that parents be strongly discouraged from making \"pick-up deals\" with their children during planned, recreational separations (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Pick-up deals'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39607/abstract/1\">",
"      Thurber CA, Walton E, American Academy of Pediatrics Council on School Health. Preventing and treating homesickness. Pediatrics 2007; 119:192.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, American Psychiatric Association., Washington, DC 1994.",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. The Classification of Child and Adolescent Mental Disorders in Primary Care: Diagnostic and Statistical Manual for Primary Care (DSM-PC) Child and Adolescent Version. American Academy of Pediatrics, Elk Grove Village, IL 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39607/abstract/4\">",
"      Thurber CA. The phenomenology of homesickness in boys. J Abnorm Child Psychol 1999; 27:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39607/abstract/5\">",
"      van Tilburg, MA, De Waal, K, Vingerhoets, AJ, van Heck, GL. Homesickness and separation anxiety: Are they different? Psychol Stud (Mysore) 1999; 44:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39607/abstract/6\">",
"      Thurber CA. The experience and expression of homesickness in preadolescent and adolescent boys. Child Dev 1995; 66:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39607/abstract/7\">",
"      Pravda, M. Homesickness: dispelling the myths. Camping Magazine 1995; 67:18.",
"     </a>",
"    </li>",
"    <li>",
"     Thurber, CA. Children's coping with homesickness: phenomenology and intervention. In: Psychological Aspects of Geographical Moves: Homesickness and Acculturation Stress, van Tilburg, MA, Vingerhoets, AJ (Eds), Tilburg University Press, Tilburg, Netherlands 1997. p.143.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39607/abstract/9\">",
"      Thurber CA. Multimodal homesickness prevention in boys spending 2 weeks at a residential summer camp. J Consult Clin Psychol 2005; 73:555.",
"     </a>",
"    </li>",
"    <li>",
"     Fisher, S. Leaving home: Homesickness and the psychological effects of change and transition. In: Handbook of Life Stress, Cognition, and Health, Fisher S, Reason J (Eds), John Wiley and Sons, New York, NY 1988. p.41.",
"    </li>",
"    <li>",
"     Eisenbruch, M. Cultural bereavement and homesickness. In: On the Move: The Psychology of Change and Transition, Fisher S, Cooper CL (Eds), John Wiley and Sons, New York, NY 1990. p.191.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39607/abstract/12\">",
"      Eurelings-Bontekoe, EH, Brouwers, EP, Verschuur, MJ. Homesickness among foreign employees of a multinational high-tech company in the Netherlands. Environ Behav 2000; 32:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39607/abstract/13\">",
"      Griffin-Pierce T. \"When I am lonely the mountains call me\": the impact of sacred geography on Navajo psychological well being. Am Indian Alsk Native Ment Health Res 1997; 7:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39607/abstract/14\">",
"      Sandal GM, Endresen IM, Vaernes R, Ursin H. Personality and coping strategies during submarine missions. Mil Psychol 1999; 11:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39607/abstract/15\">",
"      Schreier AR, Abramovitch H. American medical students in Israel: stress and coping. Med Educ 1996; 30:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39607/abstract/16\">",
"      Stroebe M, van Vliet T, Hewstone M, Willis H. Homesickness among students in two cultures: antecedents and consequences. Br J Psychol 2002; 93:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39607/abstract/17\">",
"      Tikoo M. The 1989-90 migration of Kashmiri Pandits: focus on children. Psychol Rep 1994; 75:259.",
"     </a>",
"    </li>",
"    <li>",
"     Vernberg, EM, Field, T. Transitional stress in children and young adolescents moving to new environments. In: On the Move: The Psychology of Change and Transition, Fisher S, Cooper CL (Eds), John Wiley and Sons, New York, NY 1990. p.127.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39607/abstract/19\">",
"      Thurber CA, Sigman MD, Weisz JR, Schmidt CK. Homesickness in preadolescent and adolescent girls: risk factors, behavioral correlates, and sequelae. J Clin Child Psychol 1999; 28:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39607/abstract/20\">",
"      Thurber CA, Sigman MD. Preliminary models of risk and protective factors for childhood homesickness: review and empirical synthesis. Child Dev 1998; 69:903.",
"     </a>",
"    </li>",
"    <li>",
"     Thurber, CA, Patterson, DR, Mount, K. Children's adjustment to hospitalization: Is homesickness a factor? Children's Health Care. In press.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39607/abstract/22\">",
"      Verschuur, MJ, Eurelings-Bontekoe, EH, Spinhoven, P, Duijsens, IJ. Homesickness, temperament and character. Pers Individ Dif 2003; 35:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39607/abstract/23\">",
"      Kazantzis, N, Flett, R. Family cohesion and age as determinants of homesickness in university students. Soc Behav Pers 1998; 26:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39607/abstract/24\">",
"      Urani, MA, Miller, SA, Johnson, JE, Petzel, TP. Homesickness in socially anxious first year college students. Coll Stud J 2003; 37:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39607/abstract/25\">",
"      Tognoli, J. Leaving home: Homesickness, place attachment, and transition among residential college students. J Coll Student Psychother 2003; 18:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39607/abstract/26\">",
"      Alapack, MC, Alapack, RJ. The hinge of the door to authentic adulthood: A Kierkegaardian inspired synthesis of the meaning of leaving home. J Phenomen Psychol 1984; 15:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39607/abstract/27\">",
"      van Tilburg, MA, Vingerhoets, AJ, van Heck, GL. Determinants of homesickness chronicity: Coping and personality. Pers Individ Dif 1999; 27:531.",
"     </a>",
"    </li>",
"    <li>",
"     Hamessley, ML. Handbook for Camp Nurses and Other Camp Health Workers. The Tiresias Press, New York, NY 1987.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39607/abstract/29\">",
"      Asnes RS, Feldman B, Gersony WM, et al. The medical care of children at summer camps. An evaluation of 1,412 infirmary visits. Am J Dis Child 1974; 128:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39607/abstract/30\">",
"      Thurber CA, Weisz JR. \"You can try or you can just give up\": the impact of perceived control and coping style on childhood homesickness. Dev Psychol 1997; 33:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39607/abstract/31\">",
"      Thurber, CA, Weisz, JR. Describing boys' coping with homesickness using a two-process model of control. Anxiety Stress Coping 1997; 10:181.",
"     </a>",
"    </li>",
"    <li>",
"     Vernberg, EM, Randall, CJ. Homesickness after relocation during early adolescence. In: Psychological Aspects of Geographical Moves: Homesickness and Acculturation Stress. van Tilburg, MA, Vingerhoets, AJ, (Eds), Tilburg University Press, Tilburg, Netherlands 1997. p.165.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39607/abstract/33\">",
"      Fisher S, Hood B. The stress of the transition to university: a longitudinal study of psychological disturbance, absent-mindedness and vulnerability to homesickness. Br J Psychol 1987; 78 ( Pt 4):425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39607/abstract/34\">",
"      Fisher S, Hood B. Vulnerability factors in the transition to university: self-reported mobility history and sex differences as factors in psychological disturbance. Br J Psychol 1988; 79 ( Pt 3):309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39607/abstract/35\">",
"      Fisher, S, Frazer, N, Murray, K. Homesickness and health in boarding school children. J Environ Psychol 1986; 6:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39607/abstract/36\">",
"      Burt, CD. Concentration and academic ability following the transition to university: An investigation of the effects of homesickness. J Environ Psychol 1993; 13:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39607/abstract/37\">",
"      Fisher, S, Murray, K, Frazer, NA. Homesickness, health, and efficiency in first year students. J Environ Psychol 1985; 5:181.",
"     </a>",
"    </li>",
"    <li>",
"     Furnham, A, Bochner, S. Culture Shock: Psychological Reactions to Unfamiliar Environments, Methuen, London 1986.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39607/abstract/39\">",
"      Hojat M, Herman MW. Adjustment and psychosocial problems of Iranian and Filipino physicians in the U.S. J Clin Psychol 1985; 41:130.",
"     </a>",
"    </li>",
"    <li>",
"     Thurber, CA, Malinowski, JC. The Summer Camp Handbook: Everything You Need to Know to Find, Choose, and Get Ready for Overnight Camp-and Skip the Homesickness, Perspective Publishing, Los Angeles 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39607/abstract/41\">",
"      American Academy of Pediatrics Committee on School Health, American Academy of Pediatrics Section on School Health. Health appraisal guidelines for day camps and resident camps. American Academy of Pediatrics Committee on School Health . Pediatrics 2005; 115:1770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39607/abstract/42\">",
"      Berno T, Ward C. Innocence abroad: a pocket guide to psychological research on tourism. Am Psychol 2005; 60:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39607/abstract/43\">",
"      Thurber, CA. The digital umbilical. Camping Magazine 2006; 79:44.",
"     </a>",
"    </li>",
"    <li>",
"     Britton, BK, Pellegrini, AD. Narrative Thought and Narrative Language, Lawrence Erlbaum Associates, Hillsdale, NJ 1990.",
"    </li>",
"    <li>",
"     Thurber, CA. Avoiding pick-up deals. Paper presented at: American Camp Association National Conference, Chicago, IL 2006.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 625 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-115.25.216.6-A89CC6B8BD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_43_39607=[""].join("\n");
var outline_f38_43_39607=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Clinical course",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Normalization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Planned separations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Hospitalization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Special populations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Displaced families",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Children with special health care needs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      General guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Summer camp stays",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Coping strategies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Contact with home",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Pick-up deals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Hospital stays",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      RESOURCES FOR FAMILIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/625\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/625|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/30/16877\" title=\"table 1\">",
"      Homesickness prevention for planned separation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/41/8861\" title=\"table 2\">",
"      Homesickness prevention for hospitalized children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/52/43852\" title=\"table 3\">",
"      Homesickness prevention tips for hospital staff",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/18/25899\" title=\"table 4\">",
"      Homesickness resources for families",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_43_39608="Approach to the patient with retiform (angulated) purpura";
var content_f38_43_39608=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the patient with retiform (angulated) purpura",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/43/39608/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/43/39608/contributors\">",
"     Robert Kelly, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/43/39608/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/43/39608/contributors\">",
"     Erik Stratman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/43/39608/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/43/39608/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/43/39608/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H429795\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Purpura are nonblanchable, hemorrhagic skin lesions that result from the leakage of red blood cells into the skin. The term &ldquo;retiform purpura&rdquo; describes lesions that demonstrate an angulated or branched configuration (",
"    <a class=\"graphic graphic_picture graphicRef53920 graphicRef61719 graphicRef65011 \" href=\"mobipreview.htm?38/44/39625\">",
"     picture 1A-C",
"    </a>",
"    ). Retiform purpura can occur in a variety of disorders; thus, identifying the underlying cause is an important component of patient management.",
"   </p>",
"   <p>",
"    The potential causes of retiform purpura and the approach to the assessment of patients with these lesions will be reviewed here. Additional details on the pathogenesis, clinical manifestations, and treatment of disorders that present with retiform purpura are discussed elsewhere in UpToDate. (See",
"    <a class=\"local\" href=\"#H425705\">",
"     'Associated disorders'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H425698\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retiform purpura develop as a consequence of complete vascular occlusion and vascular damage involving blood vessels in the skin. As in livedo reticularis (",
"    <a class=\"graphic graphic_picture graphicRef79545 graphicRef61842 \" href=\"mobipreview.htm?17/33/17941\">",
"     picture 2A-B",
"    </a>",
"    ) and livedo racemosa (",
"    <a class=\"graphic graphic_picture graphicRef64023 \" href=\"mobipreview.htm?35/42/36512\">",
"     picture 3",
"    </a>",
"    ) (additional disorders associated with vasculopathy or vasculitis), the angulated or branched shape of retiform purpura reflects the vascular architecture in the skin (see",
"    <a class=\"local\" href=\"#H249255\">",
"     'Differential diagnosis'",
"    </a>",
"    below). The hemorrhagic appearance of purpura results from the local extravasation of red blood cells. Often, skin necrosis due to infarction is present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H425705\">",
"    <span class=\"h2\">",
"     Associated disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple noninflammatory and inflammatory vasculopathic disorders may present with retiform purpura. Lesions may occur in the setting of intravascular abnormalities in which thrombi, proteins, or emboli obstruct cutaneous vessels, or may involve direct damage to vessel walls, as occurs in vasculitis, calciphylaxis, and some severe opportunistic infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H933744\">",
"    <span class=\"h3\">",
"     Intravascular abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, thrombosis, intravascular deposition of abnormal proteins, and embolic phenomena may result in the development of retiform purpura.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H933761\">",
"    <span class=\"h4\">",
"     Thrombotic and coagulopathic disorders",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Disseminated intravascular coagulation (DIC) &ndash;",
"      </strong>",
"      DIC may occur in the setting of sepsis, organ failure, trauma, malignancy, and other severe disorders, such as homozygous C deficiency in neonates. Patients with DIC exhibit clinical manifestations of both hemorrhage and thrombosis. Purpura may be widespread (",
"      <strong>",
"       purpura fulminans",
"      </strong>",
"      ), and the disorder can be fatal",
"      <strong>",
"      </strong>",
"      (",
"      <a class=\"graphic graphic_picture graphicRef61719 graphicRef74453 \" href=\"mobipreview.htm?35/34/36392\">",
"       picture 1B, 1D",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39608/abstract/1,2\">",
"       1,2",
"      </a>",
"      ]. Meningococcemia is a common cause of DIC. (See",
"      <a class=\"local\" href=\"#H136707379\">",
"       'Life-threatening emergency (purpura fulminans)'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/20/25929?source=see_link\">",
"       \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/31/8697?source=see_link\">",
"       \"Disseminated intravascular coagulation in infants and children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/52/841?source=see_link&amp;anchor=H10#H10\">",
"       \"Protein C deficiency\", section on 'Neonatal purpura fulminans'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Antiphospholipid syndrome &ndash;",
"      </strong>",
"      The mechanisms through which antiphospholipid antibodies in serum lead to thrombosis are not completely understood (",
"      <a class=\"graphic graphic_picture graphicRef65011 graphicRef65890 \" href=\"mobipreview.htm?16/26/16806\">",
"       picture 1C, 1E",
"      </a>",
"      ). Common additional features of this disorder include livedo reticularis, cutaneous infarctions or ulceration, recurrent venous or arterial thromboses, and fetal loss [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39608/abstract/3-6\">",
"       3-6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23034?source=see_link\">",
"       \"Clinical manifestations of the antiphospholipid syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27096?source=see_link\">",
"       \"Diagnosis of the antiphospholipid syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Thrombotic thrombocytopenic purpura (TTP) &ndash;",
"      </strong>",
"      TTP is a rare idiopathic disorder characterized by microangiopathic hemolytic anemia, thrombocytopenia, neurologic abnormalities, and renal disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39608/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. Non-retiform purpura related to thrombocytopenia are often present. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29721?source=see_link\">",
"       \"Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       Warfarin",
"      </a>",
"      <strong>",
"       -induced skin necrosis &ndash;",
"      </strong>",
"      This condition results from the development of a transient hypercoagulable state secondary to warfarin-induced reduction of protein C (an anticoagulant) early in the course of warfarin therapy. Purpura are extensive and demonstrate a predilection for areas with significant adipose tissue (eg, thighs, buttocks, abdomen, breasts) (",
"      <a class=\"graphic graphic_picture graphicRef51999 graphicRef62792 graphicRef80462 \" href=\"mobipreview.htm?37/62/38889\">",
"       picture 4A-C",
"      </a>",
"      ). Patients with underlying protein C deficiency are at increased risk for this disorder [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39608/abstract/9-11\">",
"       9-11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/52/841?source=see_link&amp;anchor=H13#H13\">",
"       \"Protein C deficiency\", section on 'Warfarin-induced skin necrosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       Heparin",
"      </a>",
"      <strong>",
"       -induced thrombocytopenia &ndash;",
"      </strong>",
"      Heparin&ndash;induced thrombocytopenia is an immune-mediated disorder that usually occurs 5 to 10 days after treatment with heparin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39608/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]. Necrotic, purpuric lesions may occur at sites of subcutaneous heparin injection or in areas distant from the site of administration (heparin necrosis). Patients may also exhibit large vessel venous or arterial thromboses",
"      <strong>",
"      </strong>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39608/abstract/12,13\">",
"       12,13",
"      </a>",
"      ].",
"      <strong>",
"      </strong>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40890?source=see_link\">",
"       \"Heparin-induced thrombocytopenia\"",
"      </a>",
"      .) Heparin necrosis may also occur in the absence of thrombocytopenia (",
"      <a class=\"graphic graphic_picture graphicRef63715 graphicRef71259 \" href=\"mobipreview.htm?40/9/41112\">",
"       picture 5A-B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Paroxysmal nocturnal hemoglobinuria &ndash;",
"      </strong>",
"      This rare disorder due to a defect in the PIG-A gene is characterized by venous thrombosis and hemolysis resulting in hemoglobinuria. In addition to retiform purpura, patients may present with bullae, petechiae, or ulcerations. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/50/14121?source=see_link\">",
"       \"Clinical manifestations of paroxysmal nocturnal hemoglobinuria\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/43/17082?source=see_link\">",
"       \"Diagnosis and treatment of paroxysmal nocturnal hemoglobinuria\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H933953\">",
"    <span class=\"h4\">",
"     Intravascular protein deposition",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Cryoglobulinemia (type I) &ndash;",
"      </strong>",
"      In type 1 cryoglobulinemia, retiform purpura develop in the setting of blood hyperviscosity and blood vessel occlusion due to the precipitation of immunoglobulins in response to cold. Lesions are often found on acral areas; livedo reticularis, acrocyanosis, and infarction may also be present [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39608/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/63/22522?source=see_link\">",
"       \"Overview of cryoglobulins and cryoglobulinemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Cryofibrinogenemia &ndash;",
"      </strong>",
"      Cryofibrinogenemia results from the precipitation of fibrin, fibrinogen,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fibronectin in plasma during cold exposure. Like cryoglobulinemia, retiform purpura are often acral. Additional findings may include livedo reticularis and painful ulcerations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39608/abstract/16\">",
"       16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7576?source=see_link\">",
"       \"Cryofibrinogenemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Paraproteinemia &ndash;",
"      </strong>",
"      Rarely, paraproteinemia induces blood hyperviscosity and plugging of vessels, resulting in the development of retiform purpura [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39608/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H933961\">",
"    <span class=\"h4\">",
"     Embolic disorders",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Cholesterol emboli &ndash;",
"      </strong>",
"      Retiform purpura associated with cholesterol embolization are often located on the distal lower extremities (",
"      <a class=\"graphic graphic_picture graphicRef69150 \" href=\"mobipreview.htm?25/43/26290\">",
"       picture 6",
"      </a>",
"      ). Other cutaneous features include livedo reticularis, gangrene, cutaneous infarction, ulceration, and cyanosis (blue toe syndrome). Renal, gastrointestinal, ocular, or central nervous system abnormalities may also occur. Many patients exhibit eosinophilia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39608/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/15/31994?source=see_link\">",
"       \"Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Septic emboli &ndash;",
"      </strong>",
"      Purpura due to septic emboli most commonly occur in the setting of infectious endocarditis, but may also occur in other forms of septicemia. Lesions typically are acral. Other cutaneous findings, such as petechiae or Janeway lesions, may be present. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/24/41352?source=see_link\">",
"       \"Diagnostic approach to infective endocarditis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Atrial myxoma &ndash;",
"      </strong>",
"      Atrial myxomas are benign tumors of the heart. Tumor fragments may embolize systemically and patients often exhibit constitutional symptoms (eg, fever, weight loss) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39608/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. As with other embolic phenomena, lesions are often acral. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/32/17930?source=see_link&amp;anchor=H14#H14\">",
"       \"Cardiac tumors\", section on 'Myxomas'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Other &ndash;",
"      </strong>",
"      Emboli resulting in vessel occlusion and retiform purpura may also occur in nonbacterial thrombotic endocarditis (marantic endocarditis, Libman-Sacks endocarditis) and hypereosinophilic syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H933969\">",
"    <span class=\"h3\">",
"     Vessel wall pathology",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Vasculitis &ndash;",
"      </strong>",
"      Vasculitis is defined by the presence of an inflammatory infiltrate invading blood vessel walls and fibrinoid necrosis (fibrin deposition within vessel walls or lumina). Retiform purpura are classically seen in vasculitides that affect medium-sized cutaneous vessels. In contrast, small vessel vasculitis most often presents with non-retiform palpable purpura. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/15/4345?source=see_link&amp;anchor=H606549#H606549\">",
"       \"Evaluation of adults with cutaneous lesions of vasculitis\", section on 'Diagnostic criteria'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/15/4345?source=see_link&amp;anchor=H1117785#H1117785\">",
"       \"Evaluation of adults with cutaneous lesions of vasculitis\", section on 'Etiology'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Examples of vasculitides that may present with retiform purpura include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Septic vasculitis &ndash;",
"      </strong>",
"      Vasculitis presenting with retiform purpura may occur in meningococcemia, gonococcemia, pseudomonal or streptococcal septicemia, rickettsial infections, infective endocarditis, and other infectious states [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39608/abstract/22-24\">",
"       22-24",
"      </a>",
"      ]. In the setting of severe infection, retiform purpura may also result from disseminated intravascular coagulation (DIC). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/52/37704?source=see_link\">",
"       \"Clinical manifestations of meningococcal infection\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H136707379\">",
"       'Life-threatening emergency (purpura fulminans)'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Vasculitis related to autoimmune disease or primary systemic vasculitis",
"      </strong>",
"      (eg, rheumatoid arthritis, systemic lupus erythematosus, cutaneous or systemic polyarteritis nodosa, granulomatosis with polyangiitis [formerly known as Wegener&rsquo;s granulomatosis], Churg-Strauss syndrome). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/15/4345?source=see_link&amp;anchor=H1117785#H1117785\">",
"       \"Evaluation of adults with cutaneous lesions of vasculitis\", section on 'Etiology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Cryoglobulinemic vasculitis (cryoglobulinemia types 2 and 3)",
"      </strong>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39608/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/63/22522?source=see_link\">",
"       \"Overview of cryoglobulins and cryoglobulinemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34040?source=see_link\">",
"       \"Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Opportunistic infections &ndash;",
"      </strong>",
"      In immunocompromised patients, invasion of infectious organisms into blood vessel walls and lumina may result in vessel occlusion and the development of retiform purpura. This phenomenon may be seen in association with pseudomonal infection (ecthyma gangrenosum (",
"      <a class=\"graphic graphic_picture graphicRef53544 \" href=\"mobipreview.htm?37/55/38771\">",
"       picture 7",
"      </a>",
"      )), invasive fungal infections (eg, mucormycosis, aspergillosis, candidiasis), disseminated strongyloidiasis, and in lepromatous leprosy as a feature of the Lucio phenomenon. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/27/14775?source=see_link&amp;anchor=H6#H6\">",
"       \"Pseudomonas aeruginosa bacteremia and endocarditis\", section on 'Ecthyma gangrenosum'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/46/6890?source=see_link\">",
"       \"Mucormycosis (zygomycosis)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34616?source=see_link\">",
"       \"Epidemiology and clinical manifestations of invasive aspergillosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/59/11193?source=see_link\">",
"       \"Strongyloidiasis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/43/18105?source=see_link&amp;anchor=H2780058#H2780058\">",
"       \"Epidemiology, microbiology, clinical manifestations, and diagnosis of leprosy\", section on 'Type 2 reaction'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Calciphylaxis",
"      </strong>",
"      (",
"      <a class=\"graphic graphic_picture graphicRef66308 \" href=\"mobipreview.htm?17/48/18180\">",
"       picture 8",
"      </a>",
"      )",
"      <strong>",
"       &ndash;",
"      </strong>",
"      Calciphylaxis is a",
"      <strong>",
"       life-threatening disorder",
"      </strong>",
"      characterized by the deposition of calcium in blood vessels. This condition almost always occurs in the setting of advanced chronic renal failure. Extremely painful retiform purpura may develop; lesions frequently occur in adipose-rich areas, such as the buttocks, abdomen, or thighs. Other cutaneous features include livedo reticularis and cutaneous infarction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39608/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/42/15017?source=see_link\">",
"       \"Calciphylaxis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Primary hyperoxaluria &ndash;",
"      </strong>",
"      Primary hyperoxaluria is a rare, autosomal recessive metabolic disorder that results in the overproduction of oxalate. Patients develop renal stones and calcium oxalate deposits in multiple tissues, including blood vessels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39608/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]. The cutaneous lesions of primary hyperoxaluria are similar to calciphylaxis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/55/12154?source=see_link\">",
"       \"Primary hyperoxaluria\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8555196\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Livedoid vasculopathy &ndash;",
"      </strong>",
"      Livedoid vasculopathy (also known as atrophie blanche) is a cutaneous disease characterized by the development of fibrin thrombi in cutaneous vessels. The condition typically manifests as recurrent, small, purpuric, ulcerative lesions on the distal lower extremities (",
"      <a class=\"graphic graphic_picture graphicRef52262 \" href=\"mobipreview.htm?26/52/27458\">",
"       picture 9",
"      </a>",
"      ). Pale scars with stippled telangiectasia are left after healing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39608/abstract/29-31\">",
"       29-31",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/61/6103?source=see_link\">",
"       \"Livedoid vasculopathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Pyoderma gangrenosum &ndash;",
"      </strong>",
"      Pyoderma gangrenosum is an inflammatory skin disorder that typically presents with ulceration. Infrequently, it may present with retiform purpura that evolve into ulcers that exhibit the violaceous edges classically seen in this disorder. Pyoderma gangrenosum may occur in association with inflammatory bowel disease, inflammatory arthritis, or hematologic malignancies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39608/abstract/32-34\">",
"       32-34",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/17/2328?source=see_link\">",
"       \"Pyoderma gangrenosum: Pathogenesis, clinical features, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Thrombotic vasculopathy or vasculitis due to levamisole-contaminated cocaine &ndash;",
"      </strong>",
"      Use of cocaine contaminated with levamisole has been associated with the development of tender purpura on the ears and necrotic, retiform purpura on the trunk or extremities (",
"      <a class=\"graphic graphic_picture graphicRef74436 graphicRef77067 graphicRef55590 \" href=\"mobipreview.htm?11/6/11370\">",
"       picture 10A-C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/15/4345?source=see_link&amp;anchor=H810822#H810822\">",
"       \"Evaluation of adults with cutaneous lesions of vasculitis\", section on 'Vasculitis due to levamisole-contaminated cocaine'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H425712\">",
"    <span class=\"h1\">",
"     PATIENT ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in the assessment of patients with retiform purpura is to exclude acute life-threatening disease. After that, a thorough history and physical examination can provide valuable clues for diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H136707379\">",
"    <span class=\"h2\">",
"     Life-threatening emergency (purpura fulminans)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute, widespread retiform purpura, also known as purpura fulminans, can occur in the setting of acute disseminated intravascular coagulation (DIC) due to sepsis, trauma, malignancy, obstetric emergencies, neonatal homozygous C deficiency, and other causes (",
"    <a class=\"graphic graphic_picture graphicRef57103 graphicRef53920 graphicRef52107 \" href=\"mobipreview.htm?37/37/38489\">",
"     picture 1A, 1F-G",
"    </a>",
"    ). Patients with purpura fulminans are often acutely ill, and frequently have signs or symptoms of shock. A diagnosis of DIC can be confirmed with serologic tests. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/20/25929?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/31/8697?source=see_link&amp;anchor=H20#H20\">",
"     \"Disseminated intravascular coagulation in infants and children\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mortality from acute DIC is high, and early management and identification of the underlying cause is essential. Sepsis is a common cause of DIC, and obtaining of blood, urine, and skin biopsy tissue cultures is appropriate. The treatment of DIC is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/20/25929?source=see_link&amp;anchor=H25#H25\">",
"     \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/31/8697?source=see_link&amp;anchor=H29#H29\">",
"     \"Disseminated intravascular coagulation in infants and children\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The possibility of life-threatening infections in the absence of DIC should also be considered in patients with retiform purpura, particularly in immunocompromised patients. (See",
"    <a class=\"local\" href=\"#H933969\">",
"     'Vessel wall pathology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H425719\">",
"    <span class=\"h2\">",
"     Patient history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medical history should be obtained with particular emphasis on factors that may assist with the identification of the underlying disorder, such as:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptoms of infection",
"     </li>",
"     <li>",
"      History of thrombotic disease, which may suggest antiphospholipid syndrome or genetic disorders characterized by hypercoagulability",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Deep venous thromboses or pulmonary emboli",
"     </li>",
"     <li>",
"      Recurrent spontaneous abortions",
"     </li>",
"     <li>",
"      Family history of thrombotic events",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Drug history, which may suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      -induced skin necrosis,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      -induced thrombocytopenia, or vasculopathy or vasculitis due to levamisole-contaminated cocaine",
"     </li>",
"     <li>",
"      History of organ dysfunction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Renal failure, which may suggest calciphylaxis",
"     </li>",
"     <li>",
"      History of heart murmur or valve dysfunction, which may suggest endocarditis or atrial myxoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      History of myeloproliferative conditions and blood dyscrasias, which may suggest occlusion related to blood hyperviscosity",
"     </li>",
"     <li>",
"      History of hyperlipidemia, ischemic heart disease, or peripheral vascular disease, which may suggest atheroemboli",
"     </li>",
"     <li>",
"      History of or symptoms of connective tissue disease or primary systemic vasculitis, which may suggest vasculitis related to rheumatoid arthritis, systemic lupus erythematosus, polyarteritis nodosa, granulomatosis with polyangiitis (formerly known as Wegener&rsquo;s granulomatosis), or Churg-Strauss syndrome",
"     </li>",
"     <li>",
"      Exacerbation of lesions with cold exposure, which may suggest cryoglobulinemia or cryofibrinogenemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H425726\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A full physical examination should be performed. The skin examination should include an assessment of the appearance, palpability, and distribution of purpuric lesions, as well as the presence of other cutaneous findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H428237\">",
"    <span class=\"h3\">",
"     Lesion color and palpability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retiform purpura are typically dark red to dark purple in color, and unlike erythema associated with nonpurpuric inflammatory skin disorders, the color of purpura fails to blanch under pressure. Diascopy (application of pressure to a lesion with a glass slide) can be used to confirm the nonblanchable nature of a purpuric lesion. With time and the breakdown of extravasated hemoglobin, purpura may develop a greenish or yellow-brown coloration.",
"   </p>",
"   <p>",
"    In some cases, early lesions demonstrate significant erythema, which suggests the presence of a primary inflammatory process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39608/abstract/35\">",
"     35",
"    </a>",
"    ]. These inflammatory lesions are frequently palpable, and may appear in the following conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Vasculitis",
"     </li>",
"     <li>",
"      Livedoid vasculopathy",
"     </li>",
"     <li>",
"      Chilblains",
"     </li>",
"     <li>",
"      Pyoderma gangrenosum",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Retiform purpura associated with noninflammatory intravascular occlusive vasculopathies may be palpable or macular, but typically lack prominent erythema (see",
"    <a class=\"local\" href=\"#H933744\">",
"     'Intravascular abnormalities'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Areas of necrosis due to tissue infarction may occur in both noninflammatory and inflammatory lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H428245\">",
"    <span class=\"h3\">",
"     Lesion distribution",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical distribution of lesions may assist in diagnosis. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Retiform purpura in areas with significant adipose tissue, such as the buttocks, thighs, and abdomen may occur in",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      -induced skin necrosis or calciphylaxis.",
"     </li>",
"     <li>",
"      Retiform purpura predominantly involving lower extremities may occur in vasculitis, livedoid vasculopathy, cholesterol emboli, or calciphylaxis.",
"     </li>",
"     <li>",
"      Retiform purpura primarily involving acral areas may occur in septic vasculitis, embolic disorders, cryoglobulinemia, or cryofibrinogenemia.",
"     </li>",
"     <li>",
"      Widespread, extensive purpura (purpura fulminans) may occur in disseminated intravascular coagulation or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      -induced skin necrosis.",
"     </li>",
"     <li>",
"      The presence of unilateral lesions may suggest embolic phenomena.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H249255\">",
"    <span class=\"h3\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retiform purpura must be distinguished from livedo reticularis and livedo racemosa, both of which are nonpurpuric disorders that present with accentuated vascular patterns in the skin. Livedo reticularis, which results from the slowing of blood flow through cutaneous vessels, presents as a blanchable, patchy, reticulated vascular pattern with a red-blue or violaceous hue (",
"    <a class=\"graphic graphic_picture graphicRef79545 graphicRef61842 \" href=\"mobipreview.htm?17/33/17941\">",
"     picture 2A-B",
"    </a>",
"    ). Livedo racemosa, which develops in the setting of irregular impairment of blood flow, is characterized by a more abrupt and broken vascular pattern with or without areas of necrosis (",
"    <a class=\"graphic graphic_picture graphicRef64023 \" href=\"mobipreview.htm?35/42/36512\">",
"     picture 3",
"    </a>",
"    ). In some conditions, retiform purpura may coexist with livedo reticularis or livedo racemosa. (See",
"    <a class=\"local\" href=\"#H425705\">",
"     'Associated disorders'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/15/4345?source=see_link&amp;anchor=H606666#H606666\">",
"     \"Evaluation of adults with cutaneous lesions of vasculitis\", section on 'Common features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Retiform purpura must also be distinguished from petechiae or purpura due to trauma or bleeding diatheses, which typically lack the angulated shape of retiform lesions (",
"    <a class=\"graphic graphic_picture graphicRef76671 graphicRef70793 \" href=\"mobipreview.htm?21/26/21928\">",
"     picture 11A-B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H428253\">",
"    <span class=\"h3\">",
"     Associated physical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of additional cutaneous or extracutaneous findings should be assessed. As examples, the detection of a heart murmur, splinter hemorrhages (",
"    <a class=\"graphic graphic_picture graphicRef72076 \" href=\"mobipreview.htm?15/63/16369\">",
"     picture 12",
"    </a>",
"    ), Osler nodes (",
"    <a class=\"graphic graphic_picture graphicRef68796 \" href=\"mobipreview.htm?28/10/28847\">",
"     picture 13",
"    </a>",
"    ), or Janeway lesions (",
"    <a class=\"graphic graphic_picture graphicRef58380 \" href=\"mobipreview.htm?30/54/31585\">",
"     picture 14",
"    </a>",
"    ) suggests infectious endocarditis, and respiratory symptoms may occur in patients with Churg-Strauss syndrome or granulomatosis with polyangiitis (Wegener&rsquo;s granulomatosis).",
"   </p>",
"   <p>",
"    The detection of additional cutaneous findings may also assist with diagnosis. As an example, livedo reticularis (",
"    <a class=\"graphic graphic_picture graphicRef79545 graphicRef61842 \" href=\"mobipreview.htm?17/33/17941\">",
"     picture 2A-B",
"    </a>",
"    ) is a common feature of several disorders that may present with retiform purpura, such as antiphospholipid antibody syndrome, polyarteritis nodosa, cholesterol emboli, and cryoglobulinemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H426722\">",
"    <span class=\"h2\">",
"     Skin biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin biopsies offer insight into the pathogenic mechanism of retiform purpura, and therefore, can be useful for diagnosis. We advocate the use of skin biopsies in most patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H428261\">",
"    <span class=\"h3\">",
"     Type and location of biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of vessels in the dermis and subcutis is important in retiform purpura. Thus, punch or incisional wedge biopsies are performed, rather than more superficial shave biopsies. Preferred sites for biopsies include areas that are painful or tender; biopsying both from the center and the edge of a lesion may also increase the diagnostic yield [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39608/abstract/36\">",
"     36",
"    </a>",
"    ]. Areas of frank necrosis or ulceration should be",
"    <strong>",
"     avoided",
"    </strong>",
"    , since necrotic tissue may fail to demonstrate diagnostic histopathological findings. In addition, biopsies of necrotic areas may demonstrate an inflammatory response resembling primary vasculitis in patients with nonvasculitic disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39608/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When infection is suspected, a tissue specimen should also be sent for culture. As mentioned above, vasculitis is a common cause of inflammatory retiform purpura. The approach to the biopsy of lesions that are suspicious for vasculitis is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/15/4345?source=see_link&amp;anchor=H16171991#H16171991\">",
"     \"Evaluation of adults with cutaneous lesions of vasculitis\", section on 'Biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H428268\">",
"    <span class=\"h3\">",
"     Assessment of biopsy results",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several histopathological patterns are associated with retiform purpura; a table correlating histopathologic findings with specific disorders is provided (",
"    <a class=\"graphic graphic_table graphicRef77042 \" href=\"mobipreview.htm?5/34/5676\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H426729\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appropriate initial laboratory studies for the stable patient with noninflammatory retiform purpura include (see",
"    <a class=\"local\" href=\"#H933744\">",
"     'Intravascular abnormalities'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39608/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete blood count with platelets and differential",
"     </li>",
"     <li>",
"      Blood smear",
"     </li>",
"     <li>",
"      Partial thromboplastin time (PTT)",
"     </li>",
"     <li>",
"      Hepatic and renal function tests",
"     </li>",
"     <li>",
"      Cryoglobulins in patients with lesions and symptoms suggestive of this disorder (eg, acral lesions exacerbated by cold exposure) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/63/22522?source=see_link&amp;anchor=H38#H38\">",
"       \"Overview of cryoglobulins and cryoglobulinemia\", section on 'Detection and analysis of cryoglobulins'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Antineutrophil cytoplasmic antibodies (ANCA)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnostic utility of these laboratory studies is described in a table (",
"    <a class=\"graphic graphic_table graphicRef62872 \" href=\"mobipreview.htm?2/17/2333\">",
"     table 2",
"    </a>",
"    ). Additional tests may be ordered based upon the results of these studies, skin biopsy findings, and suspicion of the underlying disorder. In cases in which infection is suspected, blood, urine,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tissue cultures should be obtained. Patients with inflammatory retiform purpura should be evaluated for the possibility of vasculitis. (See",
"    <a class=\"local\" href=\"#H428237\">",
"     'Lesion color and palpability'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/15/4345?source=see_link&amp;anchor=H16172005#H16172005\">",
"     \"Evaluation of adults with cutaneous lesions of vasculitis\", section on 'Additional studies'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    The laboratory evaluation to confirm disseminated intravascular coagulation (DIC) in patients with purpura fulminans is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/20/25929?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/31/8697?source=see_link&amp;anchor=H20#H20\">",
"     \"Disseminated intravascular coagulation in infants and children\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8555553\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of retiform purpura is dependent upon correction of the underlying etiology. (See",
"    <a class=\"local\" href=\"#H425705\">",
"     'Associated disorders'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12657719\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Retiform purpura are hemorrhagic skin lesions characterized by an angulated or branched appearance. The shape of retiform purpura is reflective of the pattern of the underlying vascular network. (See",
"      <a class=\"local\" href=\"#H425698\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Retiform purpura occur as a consequence of disrupted vascular flow in the skin or subcutis. Disorders that cause vessel occlusion through thrombosis, intravascular protein deposition, emboli, or vessel wall destruction are associated with the development of these lesions. (See",
"      <a class=\"local\" href=\"#H425698\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The acute appearance of extensive purpura, termed purpura fulminans, is a life-threatening disorder that occurs in the setting of disseminated intravascular coagulation (DIC). Identification of the underlying cause of DIC is essential for management. Retiform purpura may also occur in the setting of life-threatening opportunistic infections. (See",
"      <a class=\"local\" href=\"#H136707379\">",
"       'Life-threatening emergency (purpura fulminans)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A thorough history and physical examination may provide valuable clues for diagnosis and should be performed in all patients who present with retiform purpura. The skin examination should include assessment of the color and distribution of purpura. (See",
"      <a class=\"local\" href=\"#H425712\">",
"       'Patient assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Skin biopsies of retiform purpura can provide useful diagnostic information (",
"      <a class=\"graphic graphic_table graphicRef77042 \" href=\"mobipreview.htm?5/34/5676\">",
"       table 1",
"      </a>",
"      ). We perform a skin biopsy in almost all patients. A punch or excisional wedge biopsy should be performed to allow for adequate evaluation of vessels in the dermis and subcutis. Areas of necrosis should be avoided. A tissue culture should be performed if infection is suspected. (See",
"      <a class=\"local\" href=\"#H426722\">",
"       'Skin biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An appropriate initial laboratory workup for stable patients with noninflammatory retiform purpura includes a complete blood count with differential and platelets, blood smear, partial thromboplastin time, hepatic and renal function tests, cryoglobulins in patients with acral lesions exacerbated by cold exposure, and antineutrophil cytoplasmic antibodies (ANCA) (",
"      <a class=\"graphic graphic_table graphicRef62872 \" href=\"mobipreview.htm?2/17/2333\">",
"       table 2",
"      </a>",
"      ). Additional tests may be added based upon these results, skin biopsy findings, and the likelihood of specific disorders. If infection is suspected, blood, tissue,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      tissue cultures should be performed. (See",
"      <a class=\"local\" href=\"#H426729\">",
"       'Laboratory tests'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39608/abstract/1\">",
"      Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39608/abstract/2\">",
"      Levi M. Current understanding of disseminated intravascular coagulation. Br J Haematol 2004; 124:567.",
"     </a>",
"    </li>",
"    <li>",
"     Harris, EN. Antiphospholipid syndrome. In: Rheumatology, 2nd ed, Klippel, JH, Dieppe, PA (Eds), Mosby, London, UK 1998. p.7.35.1-7.35.6.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39608/abstract/4\">",
"      Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA 2006; 295:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39608/abstract/5\">",
"      Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39608/abstract/6\">",
"      Erkan D, Lockshin MD. New treatments for antiphospholipid syndrome. Rheum Dis Clin North Am 2006; 32:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39608/abstract/7\">",
"      Lau DH, Wun T. Early manifestation of thrombotic thrombocytopenic purpura. Am J Med 1993; 95:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39608/abstract/8\">",
"      Bouw MC, Dors N, van Ommen H, Ramakers-van Woerden NL. Thrombotic thrombocytopenic purpura in childhood. Pediatr Blood Cancer 2009; 53:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39608/abstract/9\">",
"      Nazarian RM, Van Cott EM, Zembowicz A, Duncan LM. Warfarin-induced skin necrosis. J Am Acad Dermatol 2009; 61:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39608/abstract/10\">",
"      Bauer KA. Coumarin-induced skin necrosis. Arch Dermatol 1993; 129:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39608/abstract/11\">",
"      Bovill EG, Bauer KA, Dickerman JD, et al. The clinical spectrum of heterozygous protein C deficiency in a large New England kindred. Blood 1989; 73:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39608/abstract/12\">",
"      Arepally G, Cines DB. Heparin-induced thrombocytopenia and thrombosis. Clin Rev Allergy Immunol 1998; 16:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39608/abstract/13\">",
"      Warkentin TE. Heparin-induced thrombocytopenia: a ten-year retrospective. Annu Rev Med 1999; 50:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39608/abstract/14\">",
"      Gorevic PD, Kassab HJ, Levo Y, et al. Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients. Am J Med 1980; 69:287.",
"     </a>",
"    </li>",
"    <li>",
"     Della Rossa, A, Tavoni, et al. Cryoglobulinemia. In: Rheumatology, 3rd ed, Hochberg, M (Eds), Mosby, Philidelphia, PA 2003. p.1697-1703.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39608/abstract/16\">",
"      Saadoun D, Elalamy I, Ghillani-Dalbin P, et al. Cryofibrinogenemia: new insights into clinical and pathogenic features. Am J Med 2009; 122:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39608/abstract/17\">",
"      Bloch KJ, Maki DG. Hyperviscosity syndromes associated with immunoglobulin abnormalities. Semin Hematol 1973; 10:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39608/abstract/18\">",
"      Lane JE, Lane TN, Shams M, Lane CE. Cutaneous cholesterol embolization. J Am Acad Dermatol 2009; 60:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39608/abstract/19\">",
"      Kusaba A, Imayama S, Furue M. Delayed appearance of livedo reticularis in 3 cases with a cholesterol embolism. Arch Dermatol 1999; 135:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39608/abstract/20\">",
"      Aggarwal SK, Barik R, Sarma TC, et al. Clinical presentation and investigation findings in cardiac myxomas: new insights from the developing world. Am Heart J 2007; 154:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39608/abstract/21\">",
"      Pinede L, Duhaut P, Loire R. Clinical presentation of left atrial cardiac myxoma. A series of 112 consecutive cases. Medicine (Baltimore) 2001; 80:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39608/abstract/22\">",
"      Callen, JP. Cutaneous vasculitis: relationship to systemic disease and therapy. Curr Probl Dermatol 1993; :45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39608/abstract/23\">",
"      Carlson JA, Cavaliere LF, Grant-Kels JM. Cutaneous vasculitis: diagnosis and management. Clin Dermatol 2006; 24:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39608/abstract/24\">",
"      Carlson JA, Ng BT, Chen KR. Cutaneous vasculitis update: diagnostic criteria, classification, epidemiology, etiology, pathogenesis, evaluation and prognosis. Am J Dermatopathol 2005; 27:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39608/abstract/25\">",
"      Wilmer WA, Magro CM. Calciphylaxis: emerging concepts in prevention, diagnosis, and treatment. Semin Dial 2002; 15:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39608/abstract/26\">",
"      Kalajian AH, Malhotra PS, Callen JP, Parker LP. Calciphylaxis with normal renal and parathyroid function: not as rare as previously believed. Arch Dermatol 2009; 145:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39608/abstract/27\">",
"      Bobrowski AE, Langman CB. Hyperoxaluria and systemic oxalosis: current therapy and future directions. Expert Opin Pharmacother 2006; 7:1887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39608/abstract/28\">",
"      Cochat P. Primary hyperoxaluria type 1. Kidney Int 1999; 55:2533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39608/abstract/29\">",
"      Jorizzo JL. Livedoid vasculopathy: what is it? Arch Dermatol 1998; 134:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39608/abstract/30\">",
"      Bard JW, Winkelmann RK. Livedo vasculitis. Segmental hyalinizing vasculitis of the dermis. Arch Dermatol 1967; 96:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39608/abstract/31\">",
"      Anavekar NS, Kelly R. Heterozygous prothrombin gene mutation associated with livedoid vasculopathy. Australas J Dermatol 2007; 48:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39608/abstract/32\">",
"      Hurwitz RM, Haseman JH. The evolution of pyoderma gangrenosum. A clinicopathologic correlation. Am J Dermatopathol 1993; 15:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39608/abstract/33\">",
"      Jorizzo JL, Solomon AR, Zanolli MD, Leshin B. Neutrophilic vascular reactions. J Am Acad Dermatol 1988; 19:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39608/abstract/34\">",
"      Su WP, Davis MD, Weenig RH, et al. Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol 2004; 43:790.",
"     </a>",
"    </li>",
"    <li>",
"     Piette W. Purpura: mechanisms and differential diagnosis. In: Dermatology, 2nd ed, Bolognia JL, Jorizzo JL, Rapini RP.  (Eds), Elsevier Limited, Spain 2008. Vol 1, p.321.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39608/abstract/36\">",
"      Wysong A, Venkatesan P. An approach to the patient with retiform purpura. Dermatol Ther 2011; 24:151.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16556 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.172.26-18D72DAC39-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_43_39608=[""].join("\n");
var outline_f38_43_39608=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12657719\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H429795\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H425698\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H425705\">",
"      Associated disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H933744\">",
"      - Intravascular abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H933761\">",
"      Thrombotic and coagulopathic disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H933953\">",
"      Intravascular protein deposition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H933961\">",
"      Embolic disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H933969\">",
"      - Vessel wall pathology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8555196\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H425712\">",
"      PATIENT ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H136707379\">",
"      Life-threatening emergency (purpura fulminans)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H425719\">",
"      Patient history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H425726\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H428237\">",
"      - Lesion color and palpability",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H428245\">",
"      - Lesion distribution",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H249255\">",
"      - Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H428253\">",
"      - Associated physical findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H426722\">",
"      Skin biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H428261\">",
"      - Type and location of biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H428268\">",
"      - Assessment of biopsy results",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H426729\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8555553\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12657719\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/16556\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/16556|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/60/40898\" title=\"picture 1A\">",
"      Purpura fulminans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/56/23426\" title=\"picture 1B\">",
"      Disseminated intravascular coagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/62/31713\" title=\"picture 1C\">",
"      Antiphospholipid antibody syndrome - purpura",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?7/14/7397\" title=\"picture 1D\">",
"      Disseminated intravascular coagulation acral purpura",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?24/17/24848\" title=\"picture 1E\">",
"      Antiphospholipid antibody syndrome purpura",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/39/15987\" title=\"picture 1F\">",
"      Purpura fulminans large lesion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/28/31168\" title=\"picture 1G\">",
"      Acute meningococcemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/33/13841\" title=\"picture 2A\">",
"      Livedo reticularis - lower extremities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/30/35311\" title=\"picture 2B\">",
"      Livedo reticularis - lower leg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/42/36512\" title=\"picture 3\">",
"      Livedo racemosa in polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/7/9330\" title=\"picture 4A\">",
"      Warfarin-induced skin necrosis on thighs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/11/32946\" title=\"picture 4B\">",
"      Warfarin-induced skin necrosis on extremity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/34/43553\" title=\"picture 4C\">",
"      Cutaneous necrosis warfarin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/29/18900\" title=\"picture 5A\">",
"      Heparin necrosis ulcers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?28/17/28947\" title=\"picture 5B\">",
"      Heparin necrosis purpura",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/43/26290\" title=\"picture 6\">",
"      Cholesterol emboli retiform purpura",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/55/38771\" title=\"picture 7\">",
"      Ecthyma gangrenosum purpura",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/48/18180\" title=\"picture 8\">",
"      Calciphylaxis retiform purpura",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/52/27458\" title=\"picture 9\">",
"      Livedoid vasculopathy - close view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/28/15810\" title=\"picture 10A\">",
"      Cocaine purpura",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?24/58/25507\" title=\"picture 10B\">",
"      Cocaine purpura on ear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?16/53/17235\" title=\"picture 10C\">",
"      Cocaine purpura on extremity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/17/8468\" title=\"picture 11A\">",
"      Immune thrombocytopenia - ITP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?28/16/28930\" title=\"picture 11B\">",
"      Multiple solar purpura",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/63/16369\" title=\"picture 12\">",
"      Splinter hemorrhages in infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?28/10/28847\" title=\"picture 13\">",
"      Oslers nodes in infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/54/31585\" title=\"picture 14\">",
"      Janeway lesion in infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/16556|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/34/5676\" title=\"table 1\">",
"      Retiform purpura histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/17/2333\" title=\"table 2\">",
"      Screening tests for occlusive vascular syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/42/15017?source=related_link\">",
"      Calciphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/32/17930?source=related_link\">",
"      Cardiac tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/20/25929?source=related_link\">",
"      Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34040?source=related_link\">",
"      Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/52/37704?source=related_link\">",
"      Clinical manifestations of meningococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/50/14121?source=related_link\">",
"      Clinical manifestations of paroxysmal nocturnal hemoglobinuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7576?source=related_link\">",
"      Cryofibrinogenemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/43/17082?source=related_link\">",
"      Diagnosis and treatment of paroxysmal nocturnal hemoglobinuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27096?source=related_link\">",
"      Diagnosis of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29721?source=related_link\">",
"      Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/24/41352?source=related_link\">",
"      Diagnostic approach to infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/31/8697?source=related_link\">",
"      Disseminated intravascular coagulation in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/15/31994?source=related_link\">",
"      Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34616?source=related_link\">",
"      Epidemiology and clinical manifestations of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/43/18105?source=related_link\">",
"      Epidemiology, microbiology, clinical manifestations, and diagnosis of leprosy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/15/4345?source=related_link\">",
"      Evaluation of adults with cutaneous lesions of vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40890?source=related_link\">",
"      Heparin-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/61/6103?source=related_link\">",
"      Livedoid vasculopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/46/6890?source=related_link\">",
"      Mucormycosis (zygomycosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/63/22522?source=related_link\">",
"      Overview of cryoglobulins and cryoglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/55/12154?source=related_link\">",
"      Primary hyperoxaluria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/52/841?source=related_link\">",
"      Protein C deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/27/14775?source=related_link\">",
"      Pseudomonas aeruginosa bacteremia and endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/17/2328?source=related_link\">",
"      Pyoderma gangrenosum: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/59/11193?source=related_link\">",
"      Strongyloidiasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_43_39609="Systematic review and meta-analysis";
var content_f38_43_39609=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Systematic review and meta-analysis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/43/39609/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/43/39609/contributors\">",
"     Ethan Balk, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/43/39609/contributors\">",
"     Peter A L Bonis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/43/39609/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/43/39609/contributors\">",
"     Robert H Fletcher, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/43/39609/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/43/39609/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/43/39609/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H2326445\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical decisions in medicine ideally should be based upon guidance from a comprehensive assessment of the body of available knowledge. A single clinical trial, even a large one, is seldom sufficient to provide a confident answer to a clinical question. Indeed, one analysis suggested that most research claims are ultimately proven to be incorrect or inaccurate when additional studies have been performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/1\">",
"     1",
"    </a>",
"    ]. At the same time, it is well-established that large randomized controlled trials do not always confirm the results of prior meta-analyses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. The &ldquo;truth&rdquo; needs to be understood by examining all sources of data as critically and objectively as possible.",
"   </p>",
"   <p>",
"    There are several potential benefits to performing systematic analysis, which may also include meta-analysis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unique aspects to a single randomized trial, involving the participating patient population, the protocol, the setting in which the trial is performed, or the expertise of the involved clinicians, may limit its generalizable to other settings or individual patients. The conclusions of systematic reviews may be more generalizable than single studies.",
"     </li>",
"     <li>",
"      Combining studies in meta-analyses increases the sample size and generally produces more precise estimates of the effect size (ie, estimates that have smaller confidence intervals) than a single randomized trial.",
"     </li>",
"     <li>",
"      Clinicians rarely have the time or resources to critically evaluate the body of evidence relevant to a particular clinical question, and a systematic review can facilitate this investigation.",
"     </li>",
"     <li>",
"      In contrast to narrative review articles, most systematic reviews focus on a narrow, clearly defined topic and include all eligible studies, not just those chosen by the author.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Systematic review and meta-analysis are methods to synthesize the available evidence using an explicit, transparent approach that considers the strengths and weaknesses of the individual studies, the populations and interventions, and specific outcomes that were assessed. Individual practitioners, policy-makers, and guideline developers can use well-conducted systematic reviews to determine best patient management decisions. Organizations that develop guidelines can use the results of systematic reviews and meta-analyses to provide evidence-based recommendations for care.",
"   </p>",
"   <p>",
"    This topic review will provide an overview of how systematic reviews and meta-analyses are conducted and how they should be interpreted. In addition, it will provide a summary of methodological terms commonly encountered in such studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2327453\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H78553622\">",
"    <span class=\"h2\">",
"     Systematic review",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review is a comprehensive summary of all available evidence that meets predefined eligibility criteria to address a specific clinical question or range of questions. It is based upon a rigorous process that incorporates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Systematic identification of studies that have evaluated specific interventions in comparable populations",
"     </li>",
"     <li>",
"      Critical appraisal of the studies, that may involve meta-analysis (see",
"      <a class=\"local\" href=\"#H78553629\">",
"       'Meta-analysis'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Presentation of key findings",
"     </li>",
"     <li>",
"      Explicit discussion of the limitations of the review",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Systematic reviews contrast with traditional &ldquo;narrative&rdquo; reviews and textbook chapters. Such reviews generally do not exhaustively review the literature, lack transparency in the selection and interpretation of supporting evidence, do not provide a quantitative synthesis of the data, and are more likely to be biased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H78553629\">",
"    <span class=\"h2\">",
"     Meta-analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meta-analysis, which is commonly included in systematic reviews, is a statistical method that quantitatively combines the results from different studies. It can be used to provide an overall estimate of the net benefit or harm of an intervention, even when these effects may not have been apparent in the individual studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/9\">",
"     9",
"    </a>",
"    ]. Meta-analysis can also provide an overall quantitative estimate of other parameters such as diagnostic accuracy, incidence, or prevalence. Meta-regression and network meta-analysis are enhancements to traditional meta-analysis. (See",
"    <a class=\"local\" href=\"#H2327476\">",
"     'Meta-regression'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H2326523\">",
"     'Network meta-analysis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H78553636\">",
"    <span class=\"h2\">",
"     Heterogeneity",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important dimension of systematic reviews is that they permit a clear description of differences among studies, typically referred to as &ldquo;heterogeneity,&rdquo; and explain the reasons why studies may have reached varied conclusions. The degree of heterogeneity across studies can be expressed graphically and quantitatively and is incorporated into the synthesis of the included studies. When heterogeneity is too large, meta-analysis cannot yield meaningful results.",
"   </p>",
"   <p>",
"    There are two general categories of heterogeneity: clinical and statistical.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Clinical heterogeneity",
"      </strong>",
"      refers to basic differences in trial design",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      participants across studies. Such heterogeneity may include differences in specific drugs (eg, different statins), drug dosages, duration of treatment, surgical technique, or patient comorbidities. As a general rule, studies with large clinical heterogeneity (a concept that can be difficult to define precisely) should not be mathematically combined (meta-analyzed).",
"     </li>",
"     <li>",
"      <strong>",
"       Statistical heterogeneity",
"      </strong>",
"      refers to variability in the range of results across studies. Statistical heterogeneity may be due to either chance or underlying clinical heterogeneity. There are several tests to measure the degree of statistical heterogeneity. Studies are described as being homogeneous when no statistical heterogeneity is detected.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2326452\">",
"    <span class=\"h1\">",
"     OVERVIEW OF SYSTEMATIC REVIEW AND META-ANALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several steps are essential for conducting a systematic review or meta-analysis. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Developing a protocol",
"     </li>",
"     <li>",
"      Formulating research questions",
"     </li>",
"     <li>",
"      Searching for the evidence",
"     </li>",
"     <li>",
"      Assessing the quality of studies",
"     </li>",
"     <li>",
"      Displaying results",
"     </li>",
"     <li>",
"      Exploring reasons for the heterogeneity of results across studies",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The basic steps, along with limitations that should be considered, are discussed here. While this topic review focuses on meta-analysis of randomized controlled trials, many of the methods and issues apply equally to meta-analyses of other comparative studies, noncomparative or retrospective studies, and studies of diagnostic tests. An overview of approaches to systematic review and meta-analysis is provided in a table (",
"    <a class=\"graphic graphic_table graphicRef80657 \" href=\"mobipreview.htm?6/17/6428\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2327460\">",
"    <span class=\"h2\">",
"     Consensus statements",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2009, the QUOROM (Quality of Reporting of Meta-analyses) guideline was updated and renamed PRISMA (Preferred Reporting Items of Systematic reviews and Meta-Analyses) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/10\">",
"     10",
"    </a>",
"    ]. The PRISMA statement emphasizes that systematic reviews should provide the protocol, data, and assessments of risk of bias from individual studies in sufficient detail to allow the reader to verify the results. It underscores the basic questions that the clinician and investigator should ask when interpreting a systematic review. In addition, readers of systematic reviews should assess the relevance to their own practice in regard to the population, intervention, and outcomes assessed.",
"   </p>",
"   <p>",
"    The Institute of Medicine has published recommended standards for developing systematic reviews [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/11\">",
"     11",
"    </a>",
"    ]. While these standards principally apply to publicly-funded systematic reviews of comparative effectiveness research that focus specifically on treatments, most of the standards pertain to all systematic reviews.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2326459\">",
"    <span class=\"h1\">",
"     DEVELOPING A PROTOCOL",
"    </span>",
"    &nbsp;&mdash;&nbsp;A written protocol serves to minimize bias and to ensure that the review is implemented according to reproducible steps. A systematic review should describe the research questions and the review methodology, including the search strategy and approach to analyzing the data. Ideally, the protocol should be a collaborative effort that includes both clinical and methodology experts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2326466\">",
"    <span class=\"h2\">",
"     Formulating research questions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Research questions (often referred to as &ldquo;key questions&rdquo;) are analogous to the research hypotheses of primary research studies. They should be focused and defined clearly, since they determine the scope of research the systematic review will address [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Broad questions that cover a range of topics may not be directly answerable and are not appropriate for systematic reviews or meta-analyses. As an example, the question &ldquo;What is the best treatment for chronic hepatitis B?&rdquo; would need to be broken down into several smaller well-focused questions that could be addressed in individual and complementary systematic reviews. Examples of appropriate key questions may include, &ldquo;How does",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    compare with placebo for achieving HBeAg seroconversion in patients with chronic HBeAg-positive hepatitis B?&rdquo; and &ldquo;What is the relationship between hepatitis B genotypes and response rates to entecavir?&rdquo; These and other related questions would be addressed individually and then, ideally, considered together to answer the more general question.",
"   </p>",
"   <p>",
"    Key questions for studies of the effectiveness of interventions are commonly formulated according to the &ldquo;PICO&rdquo; method, which fully defines the",
"    <strong>",
"     P",
"    </strong>",
"    opulation, the",
"    <strong>",
"     I",
"    </strong>",
"    ntervention, the appropriate",
"    <strong>",
"     C",
"    </strong>",
"    ontrol or",
"    <strong>",
"     C",
"    </strong>",
"    omparator, and the",
"    <strong>",
"     O",
"    </strong>",
"    utcomes of interest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/13\">",
"     13",
"    </a>",
"    ]. Investigators must also decide which study designs (eg, only randomized trials) are appropriate to include, along with other eligibility criteria. Variations of these criteria should be used for systematic reviews of other study designs, such as of cohort studies (without a comparator) or studies of diagnostic tests.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2326473\">",
"    <span class=\"h1\">",
"     PERFORMING THE LITERATURE SEARCH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The literature search provides the evidence for the review and should be systematic and comprehensive to minimize error and bias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/13\">",
"     13",
"    </a>",
"    ]. Most meta-analyses start with a search of an electronic database of the literature. MEDLINE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/14\">",
"     14",
"    </a>",
"    ] is almost universally used, but many also include searches in Embase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/15\">",
"     15",
"    </a>",
"    ] and the Cochrane Central Register of Controlled Trials (CENTRAL) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/16\">",
"     16",
"    </a>",
"    ]. Inclusion of additional databases should be considered for specialized topics such as complementary or alternative medicine, quality of care, or nursing. Electronic searches should be supplemented by searches of the bibliographies of retrieved articles and relevant review articles, and by studies known to domain experts.",
"   </p>",
"   <p>",
"    More recently, the research community has recognized a need to incorporate the &ldquo;grey literature&rdquo; to diminish the risks of publication bias (selective publication of studies, possibly based on their results) and reporting bias (selective reporting of study results, possibly based on statistical significance) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/11,17-19\">",
"     11,17-19",
"    </a>",
"    ]. There is no standard definition of grey literature, but it generally refers to information obtained from sources other than published, peer-reviewed articles, such as conference proceedings, clinical trial registries, adverse events databases, Food and Drug Administration documents, unpublished industry data, dissertations, and newspaper articles.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2326480\">",
"    <span class=\"h2\">",
"     Publication bias",
"    </span>",
"    &nbsp;&mdash;&nbsp;A potentially important limitation of systematic review is &ldquo;publication bias,&rdquo; the fact that not all research is published. Compared to positive studies, negative studies may be less likely to be published and more likely to take longer to be published [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/20\">",
"     20",
"    </a>",
"    ], which can affect the validity of systematic reviews [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/21\">",
"     21",
"    </a>",
"    ]. Similarly, outcome reporting bias relates to the concern that non-significant or non-favorable outcomes are selectively not reported in publications. Many other potential sources of bias have been identified, described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/22\">",
"     22",
"    </a>",
"    ], and included in consensus standards for developing systematic reviews [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several methods have been developed to evaluate whether publication bias is present. However, they all require making major assumptions about possible missing studies and are controversial regarding their validity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/23\">",
"     23",
"    </a>",
"    ]. Any evaluation of publication bias should not be considered definitive, but rather only exploratory in nature. Methods to evaluate for publication bias include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The funnel plot &ndash; This commonly used method is a scatter plot that displays the relationship between the weight of the study (eg, study size or standard error) and the observed effect (",
"      <a class=\"graphic graphic_figure graphicRef65012 \" href=\"mobipreview.htm?9/15/9456\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/24\">",
"       24",
"      </a>",
"      ]. In principle, larger studies should display less variability of the treatment effects. Asymmetric appearance, especially due to the absence of smaller negative studies, can suggest unpublished data. Several statistical methods have been developed to analyze funnel plots. However, the validity of funnel plots has been called into question because they lack a statistical foundation, their interpretation is subjective, and asymmetry could be due to factors other than unpublished negative studies (such as population heterogeneity or study quality) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/21,25-27\">",
"       21,25-27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The &ldquo;trim and fill&rdquo; method &ndash; This approach determines if adding hypothetical studies to an asymmetrical funnel plot (to make it symmetrical) would change the effect size estimate of the meta-analysis results [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The &ldquo;modeling selection process&rdquo; &ndash; This uses a model to determine how effect size estimates would differ with and without a selection process (ie, publication bias) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/29\">",
"       29",
"      </a>",
"      ]. Several methods have been proposed for developing these models. The &ldquo;fail-safe N&rdquo; determines the number of studies with an effect size of zero that would be needed to make the meta-analysis effect size non-significant [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A method has been developed to test for an excess of studies with significant results [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2326487\">",
"    <span class=\"h1\">",
"     ASSESSING THE QUALITY OF STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The quality of an individual study has been defined as the &ldquo;confidence that the trial design, conduct, and analysis has minimized or avoided biases in its treatment comparison&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/32\">",
"     32",
"    </a>",
"    ]. Quality assessment represents the extent to which trial design and methodology prevented systematic error, and can help explain differences in the results of systematic reviews. The process of assessing study quality is not straightforward. Many approaches have been proposed that include assessment of certain indicators of study quality as well as formal quality scoring systems that combine quality indicators. The assessment of study quality is limited by the need to rely on information presented in the manuscript and an understanding that there is no true reference standard for quality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Critical appraisal of individual studies should be performed as part of a meta-analysis, but the results should be interpreted cautiously. The primary value of such appraisal may be to determine the degree of confidence that the estimate of effect reflects the &ldquo;truth&rdquo; as best as it can be measured. Differences in the quality of individual studies can also be explored to help explain heterogeneity.",
"   </p>",
"   <p>",
"    Commonly used quality indicators include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Adequate randomization:",
"      </strong>",
"      Whether randomization was adequately performed (eg, by a computer algorithm versus an alphabetical list that may be subject to bias).",
"     </li>",
"     <li>",
"      <strong>",
"       Allocation concealment:",
"      </strong>",
"      Whether the assignment of the treatment group was adequately concealed from the investigators. For example, a study may be biased if the investigators used unsealed envelopes to assign patients to one group or another. The investigators could read the contents and thereby channel certain patients into desired treatment groups.",
"     </li>",
"     <li>",
"      <strong>",
"       Dropout rates and reporting:",
"      </strong>",
"      High rates of withdrawal of participants from a study may indicate a fundamental problem with the study design. Uneven withdrawal from different study groups can lead to bias, particularly if the reasons for withdrawal differ between interventions. Reports should describe the reasons for patient withdrawal to allow assessment of their effect on bias and study applicability.",
"     </li>",
"     <li>",
"      <strong>",
"       Reporting accuracy:",
"      </strong>",
"      The accuracy of reporting of study methodology, patient characteristics, and study results. Inconsistent or incomplete reporting, missing data on important patient characteristics, and incomplete analyses of outcomes diminish confidence in a study&rsquo;s findings.",
"     </li>",
"     <li>",
"      <strong>",
"       Statistical interpretations:",
"      </strong>",
"      The appropriateness of statistical analyses.",
"     </li>",
"     <li>",
"      <strong>",
"       Blinding:",
"      </strong>",
"      Adequate masking of study participants, study researchers, caregivers, outcome assessors, and data assessors to group assignment. Blinding is not always feasible. Some forms of surgery or behavioral modifications, for example, do not lend themselves to blinding. &ldquo;Double blinding&rdquo; generally refers to blinding of the study participants and at least one of the study investigators. For adequate blinding, treatments with a noticeable side effect (eg, niacin) should have an &ldquo;active control&rdquo; that mimics the side effect.",
"     </li>",
"     <li>",
"      <strong>",
"       Similarity between groups:",
"      </strong>",
"      Similarity of groups being compared at baseline, in concomitant treatment, and in follow-up.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In theory, studies in which these measures are poorly achieved are more likely to result in biased outcomes. For example, compared to double-blinded trials, non-blinded studies may exaggerate the benefit of treatment (eg, a larger odds ratio, or treatment effect) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/34\">",
"     34",
"    </a>",
"    ]. However, evaluation of studies using different quality scales can result in paradoxical conclusions, such that designation of a study as &ldquo;high quality&rdquo; using one scale may not be corroborated using a different scale [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Only inadequate allocation concealment or lack of double blinding have been shown to be related to exaggerated estimates of treatment effects, although with limited empirical evidence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/36\">",
"     36",
"    </a>",
"    ]. However, even these measures have been questioned for their influence on effect sizes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. Furthermore, an evaluation of the relationship between various individual quality factors (including randomization concealment and double blinding) and effect sizes in randomized controlled trials of interventions found that individual quality measures were not consistently associated with the magnitude of treatment effect across studies and clinical areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H96519889\">",
"    <span class=\"h1\">",
"     FOREST PLOTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A forest plot is a graphical presentation of individual studies, typically displayed as point estimates and their associated 95% confidence intervals on an appropriate scale, next to a description of the individual studies. The forest plot allows the reader to see the estimate and the precision of the individual studies, appreciate the heterogeneity of results, and compare the estimates of the individual studies to the overall summary estimate.",
"   </p>",
"   <p>",
"    An example of the meta-analysis of the net change in glucose concentrations with chromium supplementation is shown in a figure (",
"    <a class=\"graphic graphic_figure graphicRef59845 \" href=\"mobipreview.htm?16/54/17256\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/41\">",
"     41",
"    </a>",
"    ]. Ideally, a forest plot should provide sufficient data for the reader to make some assessment of the individual studies in the context of the overall summary (eg, to compare sample sizes, baseline values, demographic features, and study quality).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110188885\">",
"    <span class=\"h1\">",
"     META-ANALYSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2326494\">",
"    <span class=\"h2\">",
"     Statistical methods for combining data",
"    </span>",
"    &nbsp;&mdash;&nbsp;Basic meta-analysis combines results across studies to provide overall estimates and confidence intervals of treatment effects. Clinical trials often report dichotomous outcome data (outcomes with two possible states, such as death versus survival), and their results are often expressed as odds ratios, relative risks (risk ratios), risk differences, or number needed to treat (NNT). Essentially any study metric can be meta-analyzed, including continuous variable means, changes, or differences; proportions; or hazard ratios.",
"   </p>",
"   <p>",
"    For meta-analysis, odds ratio or relative risk, which measure the relative effect, are preferable to metrics that measure absolute differences (risk difference and NNT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. In meta-analyses, risk differences (and thus NNT) are more likely to be heterogeneous than relative risk or odds ratio due to varying baseline risks across studies. As a result, combining risk differences is frequently problematic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/18/22823?source=see_link&amp;anchor=H13#H13\">",
"     \"Glossary of common biostatistical and epidemiological terms\", section on 'Number needed to treat'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The summary effect estimate can be calculated under the assumption of a &ldquo;fixed&rdquo; effect or a &ldquo;random&rdquo; effects model [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Fixed effect model:",
"      </strong>",
"      A hypothetical model for a fixed effect model meta-analysis is shown in a figure (",
"      <a class=\"graphic graphic_figure graphicRef80325 \" href=\"mobipreview.htm?2/46/2799\">",
"       figure 3",
"      </a>",
"      ). The model assumes there is a single true treatment effect and that all trials provide estimates of this one true effect. The meta-analysis thus provides a pooled estimate of the single true effect.",
"      <br/>",
"      <br/>",
"      The central assumption of a fixed effect model is that estimates from each study differ solely because of random error around a common true effect. This assumes that all studies represent the same population, intervention, comparator, and outcome for which there is a single &ldquo;true&rdquo; effect size.",
"      <strong>",
"      </strong>",
"      Fixed effects models yield effect size estimates by assigning a weight to each individual study estimate that reflects the inherent variability in the results measured (ie, the &ldquo;within-study variance&rdquo; related to the standard error of the outcome).",
"     </li>",
"     <li>",
"      <strong>",
"       Random effects model:",
"      </strong>",
"      In contrast, the central assumption of random effects models is that each study estimate represents a random sample from a distribution of different populations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/48\">",
"       48",
"      </a>",
"      ]. A hypothetical model for a random effects model meta-analysis is shown in a figure (",
"      <a class=\"graphic graphic_figure graphicRef51482 \" href=\"mobipreview.htm?19/10/19616\">",
"       figure 4",
"      </a>",
"      ). The model assumes there are multiple true treatment effects and that each trial provides an estimate of its own true effect. The meta-analysis thus provides a pooled estimate across (or an average of) a range of true effects.",
"      <br/>",
"      <br/>",
"      The random effects model assumes that there is not necessarily one &ldquo;true&rdquo; effect size but rather that the studies included have provided a glimpse of a range of &ldquo;true&rdquo; effects. The random effects model incorporates both &ldquo;between-study variance&rdquo; (to capture the range of difference effects across studies) and &ldquo;within-study variance&rdquo; (to capture the range of difference effects within studies) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The choice of methods is important because of the implications for interpreting the results. When heterogeneity is present, the confidence intervals of estimates derived using the random effects model are wider than those from the fixed effect model. Thus the random effects model, generally, provides a more &ldquo;conservative&rdquo; estimate (eg, it is less likely to find a falsely significant effect within its confidence interval). As a result, most experts use random effects models.",
"   </p>",
"   <p>",
"    There are limited instances when it is appropriate to use a fixed effects model for summarizing clinical trials. These include meta-analyses in which:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is extreme confidence that the studies are comparable (ie, characteristics of the enrolled patients, the type of intervention, comparators and outcome measures) such that any difference across studies is just due to random variation. Such an assumption is typically difficult to justify.",
"     </li>",
"     <li>",
"      The studies are of rare events in which one form of a fixed effects model (the Peto odds ratio) may be less biased than other methods of pooling data [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2326501\">",
"    <span class=\"h2\">",
"     When to combine studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to combine studies should be based upon both qualitative and quantitative evaluations. Important qualitative features include the degree of similarity of populations, interventions, outcomes, study objectives, and study designs that incorporate both clinical and biological plausibility. The systematic reviewers should provide a sufficient explanation of the rationale for combining studies to allow the readers to judge for themselves whether they agree that it was appropriate to combine the individual studies.",
"   </p>",
"   <p>",
"    Quantitative methods to examine heterogeneity also should be considered in making the decision or determining if it is appropriate to combine data. These typically involve the Q statistic or I",
"    <sup>",
"     2",
"    </sup>",
"    index. These statistics, however, generally have low power and are thus prone to false negative results (eg, not detecting heterogeneity when it is present).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The &ldquo;Q&rdquo; statistic, used for many years, tests the hypothesis that results across studies are homogeneous. The Q statistic involves performing a chi square test for heterogeneity (eg, summing the squared deviations from the effect measured in each study from the overall effect and weighting the contribution from each study by the inverse of its variance). A non-significant value suggests that the studies are homogeneous. However, the Q statistic has limited power to detect heterogeneity in meta-analyses with few studies, while it tends to over-detect heterogeneity in meta-analyses with many studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/50\">",
"       50",
"      </a>",
"      ]. Commonly, the Q statistic is interpreted to indicate heterogeneity if its P value is less than 0.10.",
"     </li>",
"     <li>",
"      The I",
"      <sup>",
"       2",
"      </sup>",
"      index has been developed more recently and may be used instead of or in addition to the Q statistic. I",
"      <sup>",
"       2",
"      </sup>",
"      represents the amount of variability in the effect sizes across studies that can be explained by between-study variability. For example, an I",
"      <sup>",
"       2",
"      </sup>",
"      value of 75 percent means that 75 percent of the variability in the measured effect sizes across studies is caused by true heterogeneity among studies. By consensus, standard thresholds for the interpretation of I",
"      <sup>",
"       2",
"      </sup>",
"      are 25, 50, and 75 percent to represent low, medium, and high heterogeneity, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/51\">",
"       51",
"      </a>",
"      ]. However, the investigators who introduced the I",
"      <sup>",
"       2",
"      </sup>",
"      statistic noted that na&iuml;ve categorization of I",
"      <sup>",
"       2",
"      </sup>",
"      values is not appropriate in all circumstances and that &ldquo;the practical impact of heterogeneity in a meta-analysis also depends on the size and direction of treatment effects&rdquo; [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/51\">",
"       51",
"      </a>",
"      ]. The clinical implication and interpretability of a meta-analysis with a large I",
"      <sup>",
"       2",
"      </sup>",
"      index will be different for studies with large statistically significant effects compared with studies with smaller inconsistent effects.",
"     </li>",
"     <li>",
"      Other heterogeneity measures (eg, H",
"      <sup>",
"       2",
"      </sup>",
"      , R",
"      <sup>",
"       2",
"      </sup>",
"      , tau",
"      <sup>",
"       2",
"      </sup>",
"      ) have also been described but are rarely used.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7125075\">",
"    <span class=\"h2\">",
"     Precision",
"    </span>",
"    &nbsp;&mdash;&nbsp;Precision refers to the extent to which the observed results would be reproduced exactly given the same interventions and study design. Precision can be contrasted with validity, which refers to the extent to which the results reflect the &ldquo;truth&rdquo; (",
"    <a class=\"graphic graphic_figure graphicRef52219 \" href=\"mobipreview.htm?12/27/12725\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    An important advantage of meta-analysis is that combining studies produces more precise estimates of the effect size (ie, estimates that have smaller confidence intervals) due to the increased sample size. However, the increased precision can overshadow important differences in the included studies. The forest plot and the quantitative measures of heterogeneity can help uncover whether such differences exist and lead to further analysis to understand the reasons for the differences. As an example, a researcher interested in understanding the prevalence of hepatitis B could combine rates in various countries to derive an overall estimate. The estimate would be precise (ie, narrow confidence intervals) because it would include a large amount of data (ie, from the entire world). However, it is well known that the prevalence of hepatitis B varies greatly in different geographic regions. An analysis stratified by geography, while offering less precise estimates, would provide a more realistic (valid) assessment of the true prevalence in various regions.",
"   </p>",
"   <p>",
"    When interpreting a meta-analysis, an important clinical question is whether the pooled estimated is sufficiently precise to permit a confident conclusion about the results. Imprecision should be suspected when there is a small sample size (and particularly a small number of events) and when the confidence intervals are wide (leaving uncertainty about the magnitude of the true effect). The question is how wide should be considered too wide?",
"   </p>",
"   <p>",
"    As a general rule, results are not sufficiently precise to generate high confidence in their interpretation if the clinical decision based on the result (eg, to use or not use an intervention) would change at the outer boundaries of the 95% CI for the summary estimate. For organizations issuing guidelines, the strength of the evidence should be downgraded for imprecision. Specific criteria for imprecision have been developed in the context of grading for guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/52\">",
"     52",
"    </a>",
"    ]. .",
"   </p>",
"   <p>",
"    When an effect is suggested, but imprecision is present, more studies (or in some cases, analysis of specific subgroups of studies) may be needed to improve the precision. This is illustrated in the accompanying figures (",
"    <a class=\"graphic graphic_figure graphicRef70567 \" href=\"mobipreview.htm?14/27/14777\">",
"     figure 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef60154 \" href=\"mobipreview.htm?32/58/33704\">",
"     figure 7",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2327699\">",
"    <span class=\"h2\">",
"     Sensitivity analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis should test how stable the overall estimates are when different subgroups of studies are analyzed and should explore heterogeneity among the studies. Meta-regression and subgroup analyses can be used to examine the influence on the overall results. When feasible, meta-analysis of individual patient data allows the most rigorous exploration of heterogeneity. (See",
"    <a class=\"local\" href=\"#H2326516\">",
"     'Individual patient data'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition, explorations such as reanalyzing the data with single studies or groups of studies (eg, &ldquo;poor quality&rdquo; studies) omitted can be used to determine the degree to which overall results are being driven by these studies. Conclusions should seldom be driven by a single study, since the meta-analysis would add little additional information or confidence compared to the single study alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2327476\">",
"    <span class=\"h2\">",
"     Meta-regression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regression analysis of primary studies may be used to adjust for potential confounders or explain differences in results among subjects. This meta-analytic technique is commonly known as meta-regression. In this approach, the dependent variable in the regression is the estimate of treatment effect from each individual study, and the independent variables (eg, covariates such as drug dosage, measure of severity of illness, or treatment duration) are the aggregated characteristics derived from the individual studies. Instead of individual patients serving as the units of analysis, each individual study is considered to be one observation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. An example of a meta-regression of early trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    monotherapy for HIV infection is shown in a figure (",
"    <a class=\"graphic graphic_figure graphicRef69060 \" href=\"mobipreview.htm?39/11/40125\">",
"     figure 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/56\">",
"     56",
"    </a>",
"    ]. The meta-regression successfully explains the heterogeneity across studies, showing an association between treatment duration and the effect of treatment on death that was not apparent within the individual trials.",
"   </p>",
"   <p>",
"    There are several caveats related to the performance and interpretation of meta-regression:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Meta-regression and subgroup analyses (that rely on retrospective data from previously run trials) should be considered to yield hypothesis-generating, rather than conclusive, associations, in contrast to well-designed regressions of prospective study data.",
"     </li>",
"     <li>",
"      Meta-regression is not always feasible since covariates may not be fully reported or may not be uniformly defined.",
"     </li>",
"     <li>",
"      Data dredging (analyzing every possible variable regardless of clinical relevance) can result in spurious associations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      It may be difficult to account properly for patient-level variables (such as age, sex, or laboratory values). Most studies, for example, report averages for such variables (eg, a mean age of 47.1 years) that do not reflect the range of values across the study population. Making an assumption about individual data based upon aggregated statistics (known as &ldquo;ecological fallacy&rdquo;) can produce invalid results in meta-regression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two hypothetical examples of studies susceptible to ecological fallacy are presented in a figure (",
"    <a class=\"graphic graphic_figure graphicRef63627 \" href=\"mobipreview.htm?36/58/37794\">",
"     figure 9",
"    </a>",
"    ). The only reliable way to determine the presence of ecological fallacy is to evaluate whether analyses of patient-level data (eg, within-study data) are consistent with analyses across studies (eg, meta-regression).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2327483\">",
"    <span class=\"h2\">",
"     Subgroup analyses",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a complete range of data is not available for meta-regression, an alternative is to categorize studies into subgroups based upon clinically relevant variables. Separate meta-analyses of these subgroups can then be compared. Subgroup analysis is subject to the same limitations inherent to meta-regression, including risks associated with data dredging and ecological fallacy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2326516\">",
"    <span class=\"h2\">",
"     Individual patient data",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is sometimes possible to obtain original patient-level databases in order to reanalyze individual patient data in a meta-analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/12\">",
"     12",
"    </a>",
"    ]. Pooling individual patient data is considered to be the most rigorous form of meta-analysis. While more costly and time consuming, and limited by difficulties collecting original data, there are a number of benefits. These include the ability to perform meta-regressions of patient-level predictors (eg, age) without the risk of ecological fallacy, time-to-event analyses, and to include unpublished, previously unanalyzed data. However, analyses of partial databases (all that may be available with proprietary data) or of selected databases are subject to selection bias or limited generalizability of results, similar to other retrospective analyses of incomplete samples.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2326523\">",
"    <span class=\"h2\">",
"     Network meta-analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systematic reviews commonly compare the relative effects of several interventions (eg, different statins), not just the comparison of two specific interventions. However, individual trials generally compare selected interventions to each other (eg, one statin to another). When multiple specific interventions are compared across trials, a network of studies can be established where all the studied interventions are linked to each other by individual trials. Network meta-analysis (also termed &ldquo;mixed treatment comparison&rdquo; or &ldquo;multiple treatment comparison&rdquo;) evaluates all studies and all interventions simultaneously to produce multiple pairwise estimates of relative effects of each intervention compared with every other intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A diagram of a network meta-analysis of trials of all antihypertensive drugs and the risk of cancer is shown in a figure (",
"    <a class=\"graphic graphic_figure graphicRef79458 \" href=\"mobipreview.htm?40/33/41503\">",
"     figure 10",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/61\">",
"     61",
"    </a>",
"    ]. Although no trials directly compared combination of angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs) with placebo, an indirect comparison can be made by analyzing all the studies that compared ACEi and ARBs with either ACEi alone or ARBs alone and that compared ACEi or ARBs with placebo. Network meta-analyses with sufficient data should compare the direct comparisons (eg, ACEi versus ARBs) with the indirect comparisons (eg, the same comparison derived from trials of ACEi versus placebo and ARBs versus placebo).",
"   </p>",
"   <p>",
"    Greater care is required to ensure that a network meta-analysis is appropriate and valid than may be needed for a simple meta-analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39609/abstract/60\">",
"     60",
"    </a>",
"    ]. The benefits of randomization are lost when making comparisons across trials. Thus, it is particularly important that studies included in a network meta-analysis are similar in their participants, setting, ancillary treatments, and other relevant parameters.",
"   </p>",
"   <p>",
"    If studies of &lsquo;X&rsquo; versus placebo are systematically different than studies of &lsquo;Y&rsquo; versus placebo, then an indirect comparison of &lsquo;X&rsquo; versus &lsquo;Y&rsquo; may be biased due to the differences between studies of &lsquo;X&rsquo; and &lsquo;Y&rsquo;. As an example, if studies of &lsquo;X&rsquo; versus placebo were conducted decades ago and studies of &lsquo;Y&rsquo; versus placebo are more recent, the differences in the indirect comparison of &lsquo;X&rsquo; versus &lsquo;Y&rsquo; may be partly due to differences in disease management over the intervening decades. One method of testing the validity of a network is to compare direct and indirect comparisons of the same pairs of interventions. Networks in which direct and indirect comparisons disagree are labeled as inconsistent. Those with substantial inconsistency should be analyzed carefully or not at all. Attempts should be made to explain the inconsistency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2326530\">",
"    <span class=\"h1\">",
"     READING AND INTERPRETING A SYSTEMATIC REVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the steps involved in conducting a systematic review with meta-analysis can be difficult to understand without appropriate training. In some cases, acceptance of the assumptions made by the reviewers (eg, why certain studies were excluded, why particular outcomes were considered to be clinically similar or distinct) require a degree of faith since they are not always obvious from reading the manuscript. The temptation for readers is to accept the results on the faith that the authors and a journal&rsquo;s peer-review process have produced a valid summary of the body of evidence. However, journal readers should appraise systematic reviews, like all primary studies, for their quality and the extent to which the findings are applicable to the questions being posed.",
"   </p>",
"   <p>",
"    Systematic review and meta-analysis are subject to the same biases observed in all retrospective analyses. Researchers&rsquo; focus or biases (due to factors such as funding source, researchers&rsquo; agendas or specialties) may subtly affect systematic reviews just as they may affect the eligibility of subjects or protocols in an individual study. In addition, the value of a systematic review&rsquo;s conclusions may be limited by the quality and applicability of the underlying studies.",
"   </p>",
"   <p>",
"    Since meta-analysis is a pooling of distinct individual studies, it is important to bear in mind that the overall results, even more than individual study results, are not directly interpretable as a patient-level risk (of an outcome) and cannot make personalized predictions for patients. Results must be interpreted as an average result for a population.",
"   </p>",
"   <p>",
"    These potential biases should not discredit the process of systematic review, but instead readers should apply an equally critical eye to systematic reviews as to primary studies. Questions to consider when evaluating a systematic review are presented in a table (",
"    <a class=\"graphic graphic_table graphicRef56270 \" href=\"mobipreview.htm?24/59/25532\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2326537\">",
"    <span class=\"h1\">",
"     GLOSSARY OF TERMS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110188417\">",
"    <span class=\"h2\">",
"     Applicability (generalizability)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relevance of a study (or a group of studies) to a population of interest (or an individual patient). This requires an assessment of how similar the subjects of a study are to the population of interest, the relevance of the studied interventions and outcomes, and other PICO features. (See",
"    <a class=\"local\" href=\"#H110188348\">",
"     'PICO method (PICOD, PICOS, PICOTS, others)'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2327798\">",
"    <span class=\"h2\">",
"     Ecological fallacy (ecological inference fallacy)",
"    </span>",
"    &nbsp;&mdash;&nbsp;An error in interpreting data where inferences are made about specific individuals based upon aggregated statistics for groups of individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110188273\">",
"    <span class=\"h2\">",
"     Fixed effect model",
"    </span>",
"    &nbsp;&mdash;&nbsp;A statistical method for combining data that incorporates only within-study variance. Assumes that all studies represent the same population for which there is a single &ldquo;true&rdquo; effect size.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110188336\">",
"    <span class=\"h2\">",
"     Forest plot",
"    </span>",
"    &nbsp;&mdash;&nbsp;A graphical display of the results, with 95% confidence intervals, of the individual studies that go into a meta-analysis together with the meta-analytic summary effect size (and confidence interval). Said to look like a forest of trees.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110188387\">",
"    <span class=\"h2\">",
"     Funnel plot",
"    </span>",
"    &nbsp;&mdash;&nbsp;A graphical technique, with related statistical tests, to examine the studies within a systematic review for the possibility of publication bias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110188399\">",
"    <span class=\"h2\">",
"     Grey literature",
"    </span>",
"    &nbsp;&mdash;&nbsp;A term with varying and shifting meaning that indicates sources of evidence beyond the peer-reviewed, published literature available in major databases (eg, Medline). Examples include alternative databases, conference abstracts and proceedings, unpublished studies (eg, via clinicaltrials.gov), newspaper or internet citations, citation indexes, handsearching of journals or reference lists, and domain experts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110188136\">",
"    <span class=\"h2\">",
"     Heterogeneity (statistical heterogeneity)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Differences in study results across studies examining similar questions. Statistical heterogeneity may be due to differences in specific features of study design or to chance. Measured with a variety of statistical tests, most commonly I",
"    <sup>",
"     2",
"    </sup>",
"    and the Q statistic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110188185\">",
"    <span class=\"h3\">",
"     Clinical heterogeneity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Differences in study features, such as study eligibility criteria, interventions, or methods of measuring outcomes, that may preclude appropriate meta-analysis. These features can be explicit (such as different drug doses used) or implicit (such as differences in populations depending on setting or country). Clinical heterogeneity may or may not result in statistical heterogeneity, but often may not, for example if the effect size is similar regardless of the drug dose, of the individual drug within a class of drugs, or in different populations (eg, men and women, or Japanese and Americans). (See",
"    <a class=\"local\" href=\"#H110188136\">",
"     'Heterogeneity (statistical heterogeneity)'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110188287\">",
"    <span class=\"h2\">",
"     I2 index",
"    </span>",
"    &nbsp;&mdash;&nbsp;A statistical test to describe heterogeneity among studies. It can be interpreted as the percentage of the total variability that is due to true heterogeneity (as opposed to chance). Values of 25, 50, and 75 percent are commonly considered to represent low, medium, and high heterogeneity, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110188249\">",
"    <span class=\"h2\">",
"     Key questions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Research questions that are clearly defined and form the basis for the systematic review or meta-analysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110188324\">",
"    <span class=\"h2\">",
"     Meta-regression",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analytic technique that permits adjustment for potential confounders and analysis of different variables to help explain differences in results across studies. Equivalent to patient-level regression, except that the unit of analysis is a study instead of a person.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110188312\">",
"    <span class=\"h2\">",
"     Network meta-analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A technique to simultaneously meta-analyze a network of studies that evaluated related, but different, specific comparisons. It permits quantitative inferences across studies that have made indirect comparisons of interventions. An example would be the comparison of two or more drugs to each other, when each was studied in comparison to placebo.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110188348\">",
"    <span class=\"h2\">",
"     PICO method (PICOD, PICOS, PICOTS, others)",
"    </span>",
"    &nbsp;&mdash;&nbsp;An acronym that stands for Population, Intervention(s), Comparator(s), Outcome(s); added letters include Study Design (PICOD), Setting (PICOS), Timing and Setting (PICOTS). PICO is the basis for a systematic approach in developing a key question and research protocol. While used extensively for systematic reviews, PICO is relevant to all medical research questions. Each feature is defined explicitly and comprehensively so that it is unambiguously evident which studies are eligible for inclusion in a systematic review.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110189133\">",
"    <span class=\"h2\">",
"     Precision",
"    </span>",
"    &nbsp;&mdash;&nbsp;Precision refers to the extent to which the observed results would be reproduced exactly, given the same interventions and study design. Precision can be contrasted with validity, which refers to the extent to which the results reflect the &ldquo;truth.&rdquo;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110188452\">",
"    <span class=\"h2\">",
"     PRISMA statement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preferred Reporting Items of Systematic reviews and Meta-Analyses, an update of QUOROM (Quality of Reporting of Meta-analyses) statement. A guideline for reporting of systematic reviews, used as a standard by many journals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110188375\">",
"    <span class=\"h2\">",
"     Publication bias",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of several related biases in the available evidence being considered for inclusion in a systematic review. Conceptually, studies that have been published are systematically different than studies that have failed to be published, due to lack of acceptance by journals, lack of interest by authors or research grantors, or potentially, by deliberate withholding by funders. Theoretically, &ldquo;positive&rdquo; (statistically significant) results are more likely to be published than &ldquo;negative&rdquo; results. Strictly, publication bias refers specifically to missing publications about studies.",
"   </p>",
"   <p>",
"    Related biases include selective outcome reporting bias, where studies are published without certain outcomes; time-lag bias, where &ldquo;negative&rdquo; study results tend to be delayed in their publication compared with &ldquo;positive&rdquo; results; location bias, where &ldquo;positive&rdquo; or more interesting results tend to be published in journals that are more easily accessible; language bias, pertinent in certain fields, where non-English language publications differ in study results compared with those published (from the same countries or authors) in English; and multiple or duplicate publication bias, where certain studies may be overrepresented in the literature due to duplicate or overlapping publications (that may be difficult to tease apart).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110188300\">",
"    <span class=\"h2\">",
"     Q statistic (chi square test for heterogeneity)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A statistical method to test whether studies are heterogeneous. Commonly P&lt;0.10 indicates the likely presence of statistical heterogeneity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110188261\">",
"    <span class=\"h2\">",
"     Random effects model",
"    </span>",
"    &nbsp;&mdash;&nbsp;A statistical method for combining data that incorporates both within-study variances (differences in results, mostly due to chance) and the between-study variance (differences in results across studies due either to chance or to systematic differences among the studies). Assumes that each study represents a different population and that there is not a single &ldquo;true&rdquo; effect size.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2327805\">",
"    <span class=\"h2\">",
"     Sensitivity analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A method of exploring heterogeneity",
"    <strong>",
"    </strong>",
"    in a meta-analysis by varying which studies are included to determine the effects of such changes. Used to explore how sensitive a meta-analysis finding is to inclusion of individual studies and to evaluate possible causes of heterogeneity; for example, whether exclusion of poor quality studies influences the size of the effect. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110188989\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A systematic review is a comprehensive summary of all available evidence that meets predefined eligibility criteria to address a specific clinical question or range of questions. Meta-analysis, which is commonly included in systematic reviews, is a statistical method that quantitatively combines the results from different studies. It is commonly used to provide an overall estimate of the net benefit or harm of an intervention. Heterogeneity, differences among studies to be considered for systematic review, may be explained by random chance alone or may be due to basic differences in trial design or participants across studies. (See",
"      <a class=\"local\" href=\"#H2327453\">",
"       'Terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A systematic review should describe the research questions and the review methodology, including the search strategy and approach to analyzing the data. The literature search should be systematic and comprehensive. Several methodologies can suggest the presence of publication bias, though none are definitive. Studies should be critically appraised on the basis of multiple factors of quality to determine the degree of confidence that the estimate of effect reflects the &ldquo;truth&rdquo; as best as it can be measured. (See",
"      <a class=\"local\" href=\"#H2326459\">",
"       'Developing a protocol'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In performing a meta-analysis, the summary effect estimate can be based upon a fixed effect or random effects model; results using the random effects model are more conservative. The decision to combine studies should be based on both qualitative and quantitative evaluations of heterogeneity, including the Q statistic or the I",
"      <sup>",
"       2",
"      </sup>",
"      index. (See",
"      <a class=\"local\" href=\"#H110188885\">",
"       'Meta-analysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The forest plot allows the reader to see the estimate and the precision of the individual studies, appreciate the heterogeneity of results, and compare the estimates of the individual studies to the overall result. Sensitivity analysis of results evaluates the stability of overall estimates among different subgroups, and also explores heterogeneity. Techniques for sensitivity analysis include meta-regression and subgroup analysis. (See",
"      <a class=\"local\" href=\"#H96519889\">",
"       'Forest plots'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H110188885\">",
"       'Meta-analysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Systematic reviews, like primary studies, should be interpreted with questions raised about their quality and the applicability of their findings to the questions of the reader. Overall results reflect an average effect in a population and are not directly transferrable to an individual patient. (See",
"      <a class=\"local\" href=\"#H2326530\">",
"       'Reading and interpreting a systematic review'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/1\">",
"      Ioannidis JP. Why most published research findings are false: author's reply to Goodman and Greenland. PLoS Med 2007; 4:e215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/2\">",
"      LeLorier J, Gr&eacute;goire G, Benhaddad A, et al. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 1997; 337:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/3\">",
"      Cappelleri JC, Ioannidis JP, Schmid CH, et al. Large trials vs meta-analysis of smaller trials: how do their results compare? JAMA 1996; 276:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/4\">",
"      Villar J, Carroli G, Beliz&aacute;n JM. Predictive ability of meta-analyses of randomised controlled trials. Lancet 1995; 345:772.",
"     </a>",
"    </li>",
"    <li>",
"     Systematic reviews, Chalmers I, Altman DG (Eds), BMJ Publishing Group, London 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/6\">",
"      Cook DJ, Mulrow CD, Haynes RB. Systematic reviews: synthesis of best evidence for clinical decisions. Ann Intern Med 1997; 126:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/7\">",
"      Oxman AD, Cook DJ, Guyatt GH. Users' guides to the medical literature. VI. How to use an overview. Evidence-Based Medicine Working Group. JAMA 1994; 272:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/8\">",
"      Mulrow CD. The medical review article: state of the science. Ann Intern Med 1987; 106:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/9\">",
"      Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997; 127:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/10\">",
"      Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009; 151:W65.",
"     </a>",
"    </li>",
"    <li>",
"     Institute of Medicine. Finding what workds in health care: Standards for systematic reviews. The National Academies Press, Washington, DC, 2011. Available at: file://www.iom.edu/Reports/2011/Finding-What-Works-in-Health-Care-Standards-for-Systematic-Reviews.aspx (Accessed on October 10, 2011).",
"    </li>",
"    <li>",
"     Clarke MJ, Stewart LA. Principles of and procedures for systematic reviews. In: Systematic reviews in health care: meta-analysis in context, Egger M, Smith G, Altman D (Eds), BMJ Publishing Group, London 2001. p.23.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/13\">",
"      Counsell C. Formulating questions and locating primary studies for inclusion in systematic reviews. Ann Intern Med 1997; 127:380.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.ncbi.nlm.nih.gov/pubmed (Accessed on July 14, 2011).",
"    </li>",
"    <li>",
"     file://www.embase.com/search (Accessed on July 14, 2011).",
"    </li>",
"    <li>",
"     file://onlinelibrary.wiley.com/o/cochrane/cochrane_clcentral_articles_fs.html.",
"    </li>",
"    <li>",
"     Dickersin K, Chalmers I. Recognising, investigating and dealing with incomplete and biased reporting of clinical research: from Francis Bacon to the World Health Organisation. James Lind Library 2010. Available at: www.jameslindlibrary.org (Accessed on October 10, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/18\">",
"      Mathieu S, Boutron I, Moher D, et al. Comparison of registered and published primary outcomes in randomized controlled trials. JAMA 2009; 302:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/19\">",
"      Kirkham JJ, Altman DG, Williamson PR. Bias due to changes in specified outcomes during the systematic review process. PLoS One 2010; 5:e9810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/20\">",
"      Ioannidis JP. Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. JAMA 1998; 279:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/21\">",
"      Thornton A, Lee P. Publication bias in meta-analysis: its causes and consequences. J Clin Epidemiol 2000; 53:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/22\">",
"      Goodman S, Dickersin K. Metabias: a challenge for comparative effectiveness research. Ann Intern Med 2011; 155:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/23\">",
"      Vevea JL, Woods CM. Publication bias in research synthesis: sensitivity analysis using a priori weight functions. Psychol Methods 2005; 10:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/24\">",
"      Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/25\">",
"      Tang JL, Liu JL. Misleading funnel plot for detection of bias in meta-analysis. J Clin Epidemiol 2000; 53:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/26\">",
"      Terrin N, Schmid CH, Lau J, Olkin I. Adjusting for publication bias in the presence of heterogeneity. Stat Med 2003; 22:2113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/27\">",
"      Terrin N, Schmid CH, Lau J. In an empirical evaluation of the funnel plot, researchers could not visually identify publication bias. J Clin Epidemiol 2005; 58:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/28\">",
"      Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000; 56:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/29\">",
"      Copas J. What works?: Selectivity models and meta-analysis. Journal of the Royal Statistical Society Series A 1999; 162:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/30\">",
"      Rosenthal R. The 'file drawer problem' and tolerance for null results. Psychol Bull 1979; 86:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/31\">",
"      Ioannidis JP, Trikalinos TA. An exploratory test for an excess of significant findings. Clin Trials 2007; 4:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/32\">",
"      Moher D, Jadad AR, Nichol G, et al. Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists. Control Clin Trials 1995; 16:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/33\">",
"      Verhagen AP, de Vet HC, de Bie RA, et al. The art of quality assessment of RCTs included in systematic reviews. J Clin Epidemiol 2001; 54:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/34\">",
"      J&uuml;ni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001; 323:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/35\">",
"      J&uuml;ni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 1999; 282:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/36\">",
"      Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/37\">",
"      Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 2001; 135:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/38\">",
"      Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998; 352:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/39\">",
"      Linde K, Scholz M, Ramirez G, et al. Impact of study quality on outcome in placebo-controlled trials of homeopathy. J Clin Epidemiol 1999; 52:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/40\">",
"      Balk EM, Bonis PA, Moskowitz H, et al. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. JAMA 2002; 287:2973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/41\">",
"      Balk EM, Tatsioni A, Lichtenstein AH, et al. Effect of chromium supplementation on glucose metabolism and lipids: a systematic review of randomized controlled trials. Diabetes Care 2007; 30:2154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/42\">",
"      Deeks JJ. Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Stat Med 2002; 21:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/43\">",
"      Walter SD. Choice of effect measure for epidemiological data. J Clin Epidemiol 2000; 53:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/44\">",
"      Wu LA, Kottke TE. Number needed to treat: caveat emptor. J Clin Epidemiol 2001; 54:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/45\">",
"      Engels EA, Schmid CH, Terrin N, et al. Heterogeneity and statistical significance in meta-analysis: an empirical study of 125 meta-analyses. Stat Med 2000; 19:1707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/46\">",
"      Smeeth L, Haines A, Ebrahim S. Numbers needed to treat derived from meta-analyses--sometimes informative, usually misleading. BMJ 1999; 318:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/47\">",
"      DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/48\">",
"      Lau J, Ioannidis JP, Schmid CH. Summing up evidence: one answer is not always enough. Lancet 1998; 351:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/49\">",
"      Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 2007; 26:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/50\">",
"      Huedo-Medina TB, S&aacute;nchez-Meca J, Mar&iacute;n-Mart&iacute;nez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods 2006; 11:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/51\">",
"      Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/52\">",
"      Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines 6. Rating the quality of evidence--imprecision. J Clin Epidemiol 2011; 64:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/53\">",
"      Berkey CS, Hoaglin DC, Mosteller F, Colditz GA. A random-effects regression model for meta-analysis. Stat Med 1995; 14:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/54\">",
"      Schmid CH. Exploring heterogeneity in randomized trials via metaanalysis. Drug Inf J 1999; 33:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/55\">",
"      van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med 2002; 21:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/56\">",
"      Ioannidis JP, Cappelleri JC, Sacks HS, Lau J. The relationship between study design, results, and reporting of randomized clinical trials of HIV infection. Control Clin Trials 1997; 18:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/57\">",
"      Schulz KF, Grimes DA. Multiplicity in randomised trials II: subgroup and interim analyses. Lancet 2005; 365:1657.",
"     </a>",
"    </li>",
"    <li>",
"     Rothman KJ, Greenland S. Modern epidemiology, 2nd ed, Lippincott-Raven, Philadelphia 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/59\">",
"      Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 2011; 14:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/60\">",
"      Mills EJ, Ioannidis JP, Thorlund K, et al. How to use an article reporting a multiple treatment comparison meta-analysis. JAMA 2012; 308:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39609/abstract/61\">",
"      Bangalore S, Kumar S, Kjeldsen SE, et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol 2011; 12:65.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16293 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-3836C529BC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_43_39609=[""].join("\n");
var outline_f38_43_39609=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H110188989\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2326445\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2327453\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H78553622\">",
"      Systematic review",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H78553629\">",
"      Meta-analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H78553636\">",
"      Heterogeneity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2326452\">",
"      OVERVIEW OF SYSTEMATIC REVIEW AND META-ANALYSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2327460\">",
"      Consensus statements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2326459\">",
"      DEVELOPING A PROTOCOL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2326466\">",
"      Formulating research questions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2326473\">",
"      PERFORMING THE LITERATURE SEARCH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2326480\">",
"      Publication bias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2326487\">",
"      ASSESSING THE QUALITY OF STUDIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H96519889\">",
"      FOREST PLOTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H110188885\">",
"      META-ANALYSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2326494\">",
"      Statistical methods for combining data",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2326501\">",
"      When to combine studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7125075\">",
"      Precision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2327699\">",
"      Sensitivity analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2327476\">",
"      Meta-regression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2327483\">",
"      Subgroup analyses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2326516\">",
"      Individual patient data",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2326523\">",
"      Network meta-analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2326530\">",
"      READING AND INTERPRETING A SYSTEMATIC REVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2326537\">",
"      GLOSSARY OF TERMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H110188417\">",
"      Applicability (generalizability)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2327798\">",
"      Ecological fallacy (ecological inference fallacy)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H110188273\">",
"      Fixed effect model",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H110188336\">",
"      Forest plot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H110188387\">",
"      Funnel plot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H110188399\">",
"      Grey literature",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H110188136\">",
"      Heterogeneity (statistical heterogeneity)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H110188185\">",
"      - Clinical heterogeneity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H110188287\">",
"      I2 index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H110188249\">",
"      Key questions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H110188324\">",
"      Meta-regression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H110188312\">",
"      Network meta-analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H110188348\">",
"      PICO method (PICOD, PICOS, PICOTS, others)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H110189133\">",
"      Precision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H110188452\">",
"      PRISMA statement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H110188375\">",
"      Publication bias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H110188300\">",
"      Q statistic (chi square test for heterogeneity)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H110188261\">",
"      Random effects model",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2327805\">",
"      Sensitivity analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H110188989\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/16293\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/16293|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/15/9456\" title=\"figure 1\">",
"      Funnel plots",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/54/17256\" title=\"figure 2\">",
"      Forest plot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/46/2799\" title=\"figure 3\">",
"      Fixed effects model",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/10/19616\" title=\"figure 4\">",
"      Random effects model",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/27/12725\" title=\"figure 5\">",
"      Precision and validity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/27/14777\" title=\"figure 6\">",
"      Meta-analysis subgroup stratification I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/58/33704\" title=\"figure 7\">",
"      Meta-analysis subgroup stratification II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/11/40125\" title=\"figure 8\">",
"      Meta-regression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/58/37794\" title=\"figure 9\">",
"      Ecological fallacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/33/41503\" title=\"figure 10\">",
"      Network meta-analysis of antihypertensive drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/16293|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/17/6428\" title=\"table 1\">",
"      Methods of summarizing studies in systematic reviews",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/59/25532\" title=\"table 2\">",
"      Questions to consider",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/18/22823?source=related_link\">",
"      Glossary of common biostatistical and epidemiological terms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_43_39610="Risks of therapy with bone modifying agents in patients with advanced malignancy";
var content_f38_43_39610=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Risks of therapy with bone modifying agents in patients with advanced malignancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/43/39610/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/43/39610/contributors\">",
"     James R Berenson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/43/39610/contributors\">",
"     Alison T Stopeck, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/43/39610/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/43/39610/contributors\">",
"     Robert A Kyle, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/43/39610/contributors\">",
"     Reed E Drews, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/43/39610/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/43/39610/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/43/39610/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parenteral administration of osteoclast inhibitors (bisphosphonates and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    ) reduces the frequency of skeletal-related events among patients with multiple myeloma and in those with bone metastases from a variety of solid tumors, including breast, lung, and prostate cancer. Prolonged therapy with these bone modifying agents in patients with advanced malignancy is generally well tolerated, but some side effects are potentially serious and require periodic monitoring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will provide an overview of the risks of therapy with bone modifying agents in patients with skeletal involvement from advanced malignancy. The therapeutic use of bisphosphonates and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    in malignant disease, and their use and side effects in other conditions, such as osteoporosis and cancer treatment-related bone loss, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/18/13608?source=see_link\">",
"     \"Bisphosphonates and denosumab in patients with metastatic cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/27/30137?source=see_link\">",
"     \"The use of bisphosphonates in patients with multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/54/8042?source=see_link\">",
"     \"Osteoclast inhibition in the management of bone metastases from breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=see_link\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22040?source=see_link\">",
"     \"Denosumab for osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/42/37545?source=see_link\">",
"     \"Evaluation and management of aromatase inhibitor-induced bone loss\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/35/33336?source=see_link\">",
"     \"Overview of the use of osteoclast inhibitors in early breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/30/21993?source=see_link&amp;anchor=H9#H9\">",
"     \"Side effects of androgen deprivation therapy\", section on 'Prevention'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/36999?source=see_link\">",
"     \"Management of bone metastases in advanced prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1932654\">",
"    <span class=\"h1\">",
"     CLASSES OF BONE MODIFYING AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two classes of bone modifying agents are used for prevention of skeletal events in patients with advanced malignancy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bisphosphonates (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=see_link\">",
"       pamidronate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      ) are structural analogs of inorganic pyrophosphate. Bisphosphonates inhibit osteoclastic bone resorption by attaching to hydroxyapatite binding sites within bone. The bisphosphonate that is released during bone resorption impairs the ability of the osteoclasts to adhere to the bony surface and resorb bone. In addition, bisphosphonates also reduce osteoclast activity by decreasing osteoclast progenitor development and recruitment and by promoting osteoclast apoptosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/4/11333?source=see_link\">",
"       \"Pharmacology of bisphosphonates\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"       Denosumab",
"      </a>",
"      is a fully human monoclonal antibody that inhibits osteoclastic bone resorption by specifically binding and inhibiting receptor activator of nuclear factor-KB ligand (RANKL), a key regulator of osteoclast formation, function, and survival. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/5/34906?source=see_link\">",
"       \"Normal skeletal development and regulation of bone formation and resorption\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both classes of agents are approved for use in patients with bone metastases from a variety of solid tumors, and bisphosphonates are also approved for prevention of skeletal-related events in patients with multiple myeloma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/18/13608?source=see_link\">",
"     \"Bisphosphonates and denosumab in patients with metastatic cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/54/8042?source=see_link\">",
"     \"Osteoclast inhibition in the management of bone metastases from breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/27/30137?source=see_link\">",
"     \"The use of bisphosphonates in patients with multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/36999?source=see_link\">",
"     \"Management of bone metastases in advanced prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     Denosumab",
"    </a>",
"    shares several toxicities with bisphosphonates, including osteonecrosis of the jaw (ONJ) and hypocalcemia. However, there are differences as well. As a fully human monoclonal antibody, denosumab is administered as a subcutaneous rather than intravenous injection, and its toxicity profile differs in several respects from that of bisphosphonates (",
"    <a class=\"graphic graphic_table graphicRef67326 \" href=\"mobipreview.htm?32/33/33307\">",
"     table 1",
"    </a>",
"    ). Knowledge about the comparative side effect profiles of denosumab and bisphosphonates is primarily derived from the three large, identically designed, registration trials performed in patients with bone metastases from breast, prostate, or other solid tumors and multiple myeloma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1927316\">",
"    <span class=\"h1\">",
"     RISKS SHARED BY BOTH CLASSES OF DRUGS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1928329\">",
"    <span class=\"h2\">",
"     Osteonecrosis of the jaw",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteonecrosis of the jaw (ONJ), first described in 2002 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/7\">",
"     7",
"    </a>",
"    ], is a relatively uncommon but potentially serious side effect of treatment with either intravenous (IV) high potency bisphosphonates (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55727 \" href=\"mobipreview.htm?8/45/8927\">",
"     image 1",
"    </a>",
"    ) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1928351\">",
"    <span class=\"h3\">",
"     Definition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two working definitions of ONJ have been proposed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A task force convened by the American Society for Bone and Mineral Research defines ONJ as the presence of exposed bone in the maxillofacial region that does not heal within eight weeks after identification by a health care professional [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A task force from the American Association of Oral and Maxillofacial Surgeons (AAOMS) defines ONJ as the persistence of exposed bone in the oral cavity, despite adequate treatment for eight weeks, without local evidence of malignancy and no prior radiotherapy to the affected region [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/9\">",
"       9",
"      </a>",
"      ]. We prefer this definition.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1928358\">",
"    <span class=\"h3\">",
"     Pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;ONJ is a form of avascular necrosis. The shared complication of ONJ in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    and bisphosphonates strongly suggests that potent and prolonged inhibition of bone resorption is the primary mechanism, although it is probably not the sole contributor:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Biofilms have been identified on the",
"      <span class=\"nowrap\">",
"       bone/tooth",
"      </span>",
"      and mucosal surfaces around bisphosphonate-related ONJ that are composed of actinomyces and other organisms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/10-14\">",
"       10-14",
"      </a>",
"      ]. However, it is not known whether ONJ represents direct toxicity to the bone",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      soft tissues that becomes secondarily infected [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/15,16\">",
"       15,16",
"      </a>",
"      ] or if the disorder represents a primary infection that is exacerbated by the use of bisphosphonates or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"       denosumab",
"      </a>",
"      . Furthermore, it is unclear if the common presence of actinomyces in these lesions is actively contributing to the development or progression of ONJ, or simply related to the presence of necrotic bone in an anaerobic environment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/10\">",
"       10",
"      </a>",
"      ]. Controlled trials evaluating specific antimicrobials or an optimal duration of therapy for actinomycosis in ONJ have not been performed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Accumulating evidence on risk factors for ONJ in patients undergoing therapy with a bone modifying agent support the view that ONJ may be the consequence of a combination of events, including impaired bone repair and suppression of osteoclast activity, and impaired angiogenesis or vascular repair, with a contribution from poor dental hygiene, including poorly fitting dentures,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a dental manipulation of some sort (eg, dental extraction, advanced periodontal disease) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/15,17-23\">",
"       15,17-23",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H1928392\">",
"       'Incidence and risk factors'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The preferential localization of ONJ events to the mandible also suggests that the more frequent microdamage inflicted on the lower jaw bone with mastication might also represent a contributory factor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/24\">",
"       24",
"      </a>",
"      ]. However, it is important to note that approximately one-third of cases occur in the maxillary bone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1928365\">",
"    <span class=\"h3\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;ONJ typically presents as infection and exposed necrotic bone in the jaw [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/25\">",
"     25",
"    </a>",
"    ]. In one review of 368 reported cases, ONJ was manifested in the mandible in 65 percent, maxilla in 26 percent, and both in 9 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/26\">",
"     26",
"    </a>",
"    ]. Most lesions are painful, but in one report of 119 patients with ONJ, approximately one-third of lesions were painless [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/27\">",
"     27",
"    </a>",
"    ]. Prior to the development of exposed bone, some patients experience prolonged jaw pain, bone enlargement, gingival swelling,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sinus tract swelling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a report of 35 patients with ONJ, the most common complaints were pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    numbness in the affected area, soft tissue swelling, drainage, and tooth mobility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/10\">",
"     10",
"    </a>",
"    ]. The exposed bone appeared nonvital and was asymptomatic on being probed in all cases. Histologic examination of 12 bone tissue samples demonstrated fragments of necrotic bone associated with florid bacterial colonization morphologically consistent with actinomyces species. Soft tissue biopsy consistently revealed inflamed squamous mucosa or granulation tissue. Malignant cells were not seen in any of the specimens.",
"   </p>",
"   <p>",
"    A staging classification for ONJ related to use of bone modifying agents was initially proposed in 2006 and modified by the AAOMS (",
"    <a class=\"graphic graphic_table graphicRef69275 \" href=\"mobipreview.htm?5/27/5564\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/29\">",
"     29",
"    </a>",
"    ]. However, the suggested treatment strategies, which are based upon disease extent, are not evidence-based. (See",
"    <a class=\"local\" href=\"#H1928489\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    ONJ can be visualized using panoramic radiography, computed tomography (CT), or magnetic resonance imaging (MRI). However, the extent of these lesions may not be clear, especially in the early stages. In particular, radiographic findings such as poorly healing or non-healing extraction sockets, periapical radiolucencies, and widening of the periodontal ligament space are not specific in the early stages of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/30\">",
"     30",
"    </a>",
"    ]. Thus, there is no utility for screening radiographic studies.",
"   </p>",
"   <p>",
"    While many patients initially identified as having ONJ may be found to have other dental conditions when evaluated by experts in this field, failure to recognize the signs of ONJ can lead to unnecessary surgical procedures on the jaw, which ultimately may exacerbate the condition and impact the patient's quality of life. Thus, early diagnosis and a high index of suspicion in patients on chronic therapy with a bone modifying agent are important. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1928392\">",
"    <span class=\"h3\">",
"     Incidence and risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although potentially serious, ONJ is a relatively uncommon complication of therapy with IV bisphosphonates and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    among patients with advanced malignancy. The best information on incidence comes from a review of data on 5723 patients with a wide variety of malignancies who were enrolled on three identically designed prospective randomized trials comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    versus denosumab [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/31\">",
"     31",
"    </a>",
"    ]. ONJ was defined per the guidelines of the American Academy of Oral and Maxillofacial Surgeons (AAOMS) as described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1928351\">",
"     'Definition'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Oral adverse events potentially indicative of ONJ as well as abnormal findings identified on oral exam were considered possible ONJ events, and further clinical data was queried, including dental records for adjudication by an external, blinded, independent panel of dental experts. The following findings were noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/31\">",
"     31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fifty-two patients (1.8 percent) on the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"       denosumab",
"      </a>",
"      treatment arm developed ONJ compared to 37 (1.3 percent) on the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      arm. This difference was not significantly different between treatment groups (p=0.13).",
"     </li>",
"     <li>",
"      ONJ events were documented as early as four months after starting therapy and up to 30 months after first dose of drug; the median time of drug exposure prior to the development of ONJ was 14 months in both groups.",
"     </li>",
"     <li>",
"      Dental extraction preceded the ONJ event in 62 percent of cases; 82 percent had jaw pain, and a coincident oral infection was present in 48 percent of cases.",
"     </li>",
"     <li>",
"      When risk factors were compared between patients who developed ONJ versus those who did not, a slightly higher percentage of patients on corticosteroids (73 versus 62 percent) and antiangiogenic agents (16 versus 8 percent) developed ONJ, but the numbers were too small to draw statistical conclusions. In terms of the incidence among different tumor types, a slightly higher percentage of patients with multiple myeloma developed ONJ (3.3 versus 1.7 percent in breast cancer, 1.8 percent in prostate cancer, and 0.9 percent in other solid tumors), although only 180 patients with myeloma were included in the trials.",
"      <br/>",
"      <br/>",
"      Other series have also noted that patients with multiple myeloma appear to have a slightly higher risk of this complication than do patients with solid tumors and metastatic bone disease who receive these drugs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/31-34\">",
"       31-34",
"      </a>",
"      ]. The lower risk seen in patients with metastatic lung cancer or renal cell cancer is probably related to their shorter survival and, thus both the shorter duration of bisphosphonate therapy, and time of observation. (See",
"      <a class=\"local\" href=\"#H1928434\">",
"       'Dose, duration, and type of therapy'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1928434\">",
"    <span class=\"h4\">",
"     Dose, duration, and type of therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1931163\">",
"    <span class=\"h5\">",
"     Bisphosphonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potency of the bisphosphonate and duration of use influences ONJ risk:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk is higher with IV than with oral bisphosphonates, as are used for treatment of osteoporosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/35,36\">",
"       35,36",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=see_link&amp;anchor=H48#H48\">",
"       \"Bisphosphonates in the management of osteoporosis in postmenopausal women\", section on 'Osteonecrosis of the jaw'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The incidence is higher with longer duration of treatment. In a retrospective series of 3994 patients with malignancy who were receiving IV bisphosphonates, the median duration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=see_link\">",
"       pamidronate",
"      </a>",
"      use was longer in those who developed ONJ compared to those who did not (1.68 versus 0.59 years in breast cancer, and 1.55 versus 0.3 years in multiple myeloma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/34\">",
"       34",
"      </a>",
"      ]). The same findings were noted among patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      (2.04 versus 0.73 years in breast cancer, and 1.85 versus 0.67 years in myeloma). In another study, the cumulative hazard of developing ONJ increased according to the duration of IV bisphosphonate therapy (0 percent at one year to 11 percent at four years) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/32\">",
"       32",
"      </a>",
"      ]. However, these results may simply refect a longer observation period and not necessarily the duration of bisphosphonate treatment.",
"     </li>",
"     <li>",
"      Chronic treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      has been implicated as a greater contributor to the development of ONJ than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=see_link\">",
"       pamidronate",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/12,17,32,35,37-42\">",
"       12,17,32,35,37-42",
"      </a>",
"      ]. As an example, a web-based survey of 904 patients with multiple myeloma and 299 with breast cancer identified 75 patients with ONJ and an additional 77 with findings suspicious for early ONJ [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/37\">",
"       37",
"      </a>",
"      ]. ONJ developed in 10 and 4 percent of those treated with zoledronic acid or pamidronate, respectively. However, the diagnosis of ONJ was not necessarily confirmed in individuals who reported having this condition in this web-based survey.",
"      <br/>",
"      <br/>",
"      The possible greater risk for ONJ with zoledronic acid could be due to its greater potency, as demonstrated by larger reductions in collagen type-I degradation products (N-telopeptide) with zoledronic acid than with pamidronate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/43\">",
"       43",
"      </a>",
"      ]. However, it could also be related, in part, to the fact that it is a newer agent than pamidronate, and that patients with myeloma and other cancers are now living longer than previously, with a longer duration of anti-bone resorptive treatment and longer follow up, and are also receiving many new classes of antineoplastic agents such as anti-angiogenic agents that may contribute to the occurrence of ONJ.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1931170\">",
"    <span class=\"h5\">",
"     Denosumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with bisphosphonates, dose, schedule and the degree of osteoclast inhibition are associated with ONJ risk in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    . The approved dose of denosumab for prevention of skeletal-related events in patients with bone metastases from solid tumors is 120 mg subcutaneously every four weeks. At this dose, the risk of ONJ is roughly similar to that seen with IV bisphosphonates. As an example, in an integrated analysis of patient-level information from all three registration trials (which were conducted identically with the only difference being the tumor type (ie, breast, prostate, or other solid tumors), the risk of ONJ with denosumab was 1.8 percent versus 1.3 percent for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/44\">",
"     44",
"    </a>",
"    ]. When denosumab has been administered at a significantly lower dose (ie, 60 mg subcutaneously every six months) for the treatment of postmenopausal or cancer therapy-related osteoporosis, ONJ events have only rarely been reported. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22040?source=see_link&amp;anchor=H5#H5\">",
"     \"Denosumab for osteoporosis\", section on 'Adverse effects'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1928441\">",
"    <span class=\"h4\">",
"     Oral health-associated risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local risk factors, such as invasive dental procedures or concomitant oral disease, also increase the risk for ONJ among patients treated with bone modifying agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/17,27,31,32,34,37,38,45,46\">",
"     17,27,31,32,34,37,38,45,46",
"    </a>",
"    ]. Most cases occur after a dental intervention (tooth extraction, dental implants) at the site of the procedure. As an example, in the analysis of 5723 patients enrolled on three randomized trials comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    for a variety of malignancies described above, tooth extraction during the course of the study was reported for 65 percent of patients who developed ONJ while on zoledronic acid, and 60 percent of those who developed ONJ while receiving denosumab [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1928392\">",
"     'Incidence and risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Other local risk factors include trauma during intubation, fractures, dentures, periodontal disease, dental caries, abscessed teeth, and mandibular tori (bone exostosis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/27,46\">",
"     27,46",
"    </a>",
"    ]. However, cases can occur spontaneously without a precipitating oral event.",
"   </p>",
"   <p>",
"    The incidence of ONJ may be decreasing as a result of better oral care and recognition of the increased risk from invasive dental procedures among patients receiving these drugs and emphasis on regular dental exams and ongoing dental hygiene by patients receiving these agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8702257\">",
"     'Prevention'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1928448\">",
"    <span class=\"h4\">",
"     Other risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of ONJ may vary according to the population under study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/46\">",
"     46",
"    </a>",
"    ]. Reports from Greece and Turkey describe a much higher incidence of ONJ than in Italy and the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/39,40,48\">",
"     39,40,48",
"    </a>",
"    ]. The reasons for these differences could include differences in diagnostic criteria for ONJ in these different regions and genetic factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. However, differences in dental hygiene and frequency of dental exams are likely to be major contributing factors to this geographic variation in the occurrence of this complication.",
"   </p>",
"   <p>",
"    Retrospective reports suggest that the concomitant use of angiogenesis inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    ) may have been an additive risk factor for the development of ONJ in patients receiving bisphosphonates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/40,52-54\">",
"     40,52-54",
"    </a>",
"    ]. However, other reports have not confirmed an association with thalidomide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/10,17,32,41,55-57\">",
"     10,17,32,41,55-57",
"    </a>",
"    ] or bevacizumab [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/58\">",
"     58",
"    </a>",
"    ]. Concomitant use of anthracyclines may be a risk factor for ONJ in myeloma patients treated with IV bisphosphonates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Questions remain as to whether glucocorticoids play a similarly important role in the development of ONJ as they do in the development of osteonecrosis at sites other than the jaw. The data are conflicting, with one series reporting use of glucocorticoids as a risk factor for ONJ in patients with multiple myeloma and another failing to confirm this finding in patients with multiple myeloma or breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/34,60\">",
"     34,60",
"    </a>",
"    ]. In the large series of patients enrolled on trials comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    described above, concomitant use of glucocorticoids was observed in 73 percent of those",
"    <strong>",
"    </strong>",
"    who developed ONJ compared to 62 percent of those who did not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/43/28346?source=see_link&amp;anchor=H3#H3\">",
"     \"Osteonecrosis (avascular necrosis of bone)\", section on 'Corticosteroids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1928489\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for management of ONJ in patients being treated with a bone modifying agent are hindered by a lack of data. There are no prospective studies with long-term follow-up with which to guide therapy and no evidence-based guidelines.",
"   </p>",
"   <p>",
"    Nonetheless, treatment has shifted away from aggressive resection and surgical interventions to prevention and conservative therapy with limited debridement, antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/13,61,62\">",
"     13,61,62",
"    </a>",
"    ], and oral rinses with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    . Conservative management may result in healing in 30 to 60 percent of cases, although some cases become chronic and develop complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/12,31,63\">",
"     12,31,63",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8706104\">",
"     'Outcomes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Surgical resection of necrotic bone, which may occasionally result in even larger areas of exposed and painful infected bone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/12,27,64\">",
"     12,27,64",
"    </a>",
"    ], should be reserved for refractory cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/17,25,64-67\">",
"     17,25,64-67",
"    </a>",
"    ]. When indicated, surgical resection should only be performed by an experienced oral and maxillofacial surgeon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several therapies have been proposed to provide benefit:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/28/13765?source=see_link\">",
"       pentoxifylline",
"      </a>",
"      and oral vitamin E in addition to antimicrobial therapy was reported to be effective in a small case series of bisphosphonate-related ONJ [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Benefit for topical application of medical ozone was suggested in a small series of 10 consecutive patients with ONJ related to bisphosphonate use and in other single case reports from Italy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/71-73\">",
"       71-73",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Case reports and small series suggest benefit from hyperbaric oxygen therapy (HBO) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/26,74-76\">",
"       26,74-76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There are reports that low-level laser therapy improves healing and symptoms related to ONJ [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/77,78\">",
"       77,78",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, whether any of these treatments adds benefit over and above discontinuation of the bisphosphonate is unclear. This question can only be addressed in a randomized trial, at least one of which is underway to evaluate HBO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8706104\">",
"    <span class=\"h4\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best information on outcomes comes from a review of data from three identically designed prospective randomized trials comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    in patients with a wide variety of malignancies described above. (See",
"    <a class=\"local\" href=\"#H1928392\">",
"     'Incidence and risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The majority of patients who developed ONJ (54 percent) received treatment with oral rinses",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    antibiotics alone, with approximately 40 percent undergoing limited oral surgeries including debridement, sequestrectomy, or extraction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/31\">",
"     31",
"    </a>",
"    ]. All patients discontinued bone modifying therapy at ONJ diagnosis, though six patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    reinitiated therapy, and one patient received additional doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    after the diagnosis of ONJ.",
"    <br/>",
"    <br/>",
"    Of the 52 cases of ONJ that developed in patients treated with denosumab, 21 (40 percent) resolved, 20 (39 percent) were still present at the time of death, eight (15 percent) were ongoing, and three (6 percent) were lost to follow-up. Of the 37 patients who developed ONJ while receiving zoledronic acid, resolution of ONJ occurred in 11 patients (30 percent), 15 (41 percent) were still present at the time of death, 8 (22 percent) were ongoing, and three (8 percent) were lost to follow-up. Only one patient received additional doses of zoledronic acid after the diagnosis of ONJ, and the outcome was not reported. The higher rate of resolution observed with denosumab compared to zoledronic acid in these trials (40 versus 30 percent) may be related to the reversibility of denosumab&rsquo;s effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/80,81\">",
"     80,81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional information on the natural history of ONJ comes from a report of 97 patients with multiple myeloma who were observed prospectively for a minimum of 3.2 years following the diagnosis of ONJ [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/82\">",
"     82",
"    </a>",
"    ]. Bisphosphonates were stopped once ONJ was diagnosed. ONJ resolved in 62 percent, resolved and then recurred in 12 percent, and did not heal in 26 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8703756\">",
"    <span class=\"h4\">",
"     Discontinuation of bone modifying agent therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As bisphosphonates accumulate in the bone matrix and can be released over months to years, the rationale for discontinuation of bisphosphonate therapy in patients who develop ONJ is the interruption of its effects on the oral soft tissues, and specifically the surrounding epithelial cells and fibroblasts.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     Denosumab",
"    </a>",
"    , by contrast, is not accumulated in bone, and its effects on bone are reversible after several months of treatment discontinuation. At present, there is almost no prospective data to advise the patient or physician as to the benefits of discontinuing therapy with a bone modifying agent once ONJ develops. In particular, because bisphosphonates have long-term skeletal retention (months to years), it is unclear if stopping treatment for any duration will alter the course of the ONJ lesion.",
"   </p>",
"   <p>",
"    There are only anecdotal reports on spontaneous healing of ONJ in patients receiving adequate conservative therapy with or without discontinuation of the bone modifying agent:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the registration clinical trials described above, all patients with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"       denosumab",
"      </a>",
"      -associated ONJ had denosumab therapy discontinued. Although six patients reinitiated denosumab after resolution of ONJ, their outcomes were not specifically reported [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/31\">",
"       31",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H1928392\">",
"       'Incidence and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients receiving monthly IV bisphosphonate therapy, there have been anecdotal reports of healing and complete resolution after several months of cessation of these agents, but there are also reports of spontaneous resolution during ongoing monthly therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/59,83,84\">",
"       59,83,84",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      One study included 97 patients with multiple myeloma who developed ONJ and were followed for a minimum of 3.2 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/27\">",
"       27",
"      </a>",
"      ]. Patients who developed ONJ following a dental procedure could restart bisphosphonate therapy if skeletal-related events developed. Recurrent ONJ followed reinitiation of bisphosphonate in 6 of 12 patients. Patients who developed ONJ without a predisposing cause were at increased risk of recurrence after initial healing, especially if the agent was reintroduced. The hypothesis that decisions regarding discontinuation of therapy can be made on the basis of whether there was an inciting predisposing event or not needs to be prospectively validated.",
"     </li>",
"     <li>",
"      In another series of 14 myeloma patients with ONJ, eight patients continued treatment with the bisphosphonate, while five patients had the drug stopped, and one stopped briefly, then restarted [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/59\">",
"       59",
"      </a>",
"      ]. With a median of 19 (range 4 to 49) months of follow-up after the diagnosis of ONJ, two showed some worsening of the condition (one of whom discontinued therapy), five remained stable (two of whom discontinued therapy, two continued, and one had a brief break, then restarted), and seven improved or completely resolved (despite continued bisphosphonate therapy in five).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Guidelines from expert groups differ:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The European Myeloma Network suggests discontinuation of bisphosphonates until healing occurs, with treatment restarted if there is disease progression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/85\">",
"       85",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Canadian consensus guidelines suggest only patient education and review of indications for continued bisphosphonate therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/86\">",
"       86",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A year 2009 position paper from the American Association of Maxillofacial Surgeons (AAOMS) indicates that long-term discontinuation of IV bisphosphonates in cancer patients might be beneficial in stabilizing sites of ONJ, reducing the risk of developing new sites, and controlling symptoms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/29\">",
"       29",
"      </a>",
"      ]. However, treatment discontinuation could result in a recurrence of bone pain, progression of metastases, or an increase in skeletal-related events. The risks and benefits of continuing a bisphosphonate should be planned in a multidisciplinary consultation with the oncologist, maxillofacial surgeon, dentist, and the patient.",
"     </li>",
"     <li>",
"      A 2007 ASCO guideline for the role of bisphosphonates in multiple myeloma, and a year 2011 guideline in the role of bone modifying agents in metastatic breast cancer provide no guidance as to discontinuation versus continued use of either a bisphosphonate or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"       denosumab",
"      </a>",
"      in patients who develop ONJ while receiving therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/87,88\">",
"       87,88",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The US FDA-approved manufacturer&rsquo;s package insert for both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    state only that there are no data available to suggest whether discontinuation of bisphosphonate treatment reduces the risk of ONJ in patients who require dental procedures during therapy and that clinical judgment of the treating physician should guide the management plan of each patient based on individual",
"    <span class=\"nowrap\">",
"     benefit/risk",
"    </span>",
"    assessment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/89,90\">",
"     89,90",
"    </a>",
"    ]. The package insert for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    does not address the issue of treatment continuation in patients who develop ONJ [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Long-term prospective studies are needed to establish the efficacy of cessation of therapy with a bone modifying agent in patients with ONJ. In our view, the decision on whether to continue or discontinue therapy with a bone modifying agent after the occurrence of ONJ must be made on a case by case basis and then only after careful consideration of the risks and benefits of continuing versus discontinuing therapy. Many clinicians, including one of the authors, discontinue therapy, at least temporarily, and restart after resolution or signs of improvement. However, others, including one of the authors, continue monthly treatment as long as the patient has not had a recent dental extraction, subsequently discontinuing the drug if the ONJ worsens significantly. There is no evidence to support either strategy, and both are appropriate. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8702257\">",
"    <span class=\"h3\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;In view of the difficulty in treating this complication, prevention is emphasized. Guidelines from ASCO, the American Association of Maxillofacial Surgeons (AAOMS), and the European Medicines Agency (EMA) recommend that all patients have a comprehensive dental examination and preventive dentistry (preemptive extraction of unsalvageable teeth and optimized periodontal health) before beginning therapy with a bone modifying agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/29,87,88,92\">",
"     29,87,88,92",
"    </a>",
"    ]. Active oral infections should be treated, and sites at high risk for infection should be eliminated. While on therapy, patients should maintain excellent oral hygiene (daily flossing, brushing, and antibacterial oral rinses) to decrease rates of periodontal disease and oral infection, and avoid invasive dental procedures, if possible. Patients should be encouraged to stop smoking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients should be counseled regarding the possible occurrence of ONJ prior to initiating therapy with a bone modifying agent and their oral hygiene status should be closely monitored during treatment. Patients should be asked about possible planned dental procedures prior to administration of each dose of a bone modifying agent and reminded to avoid invasive dental procedures (dental extractions, implants, and any other procedures that involve manipulation of the jaw bone or periosteum) while being treated with these drugs.",
"   </p>",
"   <p>",
"    Two non-randomized studies have shown a reduction in the occurrence of ONJ after implementation of preventive measures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/47,93\">",
"     47,93",
"    </a>",
"    ]. As an example, in a study of 128 patients with multiple myeloma taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    , the risk of developing ONJ was significantly reduced from 0.67 to 0.23 per 100 person-months (RR 0.34; 95% CI 0.12-0.94) by the implementation of the following preventive measures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/93\">",
"     93",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dental assessment prior to institution of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      to identify existing infection, ill-fitting dentures, and compromised teeth that might eventually require intervention.",
"     </li>",
"     <li>",
"      All necessary dental work was completed prior to institution of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      . A specialized dental surgeon was employed for major dental procedures (eg, extraction).",
"     </li>",
"     <li>",
"      Whenever possible, minor dental procedures with preservation of the dental root were preferred over total tooth extraction.",
"     </li>",
"     <li>",
"      For patients requiring invasive dental procedures,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      was held until six to eight weeks after the procedure, provided that complete healing was documented.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is important to reassure patients that less invasive dental procedures such as dental cleaning, repair of cavities, placement of crowns or &ldquo;caps,&rdquo; and even routine root canals do not increase the risk of ONJ.",
"   </p>",
"   <p>",
"    The optimal management of a patient who requires an invasive dental procedure during treatment with a bone modifying agent is not established. Guidelines from the AAOMS suggest that if systemic conditions permit, the clinician could consider discontinuation of the drug for three months prior and three months after the dental invasive procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/29\">",
"     29",
"    </a>",
"    ]. Despite these measures, ONJ may still occur, although its severity may be reduced with this &ldquo;drug holiday&rdquo; before and after a dental procedure that impacts the jaw bones such as a dental extraction. However, long-term prospective studies are needed to establish the efficacy of cessation of therapy with a bone modifying agent in such patients.",
"   </p>",
"   <p>",
"    A retrospective analysis suggested that the incidence of ONJ might also be lowered by a reduced dosing schedule without negatively impacting efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/42\">",
"     42",
"    </a>",
"    ]. In this report, the risk of ONJ was eightfold lower with a reduced schedule of IV bisphosphonate (monthly injection during the first year and every three months thereafter) when compared with a standard schedule (monthly administration as tolerated). However, this small study is not definitive regarding the efficacy of less frequent dosing or its impact on the development of ONJ, and this approach cannot be recommended at present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1930509\">",
"    <span class=\"h2\">",
"     Hypocalcemia and other electrolyte abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcium homeostasis is one of the major functions of bone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/94\">",
"     94",
"    </a>",
"    ]. Consequently, effective inhibition of osteoclast activity can result in hypocalcemia and hypophosphatemia. However, most patients do not become hypocalcemic because of compensatory mechanisms, most importantly, increased secretion of parathyroid hormone. In some cases, these compensatory mechanisms may be blocked (eg, prior parathyroidectomy, low vitamin D levels, hypomagnesemic hypoparathyroidism, renal failure), resulting in hypocalcemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/3,95\">",
"     3,95",
"    </a>",
"    ]. Patients are at higher risk of electrolyte imbalance if they have renal insufficiency or decreased compensatory mechanisms.",
"   </p>",
"   <p>",
"    The incidence, severity and time course of hypocalcemia can be illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report of 120 patients who received a total of 546 infusions of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      for multiple myeloma or another malignancy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/96\">",
"       96",
"      </a>",
"      ], hypocalcemia developed following 55 infusions (10 percent) in 42 of the patients (35 percent). Symptomatic hypocalcemia requiring IV calcium supplementation occurred in 10 patients (8 percent) despite dose adjustment for creatinine clearance (CrCl) and prophylactic supplementation with oral calcium and vitamin D. Impairment of CrCl was seen more often among subjects developing hypocalcemia than in those remaining normocalcemic. Hypomagnesemia was found in all patients who developed hypocalcemia who had measurement of serum magnesium.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"       Denosumab",
"      </a>",
"      is a more potent inhibitor of bone resorption than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      as measured by changes in bone turnover markers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/4-6,97\">",
"       4-6,97",
"      </a>",
"      ]. Thus, it is not unexpected that the incidence rates of hypocalcemia and hypophosphatemia were greater with denosumab than with zoledronic acid in all three registration trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/4-6\">",
"       4-6",
"      </a>",
"      ]. In an integrated analysis of patient level data from all three identically conducted trials that differed only as to tumor type, hypocalcemia of any grade occurred in 9.6 percent of patients treated with denosumab versus 5 percent of those treated with zoledronic acid [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/44\">",
"       44",
"      </a>",
"      ]. The incidence of hypophosphatemia of any grade was 2.1 percent with denosumab versus 1.1 percent with zoledronic acid.",
"      <br/>",
"      <br/>",
"      The decreases in calcium have been mostly mild to moderate in severity, asymptomatic, and occurred within the first six months of therapy in the majority. As an example, in the prostate cancer trial, grade 3 decreases in calcium occurred in 5 percent of the patients receiving denosumab, and only 1 percent of those receiving zoledronic acid [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/6\">",
"       6",
"      </a>",
"      ]; the corresponding values for the breast cancer trial were 1.6 and 1.2 percent. Daily calcium intake &gt;500 mg and supplementation with vitamin D (&gt;400 IU daily) was strongly encouraged in patients enrolled in the registration trials, and adherent patients appeared to have lower adverse events of hypocalcemia. Treatment was predominantly with oral calcium and vitamin D supplementation with rare patients requiring IV calcium.",
"      <br/>",
"      <br/>",
"      While renal impairment does not affect denosumab pharmacokinetics or function and dose adjustments are not required for patients with renal impairment (in contrast to zoledronic acid), patients with creatinine clearance (CrCl) &lt;30",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      or end stage renal disease need to be followed more closely for hypocalcemia while receiving denosumab therapy as these patients are likely more dependent on PTH-induced bone resorption. In one report, 4 of 17 patients with severe renal dysfunction (CrCl &le;30",
"      <span class=\"nowrap\">",
"       mL/min)",
"      </span>",
"      developed albumin-adjusted serum calcium levels less than 7.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      compared to only 1 of 38 patients with CrCl",
"      <span class=\"nowrap\">",
"       &gt;30mL/min",
"      </span>",
"      (24 versus 3 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/98\">",
"       98",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Proteinuria and renal insufficiency'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H454293350\">",
"       'Renal effects'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment of hypocalcemia is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/37/44632?source=see_link\">",
"     \"Treatment of hypocalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As in patients with osteoporosis who are receiving therapy with bone resorptive agents, calcium and vitamin D levels should be assessed and low levels corrected prior to initiating therapy with a bone modifying agent. ASCO guidelines recommend regular monitoring of serum calcium, magnesium, phosphate, and electrolytes among patients receiving bone modifying agents; however, there is no evidence with which to guide the appropriate monitoring interval [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. We monitor calcium, electrolytes, phosphate and magnesium levels at least quarterly in all patients, and monitor them monthly in symptomatic patients and those with baseline renal insufficiency. We also strongly suggest supplementation with calcium and vitamin D daily, unless contraindicated (eg, patients with hypercalcemia or a history of recurrent renal stones), and that vitamin D levels be periodically reevaluated. Most patients should receive a total of 1000 mg of calcium (diet plus supplement) and 800 to 1200 IU of vitamin D daily. However, vitamin D dosing should be based upon serum levels, and recommendations regarding calcium supplementation should be individualized based upon the patient&rsquo;s underlying malignancy (and the risk for developing hypercalcemia) and renal function. Dosing of vitamin D and optimal intake of calcium is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=see_link&amp;anchor=H6#H6\">",
"     \"Calcium and vitamin D supplementation in osteoporosis\", section on 'Optimal intake'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of vitamin D deficiency in adults\", section on 'Dosing'",
"    </a>",
"    .) If patients become hypercalcemic, calcium supplements and vitamin D should be discontinued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4307611\">",
"    <span class=\"h1\">",
"     RISKS SPECIFIC TO BISPHOSPHONATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects among patients receiving oral or parenteral bisphosphonates for non-malignant conditions are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=see_link&amp;anchor=H37#H37\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following are the most important potential side effects in patients receiving parenteral bisphosphonates for malignant disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Proteinuria and renal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=see_link\">",
"     Pamidronate",
"    </a>",
"    has been associated with the development of nephrotic-range proteinuria and acute kidney injury, and a number of mechanisms have been proposed, including collapsing focal segmental glomerulosclerosis (FSGS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/99-101\">",
"     99-101",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/31/43512?source=see_link&amp;anchor=H5#H5\">",
"     \"Collapsing focal segmental glomerulosclerosis not associated with HIV infection\", section on 'Bisphosphonates and other drugs'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32041?source=see_link\">",
"     \"Overview of heavy proteinuria and the nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nephrotoxicity is both dose- and infusion time-dependent, but mostly related to infusion time; the risk appears to be higher among patients who receive the drug over less than two hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/102\">",
"     102",
"    </a>",
"    ]. Although most cases are reported in patients with multiple myeloma, albuminuria followed by azotemia has also been seen with long-term administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    in patients with other malignancies.",
"   </p>",
"   <p>",
"    Acute kidney injury has also been observed with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    , although most renal toxicity has been reported with higher doses (8 mg versus 4 mg) than are FDA-approved and with infusion durations of less than 15 minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/43,103-107\">",
"     43,103-107",
"    </a>",
"    ]. The mechanism of acute kidney injury with zoledronic acid may be different from that in patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    . In one case series of six patients with acute kidney injury associated with zoledronic acid, renal biopsies showed toxic acute tubular necrosis without evidence of glomerular damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/107\">",
"     107",
"    </a>",
"    ]. Thus, patients treated with zoledronic acid develop rises in creatinine often without proteinuria. However, with long term treatment, patients may develop albuminuria that improves upon discontinuation of the drug.",
"   </p>",
"   <p>",
"    Acute kidney injury from either drug can progress to renal failure and the need for dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/101,105,108\">",
"     101,105,108",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4308296\">",
"    <span class=\"h3\">",
"     Incidence and risk factors",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4308480\">",
"    <span class=\"h4\">",
"     Multiple myeloma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most reports of acute kidney injury during IV bisphosphonate therapy have involved patients with multiple myeloma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/59,105,109\">",
"     59,105,109",
"    </a>",
"    ]. As an example, of 72 cases of renal failure in association with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    use in the United States FDA Adverse Event Reporting System from August 2001 to March 2003, 42 were in patients with myeloma, 22 with solid tumors, two with benign conditions, and six were unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/105\">",
"     105",
"    </a>",
"    ]. Underlying risk factors (advanced cancer, previous bisphosphonate exposure, use of NSAIDs) may have contributed to the progression of renal failure; information on hydration status was not uniformly reported. Eighteen patients developed renal failure after only one dose. Of the patients who developed IV bisphosphonate-related acute kidney injury, 27 required dialysis, and 18 died.",
"   </p>",
"   <p>",
"    Among patients with multiple myeloma, elevated baseline serum creatinine is a risk factor for acute kidney injury. In a retrospective trial involving 300 patients with multiple myeloma treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    at 15 oncology sites, renal function deteriorated in 34 patients (11 percent), while the rate was 24 percent among patients who had an elevated baseline creatinine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/59\">",
"     59",
"    </a>",
"    ]. Notably, one-half of the patients who had acute kidney injury while being treated with zoledronic acid restarted zoledronic acid after a brief delay, and only five (2.7 percent) had ongoing renal function deterioration.",
"   </p>",
"   <p>",
"    Coadministration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    in multiple myeloma may increase the potential for acute kidney injury (and severe hypocalcemia, see below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/106\">",
"     106",
"    </a>",
"    ]. In an initial report, acute tubular necrosis (as determined by renal biopsy) resulting from zoledronic acid was described in five patients with multiple myeloma (two of whom were receiving thalidomide) and one with Paget disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/107\">",
"     107",
"    </a>",
"    ]. Renal function partially recovered with drug withdrawal. Patients receiving both agents simultaneously should be closely monitored. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/54/18282?source=see_link&amp;anchor=H4997000#H4997000\">",
"     \"Initial chemotherapy for symptomatic multiple myeloma in patients who are candidates for transplantation\", section on 'Thalidomide with or without dexamethasone'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, renal disease is a common problem in multiple myeloma. The pathology is very heterogeneous and may involve a variety of different mechanisms. This can make it difficult to ascertain whether bisphosphonate use is the culprit. (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/48/27400?source=see_link\">",
"     \"Types of renal disease in multiple myeloma\"",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    As an example, one large randomized study comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    (4 mg every 21 to 28 days) to oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/3/9270?source=see_link\">",
"     clodronate",
"    </a>",
"    (1600",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    in previously untreated patients with multiple myeloma showed no differences in the development of renal failure between the two arms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/110\">",
"     110",
"    </a>",
"    ]. Given that oral clodronate has not been associated with kidney problems, this study suggests that much of the deterioration in renal function among patients receiving monthly zoledronic acid is likely due to other causes, such as progressive myeloma, other comorbid conditions (eg, diabetes mellitus, hypertension),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other potentially nephrotoxic medications (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/109\">",
"     109",
"    </a>",
"    ]).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4308499\">",
"    <span class=\"h4\">",
"     Other malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of acute kidney injury during treatment with IV bisphosphonates in diseases other than multiple myeloma can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a placebo-controlled phase III trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      in men with advanced prostate cancer, acute kidney injury (defined as a change from baseline serum creatinine of &ge;0.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      for patients with a baseline creatinine &lt;1.4",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      and &ge;1.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      for patients with higher baseline levels) occurred in 15 percent of the patients who received zoledronic acid at 4 mg and 21 percent of those who initially received a 8 mg dose, later amended to 4 mg because of renal toxicity, and 11 percent of the placebo group [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/111\">",
"       111",
"      </a>",
"      ]. The risk of grade 3 increase in serum creatinine was 3.3 percent with zoledronic acid, compared to 1 percent in the placebo group.",
"     </li>",
"     <li>",
"      In a second placebo-controlled trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      versus placebo in patients with bone metastases from lung cancer and other solid tumors, there was a higher proportion of patients with acute kidney injury (defined as a change from baseline serum creatinine of &ge;0.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      for patients with a normal baseline creatinine, and &ge;1.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      for patients with an abnormal baseline creatinine, or at least two times baseline level) when zoledronic acid was infused over five minutes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/112\">",
"       112",
"      </a>",
"      ]. However, among patients receiving the drug as a 15-minute infusion following a protocol amendment, the proportion of patients with acute kidney injury was not significantly different from the placebo group (10.9 versus 6.7 percent).",
"     </li>",
"     <li>",
"      In a trial comparing",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      versus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"       denosumab",
"      </a>",
"      in 2046 women with breast cancer and bone metastases, the incidence of adverse events potentially associated with renal toxicity (ie, increased creatinine, decreased creatinine clearance (CrCl), acute renal failure, chronic renal failure, oliguria, anuria, proteinuria) was significantly higher with zoledronic acid (8.5 versus 4.9 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/4\">",
"       4",
"      </a>",
"      ]. This was especially true for severe (grade 3 or worse, 2.2 versus 0.4 percent) renal toxicity. The incidence of renal adverse events among patients with a baseline CrCl &le;60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      was also higher with zoledronic acid (20 versus 5.9 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Management and prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bisphosphonates are eliminated in the urine. The US FDA-approved package insert for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    &nbsp;recommends a lower initial dose of zoledronic acid (ranging from 3 to 3.5 mg) in patients with preexisting renal impairment (CrCl &lt;60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    but &ge;30",
"    <span class=\"nowrap\">",
"     mL/min).",
"    </span>",
"    The FDA-approved labeling information for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    &nbsp;does not contain similar guidance. Pamidronate can be used safely in patients with a CrCl &lt;30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/113\">",
"     113",
"    </a>",
"    ]; an alternative for patients with diseases other than multiple myeloma is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    , which is not renally cleared. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/27/30137?source=see_link&amp;anchor=H488895#H488895\">",
"     \"The use of bisphosphonates in patients with multiple myeloma\", section on 'Choice of agent'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    For patients receiving IV bisphosphonates, acute kidney injury may be minimized by observing recommended infusion times, optimizing hydration prior to bisphosphonate administration (particularly for patients with marked Bence Jones proteinuria), and avoiding concurrent nephrotoxic medications. It is essential that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    be infused at a dose no higher than 90 mg at a rate no faster than over two hours and that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    be given over no less than 15 minutes every three to four weeks. Physicians should not attempt to shorten the infusion time, increase the dose, or reduce the dosing interval. There is no evidence that lengthening the infusion duration from 15 to 30 minutes reduces the rate of renal toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/114\">",
"     114",
"    </a>",
"    ], although larger studies are needed to further define this issue.",
"   </p>",
"   <p>",
"    Renal function must be assessed serially in cancer patients who are being treated with these agents, and appropriate dose adjustments",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    temporary cessation of treatment may be required. Guidelines from the American Society of Clinical Oncology (ASCO) for use of bisphosphonates in breast cancer and multiple myeloma recommend that creatinine be monitored prior to each dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. Unexplained azotemia (an increase of &ge;0.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    for patients with normal baseline creatinine, or &ge;1.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    for patients with an abnormal baseline value) in a patient receiving IV bisphosphonates for any malignancy should prompt at least temporary discontinuation of the bisphosphonate until recovery of renal function.",
"   </p>",
"   <p>",
"    For patients with multiple myeloma receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    , ASCO guidelines also recommend intermittent evaluation (every three to six months) for the presence of albuminuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/88\">",
"     88",
"    </a>",
"    ]. For patients experiencing any albuminuria (defined as &gt;500",
"    <span class=\"nowrap\">",
"     mg/24",
"    </span>",
"    hours of urinary albumin), discontinuation of drug is advised until resolution of the renal problems. However, it is important to recognize that there may be other causes for the albuminuria such as comorbid conditions (eg, diabetes mellitus) or the development of primary amyloidosis in this at-risk patient population. In contrast to patients with multiple myeloma, ASCO guidelines do not support routine assessment for albuminuria in patients with other malignancies such as breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/87\">",
"     87",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/27/30137?source=see_link&amp;anchor=H487430#H487430\">",
"     \"The use of bisphosphonates in patients with multiple myeloma\", section on 'Society guidelines'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who develop acute kidney injury and temporarily discontinue IV bisphosphonates should be reassessed every three to four weeks with a serum creatinine (and, in the setting of multiple myeloma, with a 24 hour urine collection for total protein and urine protein electrophoresis). If renal function returns to within 10 percent of baseline, therapy can be reinstituted cautiously, as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"       Zoledronic acid",
"      </a>",
"      should be administered over at least 15 minutes. ASCO guidelines suggest prolonging the infusion time (to 30 to 60 minutes) once the drug is restarted following a return of renal function to within 10 percent of baseline [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/88\">",
"       88",
"      </a>",
"      ], although the benefit of this approach is unclear [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/114\">",
"       114",
"      </a>",
"      ]. The FDA-approved package insert recommends reinitiation of zoledronic acid at the same dose as that prior to treatment interruption.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=see_link\">",
"       Pamidronate",
"      </a>",
"      should be administered over four hours, at doses no greater than 90 mg every four weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/88\">",
"       88",
"      </a>",
"      ]. The FDA-approved package insert does not provide guidelines for dosing pamidronate in patients whose abnormal renal function has returned to within 10 percent of baseline.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If renal function does not return to baseline, there are no data upon which to base further management decisions. However, for patients with solid tumors, switching to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    is a reasonable option as it has no known renal toxicity and provides comparable, if not superior efficacy. &nbsp;",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Acute phase response",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 15 to 30 percent of patients, IV",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    cause transient fever and an influenza-like syndrome in patients naive to these drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/4,5,44,115-117\">",
"     4,5,44,115-117",
"    </a>",
"    ]. The syndrome is typical of an acute phase response characterized by fever, chills, bone pain, headache, nausea, myalgias, and arthralgias and is postulated to be due to transiently increased cytokine production. These symptoms are usually mild and self limited, resolving after several days, and most often do not occur with subsequent dosing of these drugs. This syndrome may be treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    or NSAIDs, but acetaminophen is preferred given the potential for renal toxicity with NSAIDs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=see_link&amp;anchor=H42#H42\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\", section on 'Flu-like symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Ocular toxicities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both oral and IV bisphosphonate use can be associated with conjunctivitis, uveitis, scleritis, and orbital inflammation. Ocular inflammation requires a prompt ophthalmologic evaluation; further treatment with the offending bisphosphonate is not recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/118,119\">",
"     118,119",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=see_link&amp;anchor=H47#H47\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\", section on 'Ocular side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Bone, joint, or muscle pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a syndrome distinct from the acute phase response, severe and sometimes incapacitating bone, joint, or muscle pain can occur within days, months, or years after starting a bisphosphonate and does not always resolve completely with discontinuation of therapy. This syndrome has been the subject of an alert by the United States FDA, as it may be overlooked by clinicians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/120\">",
"     120",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, atypical subtrochanteric and diaphyseal femoral fractures have been reported in patients receiving bisphosphonates, and fractures may occur after minimal or no trauma. Patients with otherwise unexplained thigh or groin pain should be evaluated to rule out a femoral fracture. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3214834\">",
"    <span class=\"h2\">",
"     Atrial fibrillation and stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on the potential increased risk of atrial fibrillation and stroke with oral bisphosphonate use in patients with osteoporosis are conflicting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=see_link&amp;anchor=H49#H49\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\", section on 'Atrial fibrillation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, a significantly increased risk of atrial",
"    <span class=\"nowrap\">",
"     fibrillation/flutter",
"    </span>",
"    and stroke has been reported in patients receiving IV bisphosphonates in the setting of a malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/121,122\">",
"     121,122",
"    </a>",
"    ]. Such patients may be at particular risk because of the higher doses used, advanced age,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the prior use of chemotherapeutic agents with cardiac toxicities.",
"   </p>",
"   <p>",
"    This issue was explored using SEER-Medicare-linked data in 6857 older (age &ge;65) patients with cancer who were treated with IV bisphosphonates and 13,714 matched bisphosphonate nonusers. Results included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/121\">",
"     121",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infusion of IV bisphosphonate was associated with a modestly increased risk for atrial fibrillation (HR 1.30; 95% CI 1.18-1.43), all supraventricular tachycardias (SVTs, HR 1.28; 95% CI 1.19-1.38), and stroke (HR 1.30; 95% CI 1.09-1.54).",
"     </li>",
"     <li>",
"      The risk for all SVTs increased 7 percent for every five bisphosphonate doses (HR 1.07; 95% CI 1.02-1.12).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of note, an increased risk of atrial",
"    <span class=\"nowrap\">",
"     fibrillation/stroke",
"    </span>",
"    was not reported in the bisphosphonate arms of any of the three registration trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H1928392\">",
"     'Incidence and risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H454293264\">",
"    <span class=\"h1\">",
"     RISKS SPECIFIC TO DENOSUMAB",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H454293350\">",
"    <span class=\"h2\">",
"     Renal effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     Denosumab",
"    </a>",
"    is a monoclonal antibody that is cleared predominantly through the reticuloendothelial system. As denosumab is not cleared by the kidneys, dose adjustments or monitoring of renal function is not",
"    <strong>",
"    </strong>",
"    required or recommended. In the three registration trials comparing monthly denosumab with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    therapy, renal toxicity and renal adverse events were seen significantly more frequently in the zoledronic acid arm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. This was true despite obligatory renal function testing prior to each dose and only zoledronic acid being dose adjusted for decreases in renal function as recommended by the manufacturer&rsquo;s FDA-approved package insert. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Proteinuria and renal insufficiency'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     Denosumab",
"    </a>",
"    has not been formally studied in patients with severe renal insufficiency except in a small single trial involving 55 patients with varying degrees of renal dysfunction, including 17 with severe chronic renal disease (CrCl &le;30",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    or requiring hemodialysis, who received a single 60 mg dose of subcutaneous denosumab. In this trial, denosumab pharmacokinetics and induced changes in bone resorption biomarkers were not affected by renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/98\">",
"     98",
"    </a>",
"    ]. In addition, denosumab was not dose adjusted for renal function in any of the phase III registration trials of denosumab in metastatic cancer patients. Renal adverse events were comparable to those seen in the control arms from prior bisphosphonate trials consistent with no additional renal toxicity associated with denosumab therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/112\">",
"     112",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While there are no recommendations for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    dose adjustment for renal insufficiency, patients with severe renal insufficiency (CrCl &lt;30",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    are more prone to hypocalcemia and should be monitored more closely for this toxicity when initiating therapy. (See",
"    <a class=\"local\" href=\"#H1930509\">",
"     'Hypocalcemia and other electrolyte abnormalities'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H454293358\">",
"    <span class=\"h2\">",
"     Neutralizing antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     Denosumab",
"    </a>",
"    is a fully human monoclonal antibody and thus the incidence of antibody formation against denosumab is expected to be quite low. In clinical trials involving several thousands of patients (metastatic cancer and osteoporosis trials combined), antibodies directed against denosumab have been found rarely (&lt;1 percent) in treated patients and none have been neutralizing. Testing for anti-denosumab antibodies is not recommended or available outside the research setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H454293366\">",
"    <span class=\"h2\">",
"     Infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;RANKL is expressed on subsets of activated T and B cells as well as mature dendritic cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/123\">",
"     123",
"    </a>",
"    ]. In knock-out mice depleted of the RANKL or RANK genes, there is a loss of lymph nodes and architectural changes in the thymus suggesting that inhibition of the",
"    <span class=\"nowrap\">",
"     RANK/RANKL",
"    </span>",
"    pathway may affect immune function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/124\">",
"     124",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In preclinical and clinical models, an immunologic effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    has been difficult to prove [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/80\">",
"     80",
"    </a>",
"    ]. However, an increased risk of infections in patients treated with denosumab has been seen in some trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the pivotal phase 3 FREEDOM trial demonstrating the efficacy of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"       denosumab",
"      </a>",
"      at a dose of 60 mg subcutaneously every six months for preventing fractures in postmenopausal women with osteoporosis, an increased number of serious adverse events related to skin infections was observed (15 subjects or 0.4 percent in the denosumab arm versus 3 or &lt;0.1 percent in the placebo arm; p&lt;0.05) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/125\">",
"       125",
"      </a>",
"      ]. No other infectious complication other than cellulitis was observed statistically more frequently in denosumab treated women. All patients continued on therapy after adverse events from skin infection and only one patient who had a long-standing history of varicose ulceration experienced a second serious skin infection on trial. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22040?source=see_link&amp;anchor=H8#H8\">",
"       \"Denosumab for osteoporosis\", section on 'Effects on immune system'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the placebo-controlled HALT trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"       denosumab",
"      </a>",
"      in men with bone loss secondary to androgen deprivation therapy for nonmetastatic prostate cancer, there was no statistical difference in the number of serious adverse events or deaths [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/126\">",
"       126",
"      </a>",
"      ]. However, there were a numerically higher number of serious adverse events related to infection (5.9 versus 4.6 percent) and urinary tract infections (5.1 versus 4.4 percent) in denosumab versus placebo treated men. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/30/21993?source=see_link&amp;anchor=H11#H11\">",
"       \"Side effects of androgen deprivation therapy\", section on 'Denosumab'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the three registration trials conducted in patients with skeletal involvement from advanced malignancy,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    was the comparator arm, and thus a true placebo arm is not available for comparison in any of the trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/4,6,31\">",
"     4,6,31",
"    </a>",
"    ]. Nevertheless, in none of these trials was the incidence of infectious adverse events or serious adverse events statistically different between the treatment groups despite the large number of patients randomized. An integrated analysis of patient-level data from all three trials concluded that there was no difference in the risk of infectious adverse events (43.4 versus 42.9 percent) or infectious serious adverse events (11.6 versus 10.9 percent) with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    as compared to zoledronic acid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The major side effects associated with prolonged use of parenteral bone modifying agents in patients with skeletal involvement from advanced malignancy are hypocalcemia (which is more common with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"       denosumab",
"      </a>",
"      than with the bisphosphonates) and osteonecrosis of the jaw (which is uncommon and occurs in a similar fraction of patients treated with either class of drugs). (See",
"      <a class=\"local\" href=\"#H1928329\">",
"       'Osteonecrosis of the jaw'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1930509\">",
"       'Hypocalcemia and other electrolyte abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other side effects of potential concern to cancer patients receiving IV bisphosphonate therapy include renal toxicity, flu-like symptoms (see",
"      <a class=\"local\" href=\"#H20\">",
"       'Acute phase response'",
"      </a>",
"      above), rarely incapacitating bone, joint, or muscle pain (see",
"      <a class=\"local\" href=\"#H22\">",
"       'Bone, joint, or muscle pain'",
"      </a>",
"      above), and possibly, atrial",
"      <span class=\"nowrap\">",
"       fibrillation/stroke",
"      </span>",
"      (see",
"      <a class=\"local\" href=\"#H3214834\">",
"       'Atrial fibrillation and stroke'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Osteonecrosis of the jaw (ONJ) typically presents as pain, infection, and necrotic bone in the mandible or maxilla in a patient receiving long-term treatment with high potency bone modifying agents. (See",
"      <a class=\"local\" href=\"#H1928365\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Established risk factors include dental extraction, poor dental hygiene, poorly fitting dentures, and advanced periodontal disease. (See",
"      <a class=\"local\" href=\"#H1928392\">",
"       'Incidence and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that patients be examined by a dentist and have needed dental work including removal of unsalvageable teeth, with optimization of periodontal health prior to initiating therapy, if possible (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      During therapy, all patients should practice good oral hygiene including daily brushing, flossing, and use of antibacterial oral rinses, and recommended dental check-ups, denture fittings, and routine cleanings. Patients should inform their dentists they are receiving bone-modifying agents so invasive dental procedures and especially extractions can be avoided while receiving active therapy.",
"     </li>",
"     <li>",
"      Oral exams and hygiene status should be closely monitored by the oncologist during treatment. (See",
"      <a class=\"local\" href=\"#H8702257\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who develop ONJ while receiving therapy with a bone modifying agent, recommendations on management are hindered by a lack of evidence. We suggest conservative management with limited debridement, antibiotic therapy as needed, and topical mouth rinses, rather than aggressive surgical resection (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Conservative therapy may result in healing in a significant proportion of patients. Surgical resection of necrotic bone should be reserved for only the most refractory cases.",
"      <br/>",
"      <br/>",
"      There is almost no prospective data to advise the patient or physician as to the benefits of discontinuing therapy with a bone modifying agent. While discontinuation of the bone modifying agent might stabilize sites of ONJ, reduce the risk of developing new sites, and control symptoms, treatment discontinuation could also result in a recurrence of bone pain or an increase in skeletal-related events. The decision must be made on a case by case basis, taking into account the estimated risks and benefits for an individual patient. Many clinicians, including one of the authors, discontinue therapy, at least temporarily, and restart after resolution or signs of improvement or stabilization. However, others continue monthly treatment as long as the patient has not had a recent dental extraction, subsequently discontinuing the drug if the ONJ worsens significantly. There is no evidence to support either strategy, and either is appropriate. (See",
"      <a class=\"local\" href=\"#H1928489\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients receiving parenteral therapy with a bone modifying agent for advanced cancer should have calcium and vitamin D levels assessed at baseline, and low levels supplemented prior to initiating therapy. Periodic monitoring of serum magnesium, calcium, and phosphate levels should be obtained during therapy with either bisphosphonates or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"       denosumab",
"      </a>",
"      . Increased monitoring (eg, monthly) is needed in symptomatic patients and those with baseline renal insufficiency when initiating therapy. Daily supplementation with calcium and vitamin D is strongly recommended for all patients unless otherwise contraindicated (eg, in patients with hypercalcemia or a history of recurrent renal stones). (See",
"      <a class=\"local\" href=\"#H1930509\">",
"       'Hypocalcemia and other electrolyte abnormalities'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Most patients should receive a total of 1000 mg of calcium (diet plus supplement) and 800 to 1200 IU of vitamin D daily. However, vitamin D dosing should be based upon serum levels, and recommendations regarding calcium supplementation should be individualized based upon the patient&rsquo;s underlying malignancy (and the risk for developing hypercalcemia) and renal function. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=see_link&amp;anchor=H6#H6\">",
"       \"Calcium and vitamin D supplementation in osteoporosis\", section on 'Optimal intake'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=see_link&amp;anchor=H9#H9\">",
"       \"Treatment of vitamin D deficiency in adults\", section on 'Dosing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Use of parenteral bisphosphonates is associated with nephrotoxicity (nephrotic-range proteinuria and acute renal insufficiency), which is mostly dose- and somewhat infusion time-dependent. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Management and prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Renal toxicity may be minimized by observing recommended infusion times, optimizing hydration prior to bisphosphonate administration (particularly for patients with marked Bence Jones proteinuria) and avoiding concurrent nephrotoxic medications.",
"     </li>",
"     <li>",
"      The US FDA-approved package insert for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      &nbsp;recommends a lower initial dose of zoledronic acid (ranging from 3 to 3.5 mg) in patients with preexisting renal impairment (CrCl &lt;60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      but &ge;30",
"      <span class=\"nowrap\">",
"       mL/min).",
"      </span>",
"     </li>",
"     <li>",
"      Renal function must be checked before each dose in cancer patients being treated with IV bisphosphonates. Unexplained azotemia or an absolute creatinine level &gt;1.4",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [124",
"      <span class=\"nowrap\">",
"       micromol/L]",
"      </span>",
"      in patients with normal baseline values should prompt temporary discontinuation of the bisphosphonate. Therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"       denosumab",
"      </a>",
"      is preferred as a bone modifying agent for patients with solid tumors who are requiring other nephrotoxic therapies or who have underlying renal dysfunction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with multiple myeloma receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=see_link\">",
"       pamidronate",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      , American Society of Clinical Oncology (ASCO) guidelines also recommend evaluation every three to six months for the presence of albuminuria [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/43/39610/abstract/88\">",
"       88",
"      </a>",
"      ]. For patients experiencing any albuminuria (defined as &gt;500",
"      <span class=\"nowrap\">",
"       mg/24",
"      </span>",
"      hours of urinary albumin), discontinuation of drug is advised until resolution of the renal problems. ASCO guidelines do not support routine assessment for albuminuria in patients with other malignancies such as breast cancer.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/1\">",
"      Tralongo P, Repetto L, Di Mari A, et al. Safety of long-term administration of bisphosphonates in elderly cancer patients. Oncology 2004; 67:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/2\">",
"      Mehrotra B, Ruggiero S. Bisphosphonate complications including osteonecrosis of the jaw. Hematology Am Soc Hematol Educ Program 2006; :356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/3\">",
"      Dunstan CR, Felsenberg D, Seibel MJ. Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nat Clin Pract Oncol 2007; 4:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/4\">",
"      Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28:5132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/5\">",
"      Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; 29:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/6\">",
"      Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/7\">",
"      Edwards BJ, Gounder M, McKoy JM, et al. Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol 2008; 9:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/8\">",
"      Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007; 22:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/9\">",
"      Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007; 65:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/10\">",
"      Estilo CL, Van Poznak CH, Wiliams T, et al. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy. Oncologist 2008; 13:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/11\">",
"      Hansen T, Kunkel M, Weber A, James Kirkpatrick C. Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 2006; 35:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/12\">",
"      Saussez S, Javadian R, Hupin C, et al. Bisphosphonate-related osteonecrosis of the jaw and its associated risk factors: a Belgian case series. Laryngoscope 2009; 119:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/13\">",
"      Naik NH, Russo TA. Bisphosphonate-related osteonecrosis of the jaw: the role of actinomyces. Clin Infect Dis 2009; 49:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/14\">",
"      Sedghizadeh PP, Kumar SK, Gorur A, et al. Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy. J Oral Maxillofac Surg 2008; 66:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/15\">",
"      Reid IR, Bolland MJ, Grey AB. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 2007; 41:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/16\">",
"      Scheper MA, Badros A, Chaisuparat R, et al. Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis. Br J Haematol 2009; 144:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/17\">",
"      Badros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006; 24:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/18\">",
"      Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 2008; 83:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/19\">",
"      Bertoldo F, Santini D, Lo Cascio V. Bisphosphonates and osteomyelitis of the jaw: a pathogenic puzzle. Nat Clin Pract Oncol 2007; 4:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/20\">",
"      Raje N, Woo SB, Hande K, et al. Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res 2008; 14:2387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/21\">",
"      Van den Wyngaert T, Huizing MT, Fossion E, Vermorken JB. Bisphosphonates in oncology: rising stars or fallen heroes. Oncologist 2009; 14:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/22\">",
"      Pozzi S, Vallet S, Mukherjee S, et al. High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties. Clin Cancer Res 2009; 15:5829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/23\">",
"      Allegra A, Oteri G, Nastro E, et al. Patients with bisphosphonates-associated osteonecrosis of the jaw have reduced circulating endothelial cells. Hematol Oncol 2007; 25:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/24\">",
"      Hoefert S, Schmitz I, Tannapfel A, Eufinger H. Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. Clin Oral Investig 2010; 14:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/25\">",
"      Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 2005; 104:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/26\">",
"      Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006; 144:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/27\">",
"      Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005; 63:1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/28\">",
"      Fedele S, Porter SR, D'Aiuto F, et al. Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series. Am J Med 2010; 123:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/29\">",
"      Ruggiero SL, Dodson TB, Assael LA, et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J Oral Maxillofac Surg 2009; 67:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/30\">",
"      Vescovi P, Nammour S. Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) therapy. A critical review. Minerva Stomatol 2010; 59:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/31\">",
"      Saad F, Brown JE, Van Poznak C, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 2012; 23:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/32\">",
"      Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005; 23:8580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/33\">",
"      Migliorati CA, Epstein JB, Abt E, Berenson JR. Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review. Nat Rev Endocrinol 2011; 7:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/34\">",
"      Hoff AO, Toth BB, Altundag K, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008; 23:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/35\">",
"      Palaska PK, Cartsos V, Zavras AI. Bisphosphonates and time to osteonecrosis development. Oncologist 2009; 14:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/36\">",
"      King AE, Umland EM. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates. Pharmacotherapy 2008; 28:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/37\">",
"      Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005; 353:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/38\">",
"      Filleul O, Crompot E, Saussez S. Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases. J Cancer Res Clin Oncol 2010; 136:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/39\">",
"      Dimopoulos MA, Kastritis E, Anagnostopoulos A, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 2006; 91:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/40\">",
"      Zervas K, Verrou E, Teleioudis Z, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 2006; 134:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/41\">",
"      Boonyapakorn T, Schirmer I, Reichart PA, et al. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 2008; 44:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/42\">",
"      Corso A, Varettoni M, Zappasodi P, et al. A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia 2007; 21:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/43\">",
"      Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001; 7:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/44\">",
"      Lipton A, Fizazi K, Stopeck AT, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 2012; 48:3082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/45\">",
"      Kyrgidis A, Vahtsevanos K, Koloutsos G, et al. Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients. J Clin Oncol 2008; 26:4634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/46\">",
"      Hoff AO, Toth B, Hu M, et al. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients. Ann N Y Acad Sci 2011; 1218:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/47\">",
"      Ripamonti CI, Maniezzo M, Campa T, et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 2009; 20:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/48\">",
"      Cetiner S, Sucak GT, Kahraman SA, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid. J Bone Miner Metab 2009; 27:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/49\">",
"      Sarasquete ME, Garc&iacute;a-Sanz R, Mar&iacute;n L, et al. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood 2008; 112:2709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/50\">",
"      Lehrer S, Montazem A, Ramanathan L, et al. Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene. J Oral Maxillofac Surg 2009; 67:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/51\">",
"      Nicoletti P, Cartsos VM, Palaska PK, et al. Genomewide pharmacogenetics of bisphosphonate-induced osteonecrosis of the jaw: the role of RBMS3. Oncologist 2012; 17:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/52\">",
"      Christodoulou C, Pervena A, Klouvas G, et al. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 2009; 76:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/53\">",
"      Aragon-Ching JB, Dahut WL. Osteonecrosis of the jaw and the use of antiangiogenic agents: just an association? Oncologist 2008; 13:1314; author reply 1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/54\">",
"      Brunello A, Saia G, Bedogni A, et al. Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma. Bone 2009; 44:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/55\">",
"      Tosi P, Zamagni E, Cangini D, et al. Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone. Blood 2006; 108:3951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/56\">",
"      Pozzi S, Marcheselli R, Sacchi S, et al. Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients. Leuk Lymphoma 2007; 48:56.",
"     </a>",
"    </li>",
"    <li>",
"     Morgan GJ, et al. Efficacy and side-effect profile of long-term bisphosphonate therapy in patients with multiple myeloma (MM): MRC myeloma IX study results. J Clin Oncol 30, 2012 (suppl; abstr 8015). Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=114&amp;abstractID=100635.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/58\">",
"      Guarneri V, Miles D, Robert N, et al. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat 2010; 122:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/59\">",
"      Berenson JR, Yellin O, Crowley J, et al. Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid. Am J Hematol 2011; 86:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/60\">",
"      Jadu F, Lee L, Pharoah M, et al. A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann Oncol 2007; 18:2015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/61\">",
"      Montefusco V, Gay F, Spina F, et al. Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leuk Lymphoma 2008; 49:2156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/62\">",
"      Lazarovici TS, Yahalom R, Taicher S, et al. Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients. J Oral Maxillofac Surg 2009; 67:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/63\">",
"      Bilezikian JP. Osteonecrosis of the jaw--do bisphosphonates pose a risk? N Engl J Med 2006; 355:2278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/64\">",
"      Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/65\">",
"      Farrugia MC, Summerlin DJ, Krowiak E, et al. Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates. Laryngoscope 2006; 116:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/66\">",
"      Tirelli G, Biasotto M, Chiandussi S, et al. Bisphosphonate-associated osteonecrosis of the jaws: the limits of a conservative approach. Head Neck 2009; 31:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/67\">",
"      Seth R, Futran ND, Alam DS, Knott PD. Outcomes of vascularized bone graft reconstruction of the mandible in bisphosphonate-related osteonecrosis of the jaws. Laryngoscope 2010; 120:2165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/68\">",
"      Kademani D, Koka S, Lacy MQ, Rajkumar SV. Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy. Mayo Clin Proc 2006; 81:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/69\">",
"      Lacy MQ, Dispenzieri A, Gertz MA, et al. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 2006; 81:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/70\">",
"      Epstein MS, Wicknick FW, Epstein JB, et al. Management of bisphosphonate-associated osteonecrosis: pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 110:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/71\">",
"      Ripamonti CI, Cislaghi E, Mariani L, Maniezzo M. Efficacy and safety of medical ozone (O(3)) delivered in oil suspension applications for the treatment of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: Preliminary results of a phase I-II study. Oral Oncol 2011; 47:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/72\">",
"      Agrillo A, Ungari C, Filiaci F, et al. Ozone therapy in the treatment of avascular bisphosphonate-related jaw osteonecrosis. J Craniofac Surg 2007; 18:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/73\">",
"      Petrucci MT, Gallucci C, Agrillo A, et al. Role of ozone therapy in the treatment of osteonecrosis of the jaws in multiple myeloma patients. Haematologica 2007; 92:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/74\">",
"      Freiberger JJ, Padilla-Burgos R, Chhoeu AH, et al. Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: a case series. J Oral Maxillofac Surg 2007; 65:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/75\">",
"      Shimura K, Shimazaki C, Taniguchi K, et al. Hyperbaric oxygen in addition to antibiotic therapy is effective for bisphosphonate-induced osteonecrosis of the jaw in a patient with multiple myeloma. Int J Hematol 2006; 84:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/76\">",
"      Erkan M, Bilgi O, Mutluo��lu M, Uzun G. Bisphosphonate-related osteonecrosis of the jaw in cancer patients and hyperbaric oxygen therapy. JOP 2009; 10:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/77\">",
"      Vescovi P, Merigo E, Manfredi M, et al. Nd:YAG laser biostimulation in the treatment of bisphosphonate-associated osteonecrosis of the jaw: clinical experience in 28 cases. Photomed Laser Surg 2008; 26:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/78\">",
"      Scoletta M, Arduino PG, Reggio L, et al. Effect of low-level laser irradiation on bisphosphonate-induced osteonecrosis of the jaws: preliminary results of a prospective study. Photomed Laser Surg 2010; 28:179.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.clinicaltrials.gov/ct2/show/NCT00462098?term=hyperbaric+oxygen+and+osteonecrosis+of+the+jaw&amp;rank=1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/80\">",
"      Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004; 19:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/81\">",
"      McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006; 354:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/82\">",
"      Badros A, Terpos E, Katodritou E, et al. Natural history of osteonecrosis of the jaw in patients with multiple myeloma. J Clin Oncol 2008; 26:5904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/83\">",
"      Montebugnoli L, Felicetti L, Gissi DB, et al. Biphosphonate-associated osteonecrosis can be controlled by nonsurgical management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 104:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/84\">",
"      Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007; 65:2397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/85\">",
"      Terpos E, Sezer O, Croucher PI, et al. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 2009; 20:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/86\">",
"      Khan AA, S&aacute;ndor GK, Dore E, et al. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 2008; 35:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/87\">",
"      Van Poznak CH, Temin S, Yee GC, et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 2011; 29:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/88\">",
"      Kyle RA, Yee GC, Somerfield MR, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007; 25:2464.",
"     </a>",
"    </li>",
"    <li>",
"     file://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=50538 (Accessed on November 22, 2011).",
"    </li>",
"    <li>",
"     file://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=41963 (Accessed on November 22, 2011).",
"    </li>",
"    <li>",
"     file://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=33043 (Accessed on November 22, 2011).",
"    </li>",
"    <li>",
"     European Medicines Agency. CHMP Assessment Report on Bisphosphonates and Osteonecrosis of the Jaw. London: EMA/CHMP 2011. file://www.ema.europa.eu/docs/en_GB/document_library/Other/2010/01/WC500051383.pdf (Accessed on November 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/93\">",
"      Dimopoulos MA, Kastritis E, Bamia C, et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 2009; 20:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/94\">",
"      Blair HC, Robinson LJ, Huang CL, et al. Calcium and bone disease. Biofactors 2011; 37:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/95\">",
"      Peter R, Mishra V, Fraser WD. Severe hypocalcaemia after being given intravenous bisphosphonate. BMJ 2004; 328:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/96\">",
"      Chennuru S, Koduri J, Baumann MA. Risk factors for symptomatic hypocalcaemia complicating treatment with zoledronic acid. Intern Med J 2008; 38:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/97\">",
"      Body JJ, Lipton A, Gralow J, et al. Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure. J Bone Miner Res 2010; 25:440.",
"     </a>",
"    </li>",
"    <li>",
"     Block G, Bone HG, Fang L, et al. A single dose study of denosumab in patients with various degrees of renal impairment. Presented at the National Kidney Foundation, Orlando FL, April 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/99\">",
"      Markowitz GS, Appel GB, Fine PL, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 2001; 12:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/100\">",
"      Sauter M, J&uuml;lg B, Porubsky S, et al. Nephrotic-range proteinuria following pamidronate therapy in a patient with metastatic breast cancer: mitochondrial toxicity as a pathogenetic concept? Am J Kidney Dis 2006; 47:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/101\">",
"      Kunin M, Kopolovic J, Avigdor A, Holtzman EJ. Collapsing glomerulopathy induced by long-term treatment with standard-dose pamidronate in a myeloma patient. Nephrol Dial Transplant 2004; 19:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/102\">",
"      Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int 2008; 74:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/103\">",
"      Gokden N, Zangari M, Elici F, et al. Potential effect of zoledronate therapy in heavy proteinuria. Clin Nephrol 2007; 67:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/104\">",
"      Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003; 98:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/105\">",
"      Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 2003; 349:1676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/106\">",
"      Jones SG, Dolan G, Lengyel K, Myers B. Severe increase in creatinine with hypocalcaemia in thalidomide-treated myeloma patients receiving zoledronic acid infusions. Br J Haematol 2002; 119:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/107\">",
"      Markowitz GS, Fine PL, Stack JI, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003; 64:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/108\">",
"      Munier A, Gras V, Andrejak M, et al. Zoledronic Acid and renal toxicity: data from French adverse effect reporting database. Ann Pharmacother 2005; 39:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/109\">",
"      McDermott RS, Kloth DD, Wang H, et al. Impact of zoledronic acid on renal function in patients with cancer: Clinical significance and development of a predictive model. J Support Oncol 2006; 4:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/110\">",
"      Morgan GJ, Davies FE, Gregory WM, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010; 376:1989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/111\">",
"      Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94:1458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/112\">",
"      Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003; 21:3150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/113\">",
"      Berenson JR, Rosen L, Vescio R, et al. Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function. J Clin Pharmacol 1997; 37:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/114\">",
"      Berenson JR, Boccia R, Lopez T, et al. Results of a multicenter open-label randomized trial evaluating infusion duration of zoledronic acid in multiple myeloma patients (the ZMAX trial). J Support Oncol 2011; 9:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/115\">",
"      Diel IJ, Bergner R, Gr&ouml;tz KA. Adverse effects of bisphosphonates: current issues. J Support Oncol 2007; 5:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/116\">",
"      Olson K, Van Poznak C. Significance and impact of bisphosphonate-induced acute phase responses. J Oncol Pharm Pract 2007; 13:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/117\">",
"      et al. Incidence of acute phase adverse events following denosumab or intravenous bisphosphonates: results from a randomized, controlled phase II study in patients with breast cancer and bone metastases. Community Oncol 2010; 7:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/118\">",
"      Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 2006; 17:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/119\">",
"      Tan YL, Sims J, Chee SP. Bilateral uveitis secondary to bisphosphonate therapy. Ophthalmologica 2009; 223:215.",
"     </a>",
"    </li>",
"    <li>",
"     Available on the FDA website at: www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm101551.htm (Accessed on August 08, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/121\">",
"      Wilkinson GS, Baillargeon J, Kuo YF, et al. Atrial fibrillation and stroke associated with intravenous bisphosphonate therapy in older patients with cancer. J Clin Oncol 2010; 28:4898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/122\">",
"      Erichsen R, Christiansen CF, Fr&oslash;slev T, et al. Intravenous bisphosphonate therapy and atrial fibrillation/flutter risk in cancer patients: a nationwide cohort study. Br J Cancer 2011; 105:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/123\">",
"      Leibbrandt A, Penninger JM. RANK/RANKL: regulators of immune responses and bone physiology. Ann N Y Acad Sci 2008; 1143:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/124\">",
"      Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999; 397:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/125\">",
"      Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/43/39610/abstract/126\">",
"      Smith MR, Egerdie B, Hern&aacute;ndez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361:745.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2806 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-67DC1C7482-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_43_39610=[""].join("\n");
var outline_f38_43_39610=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1932654\">",
"      CLASSES OF BONE MODIFYING AGENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1927316\">",
"      RISKS SHARED BY BOTH CLASSES OF DRUGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1928329\">",
"      Osteonecrosis of the jaw",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1928351\">",
"      - Definition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1928358\">",
"      - Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1928365\">",
"      - Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1928392\">",
"      - Incidence and risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1928434\">",
"      Dose, duration, and type of therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H1931163\">",
"      - Bisphosphonates",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H1931170\">",
"      - Denosumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1928441\">",
"      Oral health-associated risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1928448\">",
"      Other risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1928489\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8706104\">",
"      Outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8703756\">",
"      Discontinuation of bone modifying agent therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8702257\">",
"      - Prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1930509\">",
"      Hypocalcemia and other electrolyte abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4307611\">",
"      RISKS SPECIFIC TO BISPHOSPHONATES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Proteinuria and renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4308296\">",
"      - Incidence and risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H4308480\">",
"      Multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H4308499\">",
"      Other malignancies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Management and prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Acute phase response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Ocular toxicities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Bone, joint, or muscle pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3214834\">",
"      Atrial fibrillation and stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H454293264\">",
"      RISKS SPECIFIC TO DENOSUMAB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H454293350\">",
"      Renal effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H454293358\">",
"      Neutralizing antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H454293366\">",
"      Infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2806\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2806|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?8/45/8927\" title=\"diagnostic image 1\">",
"      Osteonecrosis of the jaw",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2806|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/33/33307\" title=\"table 1\">",
"      Toxicity comparison for bisphosphonates versus denosumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/27/5564\" title=\"table 2\">",
"      Clinical classification of ONJ related to bone modifying agents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/18/13608?source=related_link\">",
"      Bisphosphonates and denosumab in patients with metastatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=related_link\">",
"      Bisphosphonates in the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=related_link\">",
"      Calcium and vitamin D supplementation in osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/31/43512?source=related_link\">",
"      Collapsing focal segmental glomerulosclerosis not associated with HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22040?source=related_link\">",
"      Denosumab for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/42/37545?source=related_link\">",
"      Evaluation and management of aromatase inhibitor-induced bone loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/54/18282?source=related_link\">",
"      Initial chemotherapy for symptomatic multiple myeloma in patients who are candidates for transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/36999?source=related_link\">",
"      Management of bone metastases in advanced prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/5/34906?source=related_link\">",
"      Normal skeletal development and regulation of bone formation and resorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/54/8042?source=related_link\">",
"      Osteoclast inhibition in the management of bone metastases from breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/43/28346?source=related_link\">",
"      Osteonecrosis (avascular necrosis of bone)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32041?source=related_link\">",
"      Overview of heavy proteinuria and the nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/35/33336?source=related_link\">",
"      Overview of the use of osteoclast inhibitors in early breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/4/11333?source=related_link\">",
"      Pharmacology of bisphosphonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/30/21993?source=related_link\">",
"      Side effects of androgen deprivation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/27/30137?source=related_link\">",
"      The use of bisphosphonates in patients with multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/37/44632?source=related_link\">",
"      Treatment of hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=related_link\">",
"      Treatment of vitamin D deficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/48/27400?source=related_link\">",
"      Types of renal disease in multiple myeloma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_43_39611="Dose regimen HAV vaccine";
var content_f38_43_39611=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F67893&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F67893&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dose and administration of inactivated hepatitis A vaccine",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Age/status",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommendation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;12 months",
"       </td>",
"       <td>",
"        No available data; immune serum globulin can be given if needed",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        1 to 18 years",
"       </td>",
"       <td class=\"sublist1_start\">",
"        HAVRIX:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        0.5 mL IM (contains 720 EL.U viral antigen) at 0, 1, and booster at 6 to 12 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        VAQTA:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        0.5 mL IM (contains 25 U viral antigen) at 0 and booster at 6 to 18 months",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        &gt;18 years",
"       </td>",
"       <td class=\"sublist1_start\">",
"        HAVRIX:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1.0 mL IM (contains 1440 EL.U viral antigen) at 0 and booster at 6 to 12 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        VAQTA:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1.0 mL IM (contains 50 U viral antigen) at 0 and booster at 6 to 18 months",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Pregnancy",
"       </td>",
"       <td>",
"        No available data; immune serum globulin can be given if needed",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Allergic to vaccine",
"       </td>",
"       <td>",
"        Immune serum globulin",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Immunodeficiency syndromes",
"       </td>",
"       <td>",
"        May not induce expected response",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_43_39611=[""].join("\n");
var outline_f38_43_39611=null;
var title_f38_43_39612="Pressure sore status tool";
var content_f38_43_39612=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F72135&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F72135&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pressure sore status tool",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Stage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"5\">",
"        Exudate amount",
"       </td>",
"       <td>",
"        1 = None&nbsp;&nbsp;&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2 = Scant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3 = Small",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4 = Moderate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5 = Large",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"5\">",
"        Skin color surrounding wound",
"       </td>",
"       <td>",
"        1 = Pink or normal for ethnic group",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2 = Bright red and/or blanches to touch",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3 = White or gray pallor or hypopigmented",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4 = Dark red or purple and/or nonblanchable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5 = Black or hypopigmented",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"5\">",
"        Peripheral tissue edema",
"       </td>",
"       <td>",
"        1 = Minimal swelling around wound",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2 = Nonpitting edema extends &lt;4 cm around wound",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3 = Nonpitting edema extends &ge;4 cm around wound",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4 = Pitting edema extends &lt;4 cm around wound",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5 = Crepitus and/or pitting edema extends &ge;4 cm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"5\">",
"        Peripheral tissue induration",
"       </td>",
"       <td>",
"        1 = Minimal firmness around wound",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2 = &lt;2 cm around wound",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3 = 2 to 4 cm extending &lt;50 percent around wound",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4 = 2 to 4 cm extending &ge;50 percent around wound",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5 = &gt;4 cm in any area",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"5\">",
"        Granulation tissue",
"       </td>",
"       <td>",
"        1 = Skin intact or partial-thickness wound",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2 = Bright, beefy red; 75 to 100 percent of wound filled and/or tissue overgrowth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3 = Bright, beefy red; &lt;75 percent and &gt;25 percent of wound filled",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4 = Pink and/or dull, dusky red and/or fills &le;25 percent of wound",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5 = No granulation tissue present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"5\">",
"        Epithilization",
"       </td>",
"       <td>",
"        1 = 100 percent of wound covered, surface intact",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2 = 75 to 100 percent of wound covered and/or epithelial tissue extends &gt;0.5 cm into wound bed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3 = 50 to 75 percent of wound covered and/or epithelial tissue extends &lt;0.5 cm into wound bed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4 = 25 to 50 percent of wound covered",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5 = &lt;25 percent of wound covered",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Bates-Jensen, BM, Adv Wound Care 1998; 10:65.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_43_39612=[""].join("\n");
var outline_f38_43_39612=null;
var title_f38_43_39613="Distal acid secretion";
var content_f38_43_39613=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F51361&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F51361&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 526px\">",
"   <div class=\"ttl\">",
"    Acid-secreting type A intercalated cells",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 506px; height: 238px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transport mechanisms involved in hydrogen secretion and HCO3",
"    <sup>",
"     -",
"    </sup>",
"    and K",
"    <sup>",
"     +",
"    </sup>",
"    reabsorption in type A intercalated cells, which are present from the late distal convoluted tubule to the initial portion of the inner medullary collecting duct. Water within the cell dissociates into H",
"    <sup>",
"     +",
"    </sup>",
"    and OH",
"    <sup>",
"     -",
"    </sup>",
"    ions. The former are secreted into the lumen by H",
"    <sup>",
"     +",
"    </sup>",
"    -ATPase pumps in the luminal membrane, where they combine with urinary buffers to generate &ldquo;titratable acids&rdquo; (eg,&nbsp;convert NH3 to NH4",
"    <sup>",
"     +",
"    </sup>",
"    ).&nbsp;The OH",
"    <sup>",
"     -",
"    </sup>",
"    ions in the cell combine with CO2 to form HCO3",
"    <sup>",
"     -",
"    </sup>",
"    in a reaction catalyzed by carbonic anhydrase (CA).&nbsp;Driven by their electrochemical concentration gradients, cellular bicarbonate enters the peritubular capillaries in exchange for extracellular chloride via Cl",
"    <sup>",
"     -",
"    </sup>",
"    -HCO3",
"    <sup>",
"     -",
"    </sup>",
"    exchangers on the basolateral membrane.&nbsp; H",
"    <sup>",
"     +",
"    </sup>",
"    -K",
"    <sup>",
"     +",
"    </sup>",
"    -ATPase pumps, which secrete H",
"    <sup>",
"     +",
"    </sup>",
"    and reabsorb K",
"    <sup>",
"     +",
"    </sup>",
"    , are also present in the luminal membrane of the type A intercalated cells. The number and activity of these pumps are increased by K",
"    <sup>",
"     +",
"    </sup>",
"    depletion, suggesting that they may be important for K",
"    <sup>",
"     +",
"    </sup>",
"    conservation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_43_39613=[""].join("\n");
var outline_f38_43_39613=null;
var title_f38_43_39614="Chondrosarc endoprosthesis";
var content_f38_43_39614=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F50945&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F50945&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endoprosthetic reconstruction after resection of a lower extremity chondrosarcoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 274px; height: 376px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 45 year-old man underwent resection of a chondrosarcoma with reconstruction of the osseous defect with a metal endoprosthesis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Francis J Hornicek, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_43_39614=[""].join("\n");
var outline_f38_43_39614=null;
var title_f38_43_39615="Multiple magnets GI tract";
var content_f38_43_39615=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52524&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52524&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Multiple magnets in the gastrointestinal tract of a child",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 418px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Abdominal radiograph of a boy aged 3 years, noting three attached magnets that resulted in volvulus (twisting of the bowel) and multiple bowel perforations.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morbidity and Mortality Weekly Report 2006; 55:1296.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_43_39615=[""].join("\n");
var outline_f38_43_39615=null;
